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Summary 
 
Diabetes mellitus (DM) is the most common metabolic disease worldwide and the 
number of newly diagnosed cases is increasing. DM is strongly associated with a 
number of devastating chronic late complications, including retinopathy, nephropathy 
and neuropathy (microvascular complications), as well as cardiac, cerebrovascular 
and peripheral vascular disease (macrovascular complications). Despite lots of 
progress in therapeutic possibilities during the last decades, mortality risk due to 
macrovascular complications is still increased in patients with DM when compared to 
non diabetic individuals. It has also been suggested that specific risk factors 
influence macrovascular risk differentially in persons with and without DM. In 
addition, there is still uncertainty whether the effectiveness of certain treatment forms 
differs between patients with and without DM, and in the patients with DM, between 
type 1 and type 2. The focus of my thesis was on prevention and therapy of 
macrovascular disease in patients with type 1 and type 2 DM, as well as on 
comparisons with patients without DM. Three studies (Studies A-C) investigated the 
effectiveness of specific treatment forms on macrovascular disease by means of 
systematic reviews and meta-analyses, whereas two studies (Studies D and E) 
evaluated novel risk indicators using survival analysis based on data from the 'Swiss 
Cohort of the World Health Organisation (WHO) Multinational Study of Vascular 
Disease in Diabetes'.  
 
The aim of Study A (published in Am Heart J 2006 Jul;152(1):27-38) was to assess 
the effect of improved glycaemic control on cardiac, cerebrovascular and peripheral 
vascular complications in type 1 and type 2 DM. Outcomes included the incidence 
rate ratios (IRRs) for any macrovascular event, cardiac events, stroke, and peripheral 
arterial disease. Results showed a 62% (95% Confidence Interval (CI) 44-74%) and 
19% (95% CI 9-27%) reduction in macrovascular risk for improved glycaemic control 
in type 1 and type 2 DM, respectively. In type 1 DM the effect was mainly based on a 
reduction of cardiac and peripheral vascular events. In type 2 DM it was due to 
reductions in stroke and peripheral vascular events. The effects appeared to be 
particularly important in younger patients with shorter duration of DM.  
 
Study B (published in Curr Med Res Opin 2006 Mar;22(3):617-23) examined the 
effectiveness of fibrates (peroxisome proliferator activated receptor α-agonists) in the 
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prevention of coronary heart disease in type 2 DM. The primary outcome of this 
meta-analysis was the IRR for coronary heart disease (CHD) events (a combination 
of non fatal myocardial infarction and death due to CHD). Secondary endpoints were 
death due to CHD, fatal and non fatal myocardial infarction, and fatal and non fatal 
stroke. The results of Study B showed a 16% risk reduction for CHD events (95% CI 
4-26%) in patients with type 2 DM when treated with fibrates compared to placebo. 
For the secondary endpoints a tendency towards reduction in risk was found, 
although this did not reach conventional levels of statistical significance. 
Coronary stenting is established as a treatment of coronary heart disease. The aim of 
Study C (published in Heart 2006 May;92(5):650-7) was to indirectly compare the 
effects of polymer based sirolimus versus paclitaxel eluting coronary stents and to 
examine whether they are equally effective in the prevention of restenosis in patients 
with and without DM. The indirect comparisons were performed by calculating the 
ratio of incidence rate ratios (RIRR) of studies comparing sirolimus eluting stents 
versus conventional bare metal stents and studies comparing paclitaxel eluting 
versus bare metal stents. The overall study population and patients with and without 
DM were analysed separately. Outcomes included in-stent- and in-segment 
restenosis, target lesion revascularisation, and major adverse cardiac events. The 
results of this study showed that rates of revascularisation procedures are reduced 
by sirolimus as well as paclitaxel eluting stents when compared to bare metal stents 
independent of the study population. However, in persons without DM a superiority of 
the sirolimus eluting stent to the paclitaxel eluting stent was found for all endpoints 
under investigation. In contrast, for persons with DM no statistically significant 
differences between the two drug eluting stents were found. A meta-regression 
analysis confirmed a difference between individuals with and without DM.
Study D (published in Diabetologia 2006, DOI 10.1007/s00125-006-0483-1) 
evaluated the long-term association of two parameters with mortality, namely QT 
interval and resting heart rate (rHR) in patients with type 1 and type 2 DM. Based on 
the 23-year follow up of the 'Swiss Cohort of the WHO Multinational Study of 
Vascular Disease in Diabetes', the prognostic values of these two risk factors were 
examined on all-cause, cardiovascular and cardiac mortality and mortality due to 
ischaemic heart disease using a Cox proportional hazards model. Results showed an 
association of prolonged QT interval (corrected for heart rate, QTc) with an increased 
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mortality risk due to all causes, as well as cardiovascular and cardiac disease in type 
1 DM, whereas no association was found for rHR. In contrast, in patients with type 2 
DM elevated rHR but not QTc was associated with an increased risk of all-cause 
mortality as well as death due to cardiovascular, cardiac and ischaemic heart 
disease.
Study E (published in J Intern Med 2006 Sep;260(3):272-80) was based on an 15-
year follow up of the 'Swiss Cohort of the WHO Multinational Study of Vascular 
Disease in Diabetes'. This study evaluated the long-term association of 
apolipoprotein B (apo B) with mortality risk in patients with type 1 DM. Compared to 
Study D, follow up was shorter due to the fact that apo B was only measured later in 
the course of the study. Analyses were performed for all-cause and cardiac mortality 
and mortality due to ischaemic heart disease, using a parametric proportional 
hazards model based on the Weibull distribution. Apo B was found to be positively 
related to all-cause and cardiac mortality, and mortality due to ischaemic heart 
disease. An apo B >0.96 g/L translated into a doubling of overall mortality, and a 
sevenfold increase of mortality due to cardiac disease or ischaemic heart disease.
In conclusion, this thesis showed that:
• The incidence of macrovascular events is reduced by improved glycaemic 
control, both in type 1 and type 2 DM. Although effects on specific 
manifestations of macrovascular disease are different between the two types 
of DM, in absolute terms benefits are comparable.
• CHD events are substantially reduced in patients with type 2 DM when treated 
with fibrates. Nevertheless, their exact role in lipid lowering treatment needs to 
be investigated further.
• Compared to bare metal stents, sirolimus as well as paclitaxel eluting stents 
are effective in reducing the rates of revascularisation procedures. Based on 
indirect evidence, stents eluting sirolimus appear to be superior to paclitaxel 
eluting stents in patients without DM but not in patients with DM.
Summary
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• Prolongation of QTc is related to an increased mortality risk in patients with 
type 1 DM, whereas elevated rHR is associated with higher mortality risk in 
patients with type 2 DM.
• Increased apo B levels are consistently associated with mortality risk in type 1
DM.
In addition to these conclusions, two general statements can be made:
• The effectiveness of therapeutic interventions may be different in persons with 
compared to persons without DM.
• Within the group of patients with DM, the effectiveness of specific interventions 
may vary between type 1 and type 2 DM.
General introduction 
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1. General introduction 
 
1.1 Clinical characteristics of diabetes mellitus and its role in the 
health care system 
Diabetes Mellitus (DM) is characterised by chronic hyperglycaemia with disturbances 
of carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action, or both. Symptoms of marked hyperglycaemia include 
polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision. 
Impairment of growth and susceptibility to certain infections may also accompany 
chronic hyperglycaemia. The four most common acute, life-threatening 
consequences of uncontrolled DM are hyperglycaemia with ketoacidosis, the 
nonketotic hyperosmolar syndrome as well as profound hypoglycaemia and lactate 
acidosis [1]. Characteristic chronic late complications of DM include retinopathy, 
nephropathy and neuropathy (microvascular complications) as well as cardiac, 
cerebrovascular and peripheral vascular disease (macrovascular complications). 
 
 
1.1.1 Classification of diabetes mellitus 
The aetiology and pathophysiology leading to metabolic defects and consequently to 
hyperglycaemia are markedly different among patients with DM. Consequently, 
different prevention strategies, diagnostic screening methods and treatments are 
needed. In June 1997, an international expert committee released a report with 
recommendations for the classification and diagnosis of DM [2]. These 
recommendations were the result of a collaboration over more than two years among 
experts from the American Diabetes Association (ADA) and the World Health 
Organisation (WHO). Based on this classification system, four major forms of DM are 
identified: type 1, type 2, other specific types, and gestational diabetes. 
Characteristically, in type 1 DM the pancreas is damaged by beta-cell destruction, 
usually leading to absolute insulin deficiency [3]. In contrast, in type 2 DM – the most 
common form – characteristics range from predominant insulin resistance with 
relative insulin deficiency to a predominant secretory defect with or without insulin 
resistance [3]. An overview of all types of DM is given in Table 1. 
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Table 1. Classification and characteristics of DM [3] 
Type of Diabetes mellitus Characteristics 
I. Type 1 Destruction of β-cells (autoimmune or idiopathic), usually leading to absolute insulin deficiency 
II. Type 2 Range of predominant insulin resistance with relative insulin deficiency to a predominantly secretory defect 
III. Other specific types 
A. Genetic defects of β-cell function 
B. Genetic defects of insulin action 
C. Diseases of the exokrine pancreas 
D. Endocrinopathies 
E. Destruction of pancreas by drugs or chemicals 
F. Infections 
G. Rare forms of immune-linked diabetes (e.g. Stiff-
Person-Syndrome) 
H. Other syndromes, occasionally associated with 
diabetes (e.g. Down-Syndrome, Klinefelter-
Syndrome, Turner-Syndrome, etc) 
IV. Gestational diabetes Operational classification identifying women who develop DM during gestation 
 
 
1.1.2 Diagnosis of diabetes mellitus 
The diagnosis of DM is based on guidelines constantly adapted by the WHO (World 
Health Organisation), the ADA (American Diabetes Association) and the IDF 
(International Diabetes Federation). To date, diagnosis of DM includes the following 
criteria [2]: 
 
Table 2. Criteria for diagnosis of DM 
1) Symptoms of DM plus casual plasma glucose concentration >200 mg/dl (11.1 mmol/L). Casual 
is defined as any time of day without regard to time since last meal. The classic symptoms of DM 
include polyuria, polydipsia, and unexplained weight loss. 
or 
2) Fasting Plasma Glucose >126 mg/dl (7.0 mmol/L). Fasting is defined as no caloric intake for at 
least 8 h. 
or 
3) 2-h postload glucose >200 mg/dl (11.1 mmol/L) during an Oral Glucose Tolerance Test 
(OGTT). The test should be performed as described by WHO, using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water. 
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In the absence of unequivocal hyperglycaemia, these criteria should be confirmed by 
repeat testing on a different day. The third measure (OGTT) is not recommended for 
routine clinical use. 
 
Based on these guidelines, there is an intermediate group with glucose levels not 
meeting criteria for DM, but too high to be considered normal. This group is defined 
as having fasting plasma glucose (FPG) levels >100 mg/dl (5.6mmol/l) but <126 
mg/dl (7.0 mmol/l) or 2-h values in the oral glucose tolerance test (OGTT) of >140 
mg/dl (7.8 mmol/l) but <200 mg/dl (11.1 mmol/l). Thus, values for FPG or 2-h 
postload glucose, respectively, are considered as given in Table 3: 
 
Table 3. Criteria for fasting plasma glucose (FPG) or 2-h postload glucose, respectively 
Fasting plasma glucose  
FPG<100 mg/dl (5.6 mmol/l) Normal fasting glucose 
FPG 100-125 mg/dl (5.6-6.9 mmol/l) IFG (impaired fasting glucose) 
FPG >126 mg/dl (7.0 mmol/l) Provisional diagnosis of DM (the diagnosis must be 
confirmed) 
2-h postload glucose  
2-h postload glucose  
<140 mg/dl (7.8mmol/l) in OGTT 
Normal glucose tolerance 
2-h postload glucose  
140-199 mg/dl (7.8-11.1 mmol/l) in OGTT 
IGT (impaired glucose tolerance) 
2-h postload glucose  
>200 mg/dl (11.1 mmol/l) in OGTT 
Provisional diagnosis of DM (the diagnosis must be 
confirmed) 
 
Persons with IFG and IGT are at higher risk to develop DM compared to those with 
normal glucose values [4, 5]. In addition recent data suggest that individuals with IGT 
or IFG are predisposed to cardiovascular disease [6, 7]. Still, it is debated whether 
IFG and IGT are independent risk factors because they commonly coexist with other 
cardiovascular risk factors, as obesity (especially abdominal or visceral obesity), 
dyslipidaemia and hypertension, or, in general, with the metabolic syndrome [4, 5, 8].  
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1.1.3 Metabolic syndrome and the risk for type 2 DM 
The metabolic syndrome is an important risk factor for cardiovascular disease and 
the development of type 2 DM [9]. Building on earlier definitions put forward by the 
World Health Organisation (WHO) and the National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP III) [10], a new definition for the metabolic 
syndrome has been proposed in 2005 by the International Diabetes Foundation [11]. 
Its specifications are easy to use in clinical practice and avoid the need for 
measurements that may only be available in research settings. The definition of the 
metabolic syndrome according to the IDF is given in Table 4. 
 
Table 4. Definition of the metabolic syndrome (based on IDF 2005) [11] 
Abdominal obesity Waist circumference for men >94 cm* Waist circumference for women >80 cm* 
in addition to 2 of the following risk factors 
Hypertension Systolic blood pressure >130 mm Hg or Diastolic blood pressure >85 mm Hg 
Triglycerides >1.7 mmol/L 
HDL-Cholesterol Men <1.03 mmol/L Women <1.29 mmol/L 
Fasting Plasma Glucose >5.6 mmol/L or diagnosis of DM 
*values dependent on ethnicity, given data refer to Europids 
 
Due to the combination of several risk factors the metabolic syndrome is related to a 
high cardiovascular risk. Recent studies showed that cardiovascular risk was about 
doubled in persons with the metabolic syndrome compared to persons without risk 
factors [9, 12]. The causes of the metabolic syndrome are complex and have only 
been partially elucidated. Most individuals are obese and have some degree of 
insulin resistance. There is debate regarding whether obesity or insulin resistance is 
the pathogenetically relevant cause of the syndrome or a by-product of a more far-
reaching metabolic derangement [13]. 
 
1.1.4 Diabetes control and the role of glycated haemoglobin (HbA1c) 
The glycation of haemoglobin, estimated as HbA1c, is increasingly described as the 
' gold standard' to judge the effectiveness of glycaemic control and to set targets in 
clinical practice [14, 15]. Glycation describes the post-translational, non-enzymatic 
covalent chemical linkage of glucose onto proteins through amino groups (either N-
terminal amino acids or ε-amino groups on lysine residues) [16]. Haemoglobin is 
predominantly glycated by attaching glucose to the N-terminal valine of the β-chain. 
General introduction 
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The extent of glycation is expressed as a percentage of total haemoglobin A, the 
predominant haemoglobin form after birth. Glycation of proteins is found in tissues 
exposed to glucose and is increased at higher levels of glucose [16]. Little is known 
about the chemistry of deglycation, a process also regulating the degree of glycation 
of proteins [16]. A recently identified enzymatic mechanism in erythrocytes involving 
fructosamine 3-kinase has been suggested to be responsible for deglycation and for 
the genetic variability in HbA1c levels between individuals [17, 18]. At the time of 
measurement, the fraction of glycated haemoglobin depends on the average age of 
the erythrocytes; the older the cells the higher the percentage of HbA1c [19, 20]. 
Therefore, it has been suggested that HbA1c reflects the prevailing glycaemia over 
the previous six to eight weeks [21]. Values of a non diabetic population are generally 
between four to six percent [21]. Of note, it has been stated that there is a shortened 
red-cell life span in patients with compared to patients without DM [16]. In addition, 
HbA1c values may differ markedly dependent on the applied assay or even the 
performing laboratory [16, 21]. When interpreting HbA1c values, it is therefore 
important to be aware of the corresponding reference interval, potential assay 
interferences (e.g. haemoglobinopathies) and assay performances [21]. 
Microvascular complications have been clearly shown to increase with higher levels 
of HbA1c, especially above seven percent [22-24], which has been established as a 
target level in the therapy of DM [21]. In contrast, the influence of glycaemia on 
macrovascular complications is still debated. A meta-analysis on observational 
studies found an association of higher levels of HbA1c with the risk for cardiovascular 
disease [25]. In the context of glycaemic control within the clinical management of 
DM, postprandial hyperglycaemia has been shown to be more strongly related to 
macrovascular complications [26-28], thereby possibly reflecting a part of 
hyperglycaemia not detectable by HbA1c. More research is needed in this context. 
 
1.1.5 Epidemiological data on diabetes mellitus 
It is suggested that about 194 million people in a wide range of ethnic groups have 
DM worldwide [29]. The European Region with 48 million and the Western Pacific 
Region with 43 million currently have the highest number of people with DM. 
However, the prevalence rate of 3.1% for the Western Pacific Region is lower than 
the 7.9% in the North American Region and 7.8% in the European Region [29].  
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Type 2 DM constitutes about 85-95% of the number of persons affected with DM in 
developed countries and accounts for an even higher percentage in developing 
countries [29]. Since human environment, behaviours and way-of-life have changed 
substantially over the last fifty years, rates of obesity and type 2 DM escalated 
globally. Therefore, the number of people with DM is expected to rise to almost 366 
million by the year 2030 [30]. The combination of obesity and DM is recognised as 
one of the major threats in the 21st century and continues to affect ever-increasing 
numbers of people around the world. Moreover, not only the prevalence is 
increasing, also the age of onset of type 2 DM is falling: more and more type 2 DM is 
being reported in children and adolescents in many countries [29]. 
 
Figure 1. Number of adults
with DM worldwide in 2000,
and estimated number in
2030 (adapted from World
Health Organisation,
http://www.who.int/diabetes
/actionnow/en/diabprev.pdf, 
accessed June 2006) 
In contrast to type 2 DM, it is estimated that approximately 4.9 million people have 
type 1 DM, amounting to 0.09% of the world's population [29]. Europe has the 
highest estimated number of people with type 1 DM (1.27 million), followed by North 
America (1.04 million) and South East Asia (0.91 million) [29]. 
 
1.1.6 Impact of diabetes mellitus on health care costs 
The annual direct healthcare costs of DM worldwide, for people in the 20-79 age 
bracket, is estimated to be at least 153 billion international dollars (hypothetical 
standardised unit of currency with the same purchasing power as the US dollar in the 
United States at a given point in time, allowing for comparisons between different 
countries over time) and may be as much as 286 billion, or even more. The economic 
 15
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impact of DM is, therefore, considerable. If predictions of DM prevalence are fulfilled, 
total direct healthcare expenditure on DM will rise to about 213-396 billion 
international dollars in 2025, accounting for 7-13% or even more of the world’s 
healthcare budget being spent in 2025 in high prevalence countries [29]. 
 
The costs affect health services, national productivity as well as individuals and 
families. Hospital in-patient costs for the treatment of complications are the largest 
single contributor to direct healthcare costs [29]. The total health care costs of a 
person with DM in the USA are between twice and three times those for people 
without the condition [31]. In Switzerland, direct costs have been estimated at around 
CHF 2,380 per year for a person with type 2 DM. If late complications are present, 
the amount is considerably higher [32, 33].  
 
1.1.7 Prevention of diabetes mellitus 
Regarding the health and economic burden of diabetes it is of great interest to delay 
or prevent the onset of the disease. To date, despite intensive efforts in research no 
successful methods have been documented to prevent type 1 DM. Though the 
availability of reliable and convenient screening tools (antibodies) allow to estimate 
the risk for development of type 1 DM, several studies failed to demonstrate an 
effective intervention regarding the prevention of type 1 DM. For example, the large 
Diabetes Prevention Trial-Type 1 (DPT-1) [34] or the European Nicotinamide 
Diabetes Intervention Trial (ENDIT) [35], investigating early administration of insulin 
or nicotinamide in high risk patients (i.e. first-degree relatives of a patient with type 1 
DM), were unable to reproduce the promising results from animal research or small 
studies in humans.  
 
For type 2 DM, where insulin resistance plays a fundamental role, the risk increases 
with age, obesity and lack of physical activity [36]. Several studies investigated the 
effect of either lifestyle or pharmacologic interventions on the onset of the disease in 
high risk patients (i.e. pre-existing IGT or IFG or increased body mass index). Life-
style interventions in randomised controlled trials consisting of exercise and/or diet 
showed that the incidence of type 2 DM might be reduced by up to 58% [37, 38]. A 
meta-analysis investigating the effect of lifestyle education to prevent type 2 DM in 
high-risk individuals confirmed that lifestyle intervention is a useful tool in reducing 
the incidence of type 2 DM as well as lowering 2-h postload glucose levels [39]. 
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Evaluations based on drug interventions were based on oral hypoglycaemic agents 
and a variety of other substances, as for example orlistat, verapamil, statins or 
estrogens [40]. Not all studies were able to report a meaningful reduction in risk for 
development of type 2 DM, but the different study designs make a solid comparability 
of all studies different (randomised controlled trials vs. post hoc analyses, different 
definitions of DM, etc.) [40]. However, the risk to develop type 2 DM was found to be 
significantly reduced in most of the prospective randomised trials as for example by 
25% in the STOP-Noninsulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial [26, 
27] using acarbose, by 31% in the Diabetes Prevention Program (DPP) [41,42] 
comparing metformin to placebo, and by 37% in the XENical in the Prevention of 
Diabetes in Obese Subjects (XENDOS) study [43], using orlistat. A short overview on 
randomised controlled trials investigating effects on the incidence of type 2 DM is 
given in Table 5. Based on the findings of the large prevention studies, the American 
Diabetes Association (ADA) and the National Institute of Diabetes and Digestive and 
Kidney Diseases concluded that there is substantial evidence that type 2 DM can be 
prevented or at least delayed [44]. However, whether interventions will be cost-
effective with respect to morbidity and mortality, is still an open question [45]. Due to 
the greatest reduction in the incidence of type 2 DM in high-risk patients in trials on 
lifestyle modification, the emphasis should be on these interventions in future 
prevention policies.  
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Table 5. Randomised controlled trials (RCTs) on the incidence of type 2 DM 
Study Intervention Control Inclusion criteria 
Randomised 
patients 
Follow-up 
[years] 
Results 
RCTs with lifestyle intervention      
DPP [46] Diet + Exercise & 
Metformin§ 
Placebo M & F, IFG, BMI>24kg/m2 (Asian >22), 
age >25 years 
3234 2.8 RR Diet + Exercise vs Placebo:  
0.42 (95%CI 0.36-0.52) 
RR Metformin vs Placebo:  
0.69 (95% CI 0.57-0.83) 
Pan et al. [47] Diet, Exercise, 
Diet + Exercise§ 
Conventional 
routine advice 
M & F, IGT, age >25 years 577 6.0 RR Diet vs Control: 0.69 (p=0.028) 
RR Exercise vs Control: 0.54 (p<0.0005) 
RR Diet + Exercise vs Control: 0.58 (p=0.001) 
Tuomilehto et al. [38] Diet + Exercise Conventional 
routine advice 
M & F, IGT, BMI>25kg/m2,  
age 40-64 years 
522 3.2 HR: 0.4 (95% CI 0.3-0.7) 
Wein et al. [48] Diet + Exercise Conventional 
routine advice 
F with gestational DM, IGT 200 4.3 RR: 0.83 (95% CI 0.47-1.48) 
RCTs with drug intervention      
BIGPRO [49] Metformin Placebo M & F, high waist-to-hip ratio (men 
>0.90, females >0.80),  
age 35-65 years 
457 1.0 Only 5 cases of DM in the placebo group†
Jarrett et al. [50] Phenformin§ Placebo M, IGT, age >40 years 204 5.0 RR 0.90 (0.45-1.80)†
Li et al. [51] Metformin Placebo M & F, IGT, age 30-60 years 70 1.0 RR 0.51 (0.14-1.9)†
STOP-NIDDM [26, 27] Acarbose Placebo M & F, IGT & FPG 5.6-7.7 mmol/L, BMI 
25-40kg/m2, age 40-70 years 
1429 3.3 RR 0.75 (0.63-0.90) 
TRIPOD [52] Troglitazone Placebo Hispanic women with gestational DM, 
age >18 years 
266 2.5 RR 0.45 (0.25-0.83) 
XENDOS [43] Orlistat + Lifestyle Placebo M & F, BMI>30 kg/m2, age 30-60 years 3305 4.0 HR 0.63 (0.46-0.86) 
M, Males; F, Females; RR, Risk Ratio, HR, Hazard Ratio; IGT, Impaired glucose tolerance; IFG, Impaired fasting glucose; BMI, Body mass index; DPP, Diabetes Prevention Program; BIGPRO, BIGuanides and Prevention Risks in Obesity 
Study; STOP-NIDDM, STOP-Noninsulin-Dependent Diabetes Mellitus Trial; TRIPOD, Troglitazone In the Prevention Of Diabetes Study; XENDOS, XENical in the Prevention of Diabetes in Obese Subjects Study; § Study consisted of 
different intervention arms; †, data based on Padwal et al, [40] Note: For the RCTs with drug intervention only double-blind trials were included in this table where data on the incidence of type 2 DM was available from the publication and 
the control arm consisted of a placebo comparison 
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1.2. Late complications of diabetes mellitus 
As stated above, all types of DM share similar chronic late complications. The high 
incidence and prevalence of these complications substantially increase morbidity and 
mortality associated with the disease, contributing to the high total health care costs, 
and reducing quality of life of individuals affected. Differences are made between 
micro- and macrovascular complications although they clinically often interact and 
relate to each other. 
 
1.2.1 Microvascular complications 
Microvascular complications include effects on small vessels, including arterioles, 
capillaries and venules. The development of these complications starts early in the 
pathogenesis of DM and accounts for morbidity in the form of retinopathy, 
nephropathy and neuropathy. There is clear evidence from several interventional 
studies that the progression of microvascular disease depends mainly on the quality 
of glycaemic control and the duration of the disease [22, 23, 53-59]. This was 
conclusively shown by the large Diabetes Control and Complications Trial (DCCT) 
[22] for patients with type 1 DM, and by the United Kingdom Prospective Diabetes 
Study (UKPDS) [23] and the Kumamoto Study [55] for patients with type 2 DM. All 
studies documented substantial reductions in microvascular complications in patients 
undergoing intensified glycaemic control (i.e. intensified insulin treatment) compared 
to patients with conventional treatment. Even in secondary prevention cohorts (i.e. 
patients with established retinopathy), progression of complications was reduced with 
decreasing blood glucose levels. Further epidemiological analyses of these studies 
confirmed the association between glycaemic control and the risk of development 
and/or progression of microvascular complications [25, 60]. Unfortunately, the 
incidence of severe hypoglycaemia in type 1 DM is approximately three times higher 
in intensively treated compared to conventionally treated patients [22, 61, 62]. It has 
also been shown that in this population intensive insulin therapy is associated with 
hypoglycaemia unawareness and severe hypoglycaemia, making iatrogenic 
hypoglycaemia a major limiting factor in the attempt to achieve optimal glycaemic 
control [63]. 
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1.2.2 Macrovascular complications 
Macrovascular disease is caused by atherosclerotic lesions of large vessels and 
includes cardiac, as well as cerebrovascular and peripheral vascular complications. 
Macrovascular disease is the leading cause of morbidity and mortality among 
persons with DM in developed countries [64]: a substantial proportion of premature 
deaths in patients with type 1 DM [65], and the majority of deaths in type 2 DM are 
related to macrovascular disease. Despite intensive efforts to improve treatment 
strategies in patients with DM, mortality is still increased when compared to the non-
diabetic population [66, 67]. In contrast to the microvascular complications, the 
impact of optimal blood glucose levels on macrovascular complications is still 
debated. Trials of intensified blood glucose control showed a tendency towards a 
reduced risk of macrovascular disease with improved glycaemic control [22, 23, 59]. 
However, the question, whether improved glycaemic control could reduce the 
development and/or progression of macrovascular disease, has not been 
conclusively answered so far. Moreover, due to the fact that the beneficial effect of 
improved glycaemic control on microvascular complications has been documented, it 
would be unethical to perform further trials comparing intensified with conventional 
glycaemic control. In addition to chronic hyperglycaemia, several other factors have 
been found to contribute to the development or progression of macrovascular 
disease. Of these, especially important and commonly present in type 2 DM are 
hypertension and atherogenic dyslipidaemia. Atherogenic dyslipidaemia is 
characterised by small dense low density lipoprotein (LDL) particles, elevated very 
low density lipoprotein (VLDL) levels and low high density lipoprotein (HDL) 
cholesterol [68]. In addition, LDL cholesterol and triglycerides levels are often 
increased, which again is related to a higher cardiovascular risk [69]. Due to the 
accumulation of different risk factors within one individual, the risk of developing 
macrovascular complications is substantially increased. It is, therefore, of great 
importance to define optimal treatment strategies for these patients to reduce their 
macrovascular risk as much as possible.  
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Figure 2. Locations of major diabetic
complications. Figure based on
http://www.eatlas.idf.org/webdata/img/diag_
complications.gif, accessed June 2006. 
1.2.3 The excess risk for macrovascular disease in patients with compared to 
patients without diabetes mellitus 
The annual risk for death from cardiovascular disease has been found to be two to 
three times higher for persons with DM than for persons without DM [70]. Evidence 
suggests that even in the absence of pre-existing vascular disease, middle-aged 
people with type 2 DM exhibit a similar risk of coronary heart disease to those without 
DM who have had a myocardial infarction [71]. In this context, DM has been described 
as an independent risk factor for cardiovascular disease in both men and women [72-
74]. In the Rancho Bernardo Study, women with DM had a probability to die from 
ischemic heart disease comparable to both men with and without DM, while women 
without DM had a considerably lower risk [75]. The inherent protection against 
developing cardiovascular disease seems, therefore, to be lost in women with DM [72-
74]. Moreover, it has recently been speculated that the presence of DM might be the 
clinical equivalent of aging 15 years, putting men and women with the disease into a 
high-risk category for cardiovascular disease while still in middle age [76]. 
 
Due to autonomic neuropathy myocardial ischemia commonly occurs without 
symptoms in patients with DM, diagnosis of cardiovascular disease may be delayed, 
often leading to more advanced multivessel atherosclerosis at presentation, and 
consequently to a delay of the introduction of treatment [77]. Therefore, patients with 
DM and cardiovascular disease have worse prognosis for survival than patients 
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without DM [78-80]. Reliable risk indicators could help to identify patients at risk of late 
complications as early as possible, thereby improving prognosis and quality of life in 
these individuals. Since it has been shown that specific risk indicators may influence 
cardiovascular risk differently in individuals with and without DM [81-84], it is of interest 
to compare different risk markers in individuals with different underlying cardiovascular 
risk as patients with and without DM. 
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1.3 Methods relevant to thesis  
 
1.3.1 Systematic review and meta-analysis 
Over the last decades, the volume of the health care literature has increased 
enormously. It has, therefore, become almost impossible for health professionals to 
keep up with all publications relevant to an area of practice. In addition to the large 
volume, research results are often contradictory, which creates difficulties in 
interpreting the findings and corresponding conclusions while reading up on a 
specific topic. In this context, systematic reviews have emerged as essential tools to 
fulfil the need for accurate accounts of past research. These reviews summarise 
results and knowledge of current studies in a single document. While traditional 
narrative reviews tend to be subjective and therefore prone to bias [85], systematic 
reviews render the review process transparent. As a consequence, conclusions are 
based on the examined literature and should be replicable. Chalmers and Altman 
defined a systematic review as a review that has been prepared using a systematic 
approach to minimising biases and random errors, which is documented in a 
materials and methods section [86]. Even when the research evidence is limited or 
nonexistent, these systematic reviews summarise current best evidence on a specific 
topic. Furthermore, they can also help to determine future research needs. 
 
A systematic review may, or may not, include a meta-analysis, which will be used to 
produce a single estimate of a treatment effect [87]. The distinction between 
systematic review and meta-analysis is made because it is always appropriate and 
desirable to systematically review a body of data, but it may sometimes be 
inappropriate, or even misleading, to statistically pool results from separate studies 
[87, 88]. The quality of the contributing studies has to be considered. If the material is 
flawed, the findings based on it will also be compromised [89]. Ideally the studies 
included in systematic reviews and meta-analyses should be of high methodological 
quality and free from bias to best guarantee that differences in outcomes observed 
between patient groups can be reliably attributed to the intervention under 
investigation [89]. Biases in trials can be observed in case of systematic differences 
in patients’ characteristics at baseline (selection bias), unequal provision of care 
apart from the treatment under evaluation (performance bias), biased assessment of 
outcomes (detection bias), and bias due to exclusion of patients after they have been 
allocated to treatment groups (attrition bias) [90, 91]. For example, it has been shown 
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that the treatment effect was exaggerated in studies where treatment allocation was 
not concealed compared to studies, which reported adequately concealed treatment 
allocation [92]. Quality assessment of trials included in a systematic review is often 
hampered by the low quality of reporting of the respective studies. Thanks to the 
adoption of reporting guidelines such as the CONSORT (Consolidated Standards of 
Reporting Trials) recommendations [93] by an increasing number of journals, the 
situation is improving [94].  
 
Another issue that has to be addressed when conducting a meta-analysis is the fact 
that the publication of research findings depends on the nature and direction of the 
results: statistically significant results, indicating that a treatment is beneficial, are 
more likely to be published [95-98], more likely to be published in English [99, 100], 
more likely to be published more than once, and more likely to be cited by others, 
than results showing no beneficial or even adverse effects of a treatment. It is also 
possible that outcomes are reported selectively, again depending on their properties 
and direction. Such reporting biases are listed in Table 6.  
 
Table 6. Reporting biases (adapted from Egger M et al. [89]) 
Type of reporting bias Definition 
Publication bias 
The publication or non-publication of research 
findings, depending on the nature and direction of 
the results 
Time lag bias 
The rapid or delayed publication of research 
findings, depending on the nature and direction of 
the results 
Multiple (duplicate) publication bias 
The multiple or singular publication of research 
findings, depending on the nature and direction of 
the results 
Citation bias 
The citation or non-citation of research findings, 
depending on the nature and direction of the 
results 
Language bias 
The publication of research findings in a particular 
language, depending on the nature and direction 
of the results 
Outcome reporting bias 
The selective reporting of some outcomes but not 
others, depending on the nature and direction of 
the results 
 
The combination of the results from different published trials may, therefore, lead to 
an exaggerated or even spurious beneficial effect of the treatment under 
investigation. This has been shown in trials on cancer chemotherapy, where pooled 
results of published studies were in favour of the treatment, in contrast to the findings 
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of an analysis based on the international trials registry [101, 102]. Nevertheless, it is 
debated if unpublished data should be included in systematic reviews and meta-
analyses since this could introduce bias itself due to several reasons. First, the trials 
that can be identified may not be a representative sample of all unpublished studies. 
Second, unpublished trials may be of lower methodological quality than published 
trials [103]. A third problem is that investigators of identified unpublished studies may 
not be willing to provide their data. Finally, some editors express their concern if data 
that has not been peer reviewed is included in a meta-analysis, although the 
refereeing process does not guarantee the validity of published data [103]. Graphical 
as well as statistical methods exist to examine the presence and the impact of 
potential publication bias on overall treatment effects. One approach is to perform a 
scatter plot, a so called funnel plot, with the treatment effect of the individual studies 
on the horizontal axis against some measure of study size on the vertical axis (e.g. 
standard error of the logarithm of the odds ratio or relative risk). Effect estimates from 
small studies will be scattered more widely at the bottom of the graph, with the 
spread narrowing of larger studies. In the absence of bias, the plot will resemble a 
symmetrical funnel.  
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Figure 3. Funnel plot of
placebo-controlled trials of
homoeopahty. The plot is
asymmetrical, suggesting
the presence of publication
bias The solid line indicates
the null effect (adapted from
Egger M et al. [103]) 
An asymmetrical funnel plot may indicate publication bias. However, it can appear 
asymmetrically also for other reasons: In cases of true heterogeneity between the 
studies (e.g. intensity of intervention, differences in underlying risk), or of poor 
methodology of small studies leading to greater effect in these studies, graphs will 
also be asymmetrical. Furthermore, the symmetry may also depend on the choice of 
the effect measure (e.g. odds ratio versus risk ratio), on the choice of the 
measurements for the axis, or on chance. Therefore, the funnel plot should be seen 
as a means of examining differences in the results of smaller and larger trials rather 
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than a tool to determine specific types of bias. Together with the funnel plot, Egger's 
linear regression test [104] and Begg's rank correlation test [105] provide statistical 
tools to assess for potential bias in a meta-analysis. However, the power of all tests is 
limited, in particular, if the number of studies included in the meta-analysis is small. 
 
Meta-analysis of randomised controlled trials is based on the assumption that each 
trial provides an unbiased estimate of the effect of the treatment under investigation, 
with the variability between the studies being attributed to random variation [89]. The 
combined overall effect of carefully identified representative studies will then provide 
an unbiased estimate of the treatment effect by increasing its precision. This is 
illustrated for example in trials of the effect of beta-blockers (Figure 4): the forest plot 
shows quite homogeneous results for all component trials with overlapping 
confidence intervals. 
Relative risk
(95% confidence interval)
0.1 0.2 0.5 1 2 5 10
Trial (Year) % WeightRelative risk
(95% CI)
0.89 (0.58,1.37)Baber (1967) 2.8
1.03 (0.22,4.77)Reynolds (1972) 0.2
0.51 (0.21,1.21)Wilhelmsson (1974) 1.0
0.61 (0.22,1.68)Ahlmark (1974) 0.7
0.80 (0.62,1.02)Multicentre International (1975) 9.5
1.00 (0.07,14.05)Yusuf (1979) 0.1
1.00 (0.74,1.36)Andersen (1979) 4.6
0.59 (0.18,1.97)Rehnqvist (1980) 0.5
1.07 (0.64,1.77)Baber (1980) 2.0
0.87 (0.48,1.61)Wilcox Atenolol (1980) 1.4
1.02 (0.56,1.83)Wilcox Propanolol (1980) 1.4
0.64 (0.44,0.95)Hjalmarson (1981) 4.6
0.64 (0.51,0.81)Norwegian Multicentre (1981) 11.4
0.69 (0.42,1.11)Hansteen (1982) 2.7
0.82 (0.58,1.17)Julian (1982) 4.7
0.74 (0.60,0.91)BHAT (1982) 14.0
0.93 (0.65,1.34)Taylor (1982) 4.1
0.58 (0.26,1.28)Manger Cats (1983) 1.2
0.77 (0.48,1.24)Rehnqvist (1983) 2.4
0.97 (0.67,1.40)Australian-Swedish (1983) 3.5
0.46 (0.17,1.29)Mazur (1984) 0.8
1.31 (0.90,1.92)EIS (1984) 3.3
0.79 (0.55,1.13)Salathia (1985) 4.2
0.56 (0.23,1.36)Roque (1987) 0.9
0.93 (0.70,1.23)LIT (1987) 6.9
1.00 (0.22,4.49)Kaul (1988) 0.2
0.52 (0.30,0.91)APSI (1990) 2.5
0.55 (0.30,1.02)Schwartz low risk (1992) 2.0
0.19 (0.05,0.83)Schwartz high risk (1992) 0.8
1.79 (0.83,3.86)SSSD (1993) 0.7
3.13 (0.35,27.96)Darasz (1995) 0.1
0.63 (0.11,3.67)Basu (1997) 0.2
0.73 (0.58,0.93)Aronow (1997) 4.5
0.80 (0.74,0.86)Overall (95% CI)
 
Figure 4. Forest plot of
controlled trials of beta-
blockers in secondary
prevention of mortality after
myocardial infarction. The
centre of the square and
the horizontal line
correspond to the relative
risk (RR) and 95%
confidence intervals for
each trial. The area of the
square is proportional to the
weight of the trial in the
meta-analysis. The
diamond at the bottom
represents the combined
estimate and its 95%
confidence interval. The
solid vertical line indicates
no effect of treatment
(RR=1.0), the dotted line
the combined effect
(RR=0.8) (adapted from
Egger M et al. [89])
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In other situations results of individual trials may be heterogenous, which precludes 
meaningful meta-analysis of the data. For example, as shown in Figure 5, trials of the 
efficacy of BCG vaccination to prevent tuberculosis revealed fairly heterogeneous 
results with non compatible confidence intervals for all trials.  
Trial     (Latitude)
Madanapalle (13)
Madras (13)
Puerto Rico     (18)
Haiti (18)
South Africa    (27)
Georgia (33)
Georgia   (33)
Chicago  (42)
Chicago (42)
Northern USA  (52)
Northern USA  (52)
UK (53)
Canada (55)
Relative risk
0.1 1 10
Risk ratio (95% CI)
0.80 (0.52,1.25)
1.01 (0.89,1.14)
0.71 (0.57,0.89)
0.20 (0.08,0.50)
0.63 (0.39,1.00)
1.56 (0.37,6.53)
0.98 (0.58,1.66)
0.26 (0.07,0.92)
0.25 (0.15,0.43)
0.46 (0.39,0.54)
0.41 (0.13,1.26)
0.24 (0.18,0.31)
0.20 (0.09,0.49)
 
Figure 5. Forest plot of trials of BCG
vaccine to prevent tuberculosis.
Trials are ordered according to the
latitude of the study location,
expressed as degrees from the
equator. No meta-analysis is shown
(adapted from Egger M et al. [89]) 
Combining these study results would lead to a misleading overall finding of vaccine 
efficacy. In this situation, it is of interest why results differ. In the BCG example it can 
be shown that BCG vaccination appears to be effective at higher latitudes but not in 
warmer regions (possibly because exposure to certain environmental mycobacteria 
acts as a 'natural' BCG inoculation in warmer regions).  
 
1.3.1.1 Statistical methods used in meta-analysis 
Meta-analysis has been defined by Huque as a statistical analysis which combines 
the results of several independent studies considered by the analyst to be 
' combinable' [106].  
 
In situations where study results of the contributing trials are in agreement, a so-
called fixed effects model will be used to combine the results of the different studies. 
It is thereby assumed that the observed variation in treatment effects is entirely due 
to sampling variation, and that the underlying true treatment effect is the same in all 
the studies [107].  
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The summary estimate of the treatment effect is calculated as a weighted average of 
the logarithm of the risk ratio or odds ratio or incidence rate ratio, etc:  
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There are several methods to define the weight of the individual studies. In the 
inverse variance method, the weight wi for study i equals the inverse of the variance, 
vi, of the estimated logarithm of the risk ratio in that study. 
Inverse variance weights:  
i
i
v
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d1: Number of patients with outcome in intervention arm 
d0: Number of patients with outcome in control arm 
h1: Number of patients without outcome in intervention arm 
h0: Number of patients without outcome in control arm 
where 
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An alternative approach is to use Mantel-Haenszel weights to combine the results of 
the individual studies.  
 
i
i
n
hdw 10=  
This method is preferable when data are sparse; in other situations Mantel-Haenszel 
methods give similar results to the inverse-variance weighting method. 
 
In case of evidence of heterogeneity between studies, it is possible to calculate a 
summary estimate allowing for the heterogeneity by using a so-called random effects 
model. This can be seen as a last resort when heterogeneity cannot be explained. 
With this approach it is assumed that the true effect in each study derives from a 
normal distribution, whose mean equals the true overall effect and whose variance is 
usually denoted by τ2.  
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This between-study variance is estimated from the observed data and is used in 
calculation of the weights and thus in the calculation of the random effects summary 
estimate: 
 
∑
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d1: Number of patients with outcome in intervention arm 
d0: Number of patients with outcome in control arm 
h1: Number of patients without outcome in intervention arm 
h0: Number of patients without outcome in control arm 
 
The commonly used method for calculating the between-study variance τ2 was 
suggested by DerSimonian and Laird in 1986 [108]. Random effects weights are 
smaller and more similar across studies than their fixed effects counterparts. In a 
random effects meta-analysis smaller studies receive greater relative weight. The 
summary estimate will, therefore, be influenced by smaller studies more than in a 
fixed effects model. In addition, random effects model will reveal wider confidence 
intervals and a larger p-value. However, if heterogeneity of identified studies is 
present, it needs careful reflection whether a meta-analysis is appropriate at all. In 
case of apparent heterogeneity as illustrated in the example of BCG vaccination 
(Figure 5), stratifying of studies with similar inclusion criteria or other subgroup 
analyses might be more appropriate.  
 
The investigation of sources of heterogeneity (such as study latitude in the BCG 
example) may yield important insights. To examine whether a particular characteristic 
of the trial or the study population (covariate), is related to the extent of the treatment 
effect, can be explored in so-called meta-regression models [109]. In this approach, it 
is postulated that the treatment effect is related in a linear manner to one or more 
study-level covariates. There are several statistical models to investigate such a 
relationship. A commonly used form uses assumptions as in the random effects 
model for meta-analysis – i.e. the observed treatment effects are normally distributed. 
The analysis is then based on a weighted regression model of the individual study 
estimates using the weights as described for the random effects meta-analysis. 
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The reporting of systematic reviews and meta-analyses is based on 
recommendations referred to as the Quality Of Reporting Of Meta-Analyses 
(QUOROM) statement [110]. The QUOROM statement consists of a checklist with 18 
items referring primarily to the abstract, introduction, methods and results section of a 
report, pointing out the information that should be provided by the authors. 
Furthermore, the inclusion of a flow diagram showing details of the process of 
identifying potentially relevant trials and selecting eligible trials is also recommended. 
 
 
1.3.2 Survival analysis 
The time to an event of interest is one of the common major outcomes in clinical trials 
and cohort studies. This is also known as ‛survival time‛ and indicates the time period 
from a well defined starting point, for example time of diagnosis of the disease or time 
of first clinical examination to the event of interest, for example death. In a time to 
event analysis information on the probability of survival following the predefined 
starting point is provided and also on the prognosis according to patient 
characteristics (sex, age, etc), disease characteristics (site, histology, etc) and 
methods of treatment. At the end of follow up not all individuals usually have had the 
event of interest, and thus their true time to event is unknown. Either a patient has 
not yet experienced the event of interest by the time of the close of the study or a 
patient is lost to follow up during the study period, or, a patient experiences a 
different event that makes further follow up impossible. In these situations the 
observation time is censored. Such censored survival times may underestimate the 
true (but unknown) time to event. Therefore, special methods of analysis are needed, 
including standard graphical methods of data exploration and presentation.  
 
In general, survival data can be described and modelled in terms of two related 
functions, the survival and hazard functions, respectively. The survival probability 
(survival function) S(t) is the probability that an individual survives from the time origin 
to a specified future time t. These values provide direct information on the survival 
experience of a study cohort. In contrast, the hazard function, usually denoted as h(t) 
or λ(t), specifies the instantaneous rate at which failures occur for individuals that are 
surviving at time t [111]. There are several possibilities to estimate the survival and 
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hazard function differing in the respective assumptions of each method. The 
calculations used in the present thesis are described in more detail as follows: 
 
1.3.2.1 Kaplan-Meier survival estimate 
In cases where the exact follow up time for each individual is known, survival 
probability can be estimated nonparametrically according to Kaplan-Meier [112]. The 
follow up times of all observations are arranged in increasing order of magnitude and 
time intervals are determined by the occurrences of the outcome of interest, as and 
when they occur. As events are assumed to occur independently of one another, the 
probabilities of surviving from one interval to the next may be multiplied together to 
give the cumulative survival probability. Therefore, the probability of being alive at 
time tj, S(tj), is calculated from S(tj-1) the probability of being alive at tj-1, nj the number 
of patients alive before tj, and dj the number of events at tj, as follows: 
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The value of S(tj) is constant between time of events, and, the estimated probability 
changes value only at the time of each event. The Kaplan-Meier survival curve, a plot 
of the Kaplan Meier survival probability against time, provides a useful summary of 
the data that can be used to estimate measures such as median survival time.  
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Figure 6 is based on data of the Swiss Cohort of the WHO Multinational Study of 
Vascular Disease in Diabetes and shows the survival probability at any given time 
point during the study follow up for the individuals under observation. 
 
Kaplan-Meier survival estimate 
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 Figure 6. Example for Kaplan-
Meier survival estimate, based on 
data of the Swiss Cohort of the 
WHO Multinational Study of 
Vascular Disease in Diabetes, 
showing survival probabilities for 
all subjects included in the cohort. 
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1.3.2.2 Nonparametric test comparing survival 
Using a nonparametric test, survival rates in different groups can be compared. The 
most widely used method is the log rank test [113]. Groups may be defined for 
example by treatment or by demographic or prognostic criteria. For each group the 
number of events is calculated that would be expected if there were no differences 
between the groups. The number of observed events, O, in group i is then compared 
to the expected number, E, by calculating the test statistic 
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This value is compared to a χ2 distribution with (g-1) degrees of freedom, where g is 
the number of groups, and a p-value can be computed to calculate the statistical 
significance of the difference between the survival curves of different groups. When 
two groups are compared, the null hypothesis that the ratio of the hazard rates in the 
two groups equals to 1, is examined using the log rank test. In practise, it is often 
more powerful to estimate hazard ratios by multivariable regression modelling since 
several factors influencing survival can be taken into account in such models. 
 
1.3.2.3 Survival analysis adjusting for covariates 
Adjusting for subject-related factors (covariates or confounders) potentially affecting 
the survival time (i.e. age, gender) in time to event analyses, is performed by
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multivariate modelling, using multiple regression. The Cox proportional hazard model 
is the most common multivariate approach. The relation between the event 
incidence, expressed by the hazard function and a set of covariates, is described as 
follows:  
 
{ }ppo xbxbxbthth +++×= K2211exp)()(  
h(t), hazard function; h0(t), baseline hazard (hazard if all covariates equal to zero, may vary with time t); x, 
covariate; b, regression parameter of the respective covariate; p, number of covariates 
 
It is essentially a multiple linear regression of the logarithm of the hazard on all the 
included variables with the baseline hazard being an ‛intercept‛ term that varies with 
time. The baseline hazard is estimated nonparametrically. Consequently, survival 
times in Cox regression models are not assumed to follow a particular statistical 
distribution.  
 
As a key assumption of the Cox proportional model, the hazard of the event in any 
group is assumed to be a constant multiple of the hazard in any other. Therefore, 
plots of the hazard function should be proportional and curves should not cross. In 
contrast to the Cox model where no parametric assumptions are made for the 
distribution of the hazard, in parametric proportional models, the hazard is assumed 
to follow a specific statistical distribution. However, hazard ratios have the same 
interpretation, whether derived from a Cox model or a fully parametric regression 
model, and the proportionality of hazards is often assumed. Models commonly 
applied use the exponential, Weibull or Gompertz distribution. They take their names 
from the distribution that the survival times are assumed to follow, but the most 
distinguishing features between them are the hazard function. Although both, the Cox 
model and the parametric models, reveal comparable hazard ratios, the parametric 
approach allows for the calculation of predictions. 
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1.4 Aim of the thesis 
The aim of this thesis was to critically synthesise the current knowledge in important 
clinical research areas focussing on prevention and reduction of macrovascular 
disease and consequently of mortality in patients with DM. For this purpose, five 
different studies were performed (Studies A-E).  
 
According to the methodology, the studies can be grouped into two parts: Studies A-
C include a systematic review and meta-analysis, focussing on treatment strategies 
in patients with type 1 and type 2 DM, and in comparison to individuals without DM:  
 
• Study A investigated the effect of improved glycaemic control on 
macrovascular complications in type 1 and type 2 DM.  
 
• Study B examined the efficacy of fibrates on coronary heart disease in 
patients with type 2 DM.  
 
• Study C analysed the impact of two currently available coronary drug eluting 
stents on cardiovascular complications in individuals with compared to 
individuals without DM. 
 
The second part of this thesis (Studies D and E) dealt with the definition of novel 
mortality risk indicators in patients with type 1 and type 2 DM using survival analyses. 
Both studies, Studies D and E, were based on data of the 'Swiss Cohort of the WHO 
Multinational Study of Vascular Disease in Diabetes'. 
 
• Study D evaluated the prognostic value of the QT-interval corrected for heart 
rate (QTc) and of resting heart rate (rHR) on mortality in type 1 and type 2 DM. 
 
• In Study E, the impact of apolipoprotein B on mortality was assessed in type 1 
DM. 
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1.4.1     Brief summary of studies 
 
1.4.1.1 Study A: Glycaemic control and macrovascular disease in type 1 and 
type 2 diabetes mellitus: Meta-analysis of randomised controlled trials 
Main causes of mortality in type 1 and type 2 DM are related to macrovascular 
disease. Although a beneficial effect of optimal glycaemic control has been 
documented in several randomised trials for microvascular complications, the impact 
on macrovascular disease is still uncertain. The aim of this project was to assess the 
effect of improved glycaemic control on cardiac, cerebrovascular and peripheral 
vascular complications. Analyses revealed a 62% reduction in the incidence of any 
macrovascular event (95% CI 44-74%) in type 1 and a 19% reduction (9-27%) in type 
2 DM for treatment with improved glycaemic control. In type 1 DM, the effect was 
mainly based on reduction of cardiac and peripheral vascular events, whereas in type 
2 DM it was related to reduced rates of stroke and peripheral vascular events. Effects 
appeared to be particularly important in younger patients with shorter duration of 
diabetes. 
 
1.4.1.2 Study B: Fibrates in the prevention of cardiovascular disease in 
patients with type 2 diabetes mellitus: Meta-analysis of randomised 
trials 
Fibrates are well-known agonists of the peroxisome proliferator-activated receptor 
alpha (PPARα), which is mainly expressed in liver, heart and skeletal muscle. Based 
on their mechanism of action, they have been shown to reduce triglyceride levels and 
increase HDL cholesterol, which is of particular interest for treatment of the 
characteristic dyslipidaemia of insulin resistance (increased concentrations of 
triglycerides and small dense low density lipoproteins, decreased levels of HDL 
cholesterol). In contrast to the documented lipid-lowering effect, there is still 
uncertainty about the role of fibrates in the prevention of cardiovascular disease. In 
this systematic review and meta-analysis the effectiveness of PPARα-agonists in the 
prevention of cardiovascular disease was examined. Results showed a 16% 
reduction (95% CI 4-26%) in the risk for coronary events in patients with type 2 DM 
when treated with fibrates compared to placebo. Benefits were even larger when 
analyses were restricted to trials that were not confounded by unequal provision of 
additional lipid-lowering therapy. 
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1.4.1.3 Study C: Efficacy of drug eluting stents in patients with and without 
diabetes mellitus: indirect comparison of controlled trials 
At the time of planning this study, two drug eluting stents have been approved by the 
Food and Drug Administration (FDA) for the treatment of coronary heart disease, a 
sirolimus and a paclitaxel eluting stent. Both have shown to effectively reduce the 
number of repeated revascularisations compared to uncoated bare metal stents. 
There is some evidence that sirolimus is superior to paclitaxel in reducing restenosis 
rates. However, results from head-to-head trials are conflicting. Open questions 
remain regarding the clinical benefits across patient groups with different underlying 
cardiovascular risk. Patients with DM tend to present with more advanced coronary 
artery disease, and outcomes after percutaneous intervention tend to be poorer than 
for patients without DM. The objective of this project was to indirectly compare the 
effects of polymer based sirolimus versus paclitaxel eluting stents, and to examine 
whether they are equally effective in the prevention of restenosis in patients with and 
without DM. Indirect comparisons were performed by calculating the ratio of the 
incidence rate ratios of the direct comparisons (sirolimus versus bare metal stents / 
paclitaxel versus bare metal stents) using meta-regression modelling. In patients 
without DM sirolimus eluting stents were superior to paclitaxel eluting stents with 
respect to in-stent- and in-segment restenosis, target lesion revascularisation, and 
major adverse cardiac events. In patients with DM the two drug eluting stents did not 
differ significantly in any of these end points. Meta-regression analysis confirmed a 
difference between patients with and without DM (tests for interaction for in-stent and 
insegment restenosis, p = 0.036 and p = 0.016). 
 
1.4.1.4 Study D: QTc interval and resting heart rate as long term predictors of 
mortality in type 1 and type 2 diabetes mellitus: a 23-year follow up 
In an effort to identify easily available and reliable predictors for cardiovascular risk 
and mortality in DM, the evaluation of parameters reflecting myocardial ventricular 
repolarisation has been of particular interest. In type 1 DM prolongation of the QT 
interval corrected for heart rate (QTc) and heart rate variability have both been shown 
to be associated with increased risk of arrhythmia and death, whereas QT dispersion 
has been suggested to be less reliable. The association between QTc and 
cardiovascular mortality in type 2 DM, however, is controversial: There have been 
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reports suggesting that QTc is associated with increased cardiovascular mortality risk. 
Other studies have indicated that QT dispersion might more accurately predict 
cardiovascular mortality in this patient group. Based on data of the 'Swiss Cohort of 
the WHO Multinational Study of Vascular Disease in Diabetes', the long-term 
association of QTc and resting Heart Rate (rHR) with mortality was evaluated in 
patients with type 1 and type 2 DM. Analyses showed that QTc was associated with 
long-term mortality in patients with type 1 DM, whereas rHR was related to increased 
mortality risk in patients with type 2 DM. 
 
1.4.1.5 Study E: Apolipoprotein B as a long term predictor of mortality in type 
1 diabetes mellitus: a 15-year follow up 
Apolipoprotein B (apo B) is an easily measurable clinical parameter and has been 
shown to be a valuable marker of cardiovascular risk in several prospective or cross-
sectional clinical trials and a recent meta-analysis. However, these studies were 
either performed in a general population or in patients with type 2 DM. Data on the 
association of apo B with cardiovascular risk in type 1 diabetes is scarce, only one 
trial prospectively assessed its relationship. The aim of this project was to evaluate 
the long term association of apo B with mortality risk in patients with type 1 DM based 
on a 15-year follow up of the 'Swiss Cohort of the WHO Multinational Study of 
Vascular Disease in Diabetes'. Compared to Study D, follow up for this study was 
shorter due to the fact that measurement of apo B was available only later in the 
course of the study. Apo B was positively related to all cause and cardiac mortality as 
well as to mortality due to ischemic heart disease. An apo B >0.96 g L-1 translated 
into a duplication of overall mortality hazard and a sevenfold increase of mortality 
because of cardiac disease or IHD. 
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2 Systematic reviews and meta-analyses on the 
effectiveness of specific treatment forms on 
macrovascular complications 
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Methods We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions
to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate
ratios for any macrovascular event, cardiac events, stroke, and peripheral arterial disease, and the number needed to treat
intensively during 10 years to prevent one macrovascular event.
Results The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134
macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of
follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 macrovascular events, 1197 cardiac events,
87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any
macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was
mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and
peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes.
Conclusions Our data suggest that attempts to improve glycemic control reduce the incidence of macrovascular events
both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of
macrovascular disease differ. (Am Heart J 2006;152:27-38.)There is uncertainty about the place of improved
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doi:10.1016/j.ahj.2005.09.015The beneficial effects of improved glycemic control
on microvascular complications, including retinopathy,
nephropathy, and neuropathy, have been documented
in several randomized studies published during the last
20 years. In patients with type 1 DM, this was conclu-
sively shown by DCCT5 and, in patients with type 2 DM,
by UKPDS.6 Although these and other studies5,7-13
prospectively recorded the occurrence of macrovascular
complications, they did not conclusively answer the
question whether improved glycemic control effectively
reduces macrovascular complications. By pooling data
from several studies, meta-analysis of the existing data
could clarify this issue.14 In collaboration with the
original investigators who provided additional informa-
tion on macrovascular outcomes, we did a comprehen-
sive systematic review and meta-analysis of all randomized
controlled trials in patients with type 1 and type 2 DM.
Methods
Literature search and eligibility criteria
We aimed to identify all randomized controlled comparisons
of improved glycemic control that assessed macrovascular
disease in types 1 and 2 DM. Using Cochrane methodology,15
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28 Stettler et alwe searched MEDLINE, EMBASE, and the Cochrane Con-
trolled Trials Register for relevant studies. We considered
studies in any language. Electronic searches were supple-
mented by hand-searching of reference lists, reviews, relevant
book chapters, conference abstracts, and specialist journals.
We evaluated each study for inclusion in the meta-analysis on
the basis of 6 criteria: (1) study design (randomized controlled
trial), (2) target population (general population of patients
with either type 1 or type 2 DM), (3) comparison of regimens
aiming to improve glycemic control (subcutaneous insulin
injections, insulin pump, oral antidiabetic agents, or a
combination of the previous) with conventional treatments,
(4) documentation of glycemic control by measurement of
glycated hemoglobin (HbA1c), (5) follow-up of at least 2 years,
and (6) prospective recording of macrovascular events.
Two reviewers (CS, SA) independently assessed publications
for eligibility, with discrepancies being resolved in consulta-
tion with a third reviewer (PD).
Data extraction and outcome measures
Data on the characteristics of studies, patient populations,
and interventions were extracted independently by 2 inves-
tigators (CS and SA), with disagreements resolved by a third
reviewer (PD). This included the extraction of data on the
distribution of cardiac risk factors at study end (blood
pressure, lipid factors, body mass index, and smoking). All
relevant publications from a study were considered, includ-
ing, for example, early publications describing the study
design. Authors from all studies were sent a standardized data
extraction form and were asked to check the information
extracted from published articles and, where necessary, to
provide additional clinical and biochemical data. We defined
macrovascular end points as (1) cardiac events, including fatal
and nonfatal myocardial infarction (defined as evidence of
acute myocardial infarction confirmed by electrocardiogram
[ECG] and/or serum enzymes, confirmed nonacute myocardial
infarction based on serial reading of baseline and biennial
ECG and/or serum enzymes), any type of bypass graft and
percutaneous transluminal angioplasty, angina pectoris (de-
fined as evidence of ischemic heart disease confirmed by a
new ECG abnormality or an ECG that becomes abnormal on
exercise), congestive heart failure (based on clinical criteria,
eg, Kerley’s B lines, rales, raised jugular venous pressure, or
third heart sound), and death due to cardiac disease or
sudden death; (2) stroke (fatal and nonfatal, thrombotic or
hemorrhagic); and (3) peripheral vascular disease, including
intermittent claudication (defined as pain in leg(s) occurring
with exercise, no pain at rest, no tissue necrosis, clinical
impression combined with objective evidence [measurement
of ankle blood pressure, examination of pulse rates, Doppler,
angiography]), diabetes-related amputation of lower extremity,
any type of peripheral artery bypass or angioplasty, and death
due to peripheral arterial disease. The incidence of fatal or
nonfatal macrovascular events of any type was the primary
end point. Secondary outcomes included fatal or nonfatal
cardiac events, stroke, peripheral arterial disease, and macro-
vascular deaths.
Assessment of methodological quality
Two of us (CS and SA) independently assessed the adequacy
of the concealment of allocation of patients to treatmentgroups, blinding of care providers and research staff ascer-
taining macrovascular outcomes, and the proportion of
randomized patients included in analyses.16 Disagreements
were resolved in discussion with a third reviewer (PJ).
Statistical analysis
We calculated the incidence of macrovascular events sepa-
rately for each treatment group by dividing the number of events
by the number of person-years of follow-up. For each compar-
ison and end point, the incidence rate ratio (IRR) was obtained
by dividing the incidence in the intensified treatment group by
the incidence in the control group. Comparisons with no
outcome events in either group were excluded from the
respective analysis. Comparisons with events only in one group
were analyzed by adding one half to all cells. We combined IRRs
in fixed-effects meta-analysis, assuming that the observed
variation in treatment effects in the different studies is entirely
due to sampling variation and that the underlying treatment
effect is the same in all study populations. The weight for each
study was calculated by using the inverse of the variance of the
estimated log IRR in the corresponding study (inverse variance
weighting). In addition, we calculated the I2 statistic, which
describes the percentage of total variation across studies that is
due to heterogeneity rather than chance: I2 = 100% (Q  df)/
Q, where Q is the Cochran heterogeneity statistic and df is the
degrees of freedom.17 Mild heterogeneity will account for b30%
of the variation, and pronounced heterogeneity will account
for substantially N50%. The number of patients that need to be
treated intensively to prevent one macrovascular event18 was
calculated by applying the combined IRRs to incidence rates
typical for conventionally treated patients. In sensitivity
analyses, we repeated calculations using random-effects models
(attributing increased weight to smaller comparisons) and did
tests of funnel plot asymmetry to assess for publication bias.19,20
The extent to which the effect of improved glycemic control
was modified by study-level variables was explored in univari-
able metaregression models.21 The following variables were
considered: reduction of HbA1c achieved with intensified
treatment, duration of DM, mean age at baseline, proportion
women, year of study begin, year of study reporting, and study
quality (concealment of allocation, blinding, and the proportion
of randomized patients included in analyses). Finally, we
repeated analyses excluding one study22 where the prevalence
of smoking was substantially higher in the intensive treatment
group. Results are presented as IRRs with 95% CIs and numbers
needed to treat (NNTs) to prevent one macrovascular event. All
analyses were performed using Stata version 8.2 (Stata Corpo-
ration, College Station, TX).Results
Identification of eligible studies and comparisons
We screened 1438 reports and excluded 1313. The
remaining 125 reports, which reported on 14 different
studies, were retrieved for detailed evaluation. Ten
studies that included 14 randomized comparisons of
intensified and conventional treatment were included
(Figure 1). Eight comparisons had been performed in
patients with type 1 DM5,7,8,10 - 12 and 6 in patients
with type 2 DM.6,9,22,23 The DCCT in patients with
Figure 1
Identification of eligible randomized controlled trials. RCTs, Ran-
domized controlled trials.
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type 2 DM9 included 2 parallel comparisons in patients
with and without diabetic complications (secondary
and primary prevention arms). The UKPDS contributed
3 comparisons: (1) comparison of an intensified
regimen based on sulfonylurea or insulin with con-
ventional treatment in nonoverweight patients
(bUKPDS 1Q in this article); (2) comparison of an
intensified regimen based primarily on sulfonylurea or
insulin with conventional treatment in overweight
patients (N120% of ideal body weight, bUKPDS 2Q); and
(3) comparison of intensified metformin-based regimen
with conventional treatment in overweight patients
(bUKPDS 3Q ). There was overlap in groups receiving
conventional treatment in UKPDS 2 and 3; this wastaken into account in the meta-analysis by reducing
the weight of the respective groups.
Characteristics of trials, patients, and interventions
Nine comparisons were performed in
Europe,6-8,10-12,23 3 in North America,5,22 and 2 in Asia.9
Mean follow-up ranged from 2.0 to 8.0 years in patients
with type 1 DM and from 2.3 to 10.7 years in type 2
DM. Appropriate methods of allocation concealment
were described for 8 comparisons.5,8,11,12,24 For
7 comparisons, the degree of blinding of outcome
assessors remained unclear.7-10,12 Eleven comparisons
had been analyzed according to the intention-to-treat
principle.5-7,9,12,22,23 In the remaining 3, the proportion
of patients excluded from the analysis ranged from
5.4% to 13.6%.
The 14 randomized comparisons included a total of
6272 patients, 1800 patients with type 1 DM (11293
person-years of follow-up) and 4472 patients with type
2 DM (43607 person-years of follow-up). Study pop-
ulations were heterogeneous, both in type 1 and type 2
DM, with a range of mean ages and durations of DM at
baseline (Table I). In type 1 DM, intensified treatment
typically consisted of multiple injection therapy or
continuous subcutaneous insulin infusion using a
pump, with intensive self-monitoring of blood glucose.
Conventional treatment was based on 1 to 3 injections,
with or without occasional blood glucose monitoring.
In type 2 DM, attempts to improve glycemic control
consisted of subcutaneous insulin injections or hypo-
glycemic agents combined with insulin injections,
generally with blood glucose monitoring, whereas for
conventional treatment, the number of insulin injec-
tions was either reduced or treatment was with
hypoglycemic agents or diet alone, with less intensive
blood glucose monitoring. Mean baseline HbA1c ranged
from 8.8% to 11.8% in patients with type 1 DM and
from 7.0% to 9.5% in type 2 DM (Table II). At the
conclusion of studies, differences in HbA1c between
intensified and conventional treatment groups ranged
from 0.5% to 1.9% in type 1 and from 0.3% to
2.2% in type 2 DM. The prevalence of cardiac risk
factors was similar between treatment groups
(Table III), with one exception: in the Veterans Affairs
study,22 smoking was more prevalent in the intensive
group, 23% versus 13% at baseline and 21% versus 8%
at study end.
Macrovascular events and mortality
Additional outcome data were obtained for 12
comparisons.5-10,12,22,23 A total of 134 macrovascular
events of any type were recorded in type 1 DM and
1587 events in type 2 DM. The number of events and
personyears of follow-up is shown in Table IV. The
results from fixed-effects meta-analyses are shown in
Figure 2 and Table V. Combined IRRs were 0.38
Table I. Baseline characteristics of randomized trials comparing intensified blood glucose control with conventional control in patients with
type 1 and type 2 DM
Study (year of
publication)
n (intensified/
conventional)
Female
(%)
Mean
age (y)
Mean
duration of
diabetes (y)
Mean
follow-up (y)
Intervention in
intensified
group
Intervention in
conventional
group
Type 1 DM
Holman et al
(1983)11
36/38 36 42.4 18.7 2.0 2 daily injections,
iSMBG
2 daily injections,
SMBG
Verrillo et al
(1988)10
22/22 45 37.5 20.0 5.0 3 daily injections,
iSMBG
1-2 daily injections,
SMBG
Lauritzen (1991)7 18/16 41 34.0 19.0 8.0 CSII, iSMBG 1-3 daily injections,
SMBG
Feldt-Rasmussen
et al(1992)7
18/17 43 30.5 15.0 5.0 CSII, iSMBG 2-3 daily injections,
SMBG
DCCT Primary
Prevention
(1993)5
348/378 49 26.5 2.6 6.5 CSII, MIT, iSMBG 1-2 daily injections,
SMBG
DCCT Secondary
Intervention
(1993)5
363/352 47 27.0 8.8 6.5 CSII, MIT, iSMBG 1-2 daily injections,
SMBG
SDIS (1993)8 48/54 47 30.9 17.0 7.5 MIT, iSMBG 2-3 daily injections,
SMBG
MCSG (1995)12 36/34 27 37.0 19.5 5.0* CSII, MIT, iSMBG 2 daily injections,
SMBG
Type 2 DM
Veterans Affairs
(1997)22
75/78 0 60.2 7.9 2.3 Stepwise regimen
(insulin, SU).
iSMBG
1-2 daily injections,
SMBG
UKPDS 1
(1998)6
1433/589 26 53.7 0 10.3 Stepwise regimen
beginning with SU
or insulin
(metformin, MIT if
needed), iSMBG
Stepwise regimen
beginning with diet
(SU, metformin,
insulin if needed),
SMBG
UKPDS 2
(1998)6
1296/549 53 52.7 0 9.7 Stepwise regimen
beginning with SU
or insulin
(metformin, MIT if
needed), iSMBG
Stepwise regimen
beginning with diet
(SU, metformin,
insulin if needed),
SMBG
UKPDS 3
(1998)23
342/411 54 52.9 0 10.7 Stepwise regimen
beginning with
metformin (SU,
MIT if needed),
iSMBG
Stepwise regimen
beginning with diet
(SU, metformin,
insulin if needed),
SMBG
Kumamoto
Primary
Prevention
(2000)9
28/27 49 48.0 6.6 8.0 MIT, iSMBG 1-2 daily injections,
SMBG
Kumamoto
Secondary
Intervention
(2000)9
27/28 53 51.0 10.6 8.0 MIT, iSMBG 1-2 daily injections,
SMBG
UKPDS 1, nonoverweight and sulfonylurea based; UKPDS 2, overweight and sulfonylurea based; UKPDS 3, overweight and metformin based. iSMBG, Intensive self-monitoring of
blood glucose; SMBG, self-monitoring of blood glucose; CSII, continuous subcutaneous insulin infusion; MIT, multiple insulin injection therapy; SU, sulfonylurea.
4Median.
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type 2 DM, indicating a substantial risk reduction in
type 1 DM and a smaller risk reduction in type 2 DM
(P b .001 for difference between the 2 diabetes types).
Thirteen comparisons contributed to the analysis of
cardiac events. Forty events were recorded in type 1and 1197 in type 2 DM. The combined IRRs were
0.41 (0.19 -0.87) and 0.91 (0.80-1.03) (P = .040 for
difference). The analysis of peripheral vascular events
was based on 10 comparisons. Eighty-eight events were
recorded in type 1 and 87 events in type 2 DM. The
combined IRRs in type 1 DM were 0.39 (0.25-0.62)
Table II. Glycated hemoglobin levels at baseline and differences between intensified and conventional treatment groups at study end
Study (year of publication)
HbA1c at baseline(%) HbA1c at study end(%)
Intensified Control Intensified Control Difference
Type 1 DM
Holman et al (1983)11 11.7 11.8 9.5 10.2 0.7
Verrillo et al (1988)10 10.8 11.1 7.9 8.7 0.8
Lauritzen (1991)7 9.6 8.8 7.6 8.1 0.5
Feldt-Rasmussen et al (1992)7 9.5 9.3 7.3 9.2 1.9
DCCT Primary Prevention (1993)5 8.8 8.8 7.1 9.0 1.9
DCCT Secondary Intervention (1993)5 9.0 8.9 7.1 9.0 1.9
SDIS (1993)8 9.5 9.4 7.1 8.5 1.4
MCSG (1995)12 10.3 9.8 8.9 9.8 0.9
Type 2 DM
Veterans Affairs (1997)22 9.3 9.5 7.1 9.2 2.1
UKPDS 1 (1998)6 7.1 7.0 7.5 8.3 0.8
UKPDS 2 (1998)6 7.1 7.2 8.0 8.3 0.3
UKPDS 3 (1998)23 7.2 7.0 8.0 8.3 0.3
Kumamoto Primary Prevention (2000)9 9.5 8.8 7.2 9.4 2.2
Kumamoto Secondary Intervention (2000)9 9.3 9.0 7.2 9.4 2.2
UKPDS 1, nonoverweight and sulfonylurea based; UKPDS 2, overweight and sulfonylurea based; UKPDS 3, overweight and metformin based.
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difference). Six strokes were observed in type 1 and 303
in type 2 DM. Combined IRRs were 0.34 (0.05-2.57) and
0.58 (0.46-0.74), respectively (P = .54 for difference).
Figure 3 summarizes effect estimates for any macro-
vascular event and for cardiac, peripheral vascular, and
stroke events by type of DM. In 3 studies7,10,11 (all in
patients with type 1 DM), no macrovascular deaths
occurred. Nine deaths occurred in type 1 DM and 441
in type 2 DM. Combined IRRs were comparable: 0.89
(0.27 to 2.98) and 0.88 (0.72 to 1.08) for type 1 and
2 DM, respectively.
Numbers needed to treat to prevent one
macrovascular event
The incidence of macrovascular events in conven-
tionally treated patients with type 1 DM ranged from
0.6 per 100 person-years in the MCSG trial12 to 4.7 in
the study of Feldt-Rasmussen et al.7 For calculation of
NNTs, we assumed a typical incidence of 1 per 100
person-years. In conventionally treated patients with
type 2 DM, incidences were more heterogeneous and
ranged from 1.3 per 100 person-years in the Kuma-
moto secondary intervention arm9 to 13.7 in the
Veterans Affairs study.22 We calculated NNTs assuming
typical incidences of 4 per 100 person-years (lower
risk) and 8 per 100 person-years (higher risk). Using
the IRRs from our meta-analysis (0.38 for type 1 DM
and 0.81 for type 2 DM), the numbers of patients that
need to receive intensified treatment for 10 years to
prevent one macrovascular event were 16 for type 1
DM, 14 for low-risk type 2 DM, and 7 for high-risk
type 2 DM.Sensitivity and metaregression analyses
Combined IRRs from random-effects models were
similar to those from the fixed-effects models. There
was little evidence of funnel plot asymmetry in both
types of DM (P N .3 for all end points). In type 1 DM,
the reduction in the risk for macrovascular events
associated with improved glycemic control was greater
in studies that achieved larger reductions in HbA1c
levels (P = .050). No such interaction was evident for
type 2 DM. In type 2 DM, the beneficial effect of
improved glycemic control decreased with longer
diabetes duration (P = .040). Similarly, older age of
study populations was associated with smaller effect
(P = .024). A comparable trend was found for type 1
DM, although it did not reach statistical significance.
There was little evidence for associations with the
proportion of women or dimensions of study quality
and the inclusion of the year of study begin or
reporting did not significantly influence the results.
Finally, when excluding the Veterans Affairs study,22
the IRR for macrovascular event of any type was 0.79
(95% CI 0.71-0.88).
Discussion
In this systematic review and meta-analysis, we found
that improved glycemic control translated into substantial
reductions in macrovascular risk in type 1 DM while
producing a smaller reduction in patients with type 2 DM.
In type 1 DM, important beneficial effects were evident
for cardiac and peripheral vascular events. In type 2 DM,
substantial effects were observed for peripheral vascular
disease and stroke, whereas cardiac events were not
Table III. Other cardiac risk factors at study end
Study
Systolic blood
pressure (mm Hg)
Diastolic blood
pressure (mm Hg)
Total cholesterol
(mmol/L)
HDL cholesterol
(mmol/L)
Int Conv Int Conv Int Conv Int Conv
Type 1 DM
Holman et al (1983)11 129 133 79 85 4.8 5.1 1.4 1.4
Verrillo et al (1988)10 142 140 96 94 na na na na
Lauritzen (1991)7 131 131 85 85 na na na na
Feldt-Rasmussen et al (1992)7 131 133 82 90 na na na na
DCCT Primary Prevention (1993)13 111 114 71 72 4.6 5.0 1.3 1.3
DCCT Secondary Intervention (1993)13 111 114 71 72 4.6 4.7 1.2 1.2
SDIS (1993)8 126 133 77 78 na na na na
MCSG (1995)12 130 127 79 73 na na na na
Type 2 DM
Veterans Affairs (1997)22 137 139 80 83 5.2 5.2 1.0 1.0
UKPDS 1 (1998)6 137 137 76 76 5.0 5.0 1.1 1.1
UKPDS 2 (1998)6 141 139 79 77 5.2 5.2 1.1 1.0
UKPDS 3 (1998)23 141 140 78 77 5.3 5.2 1.1 1.1
Kumamoto Primary Prevention (2000)9 126 120 69 68 5.3 5.3 1.3 1.3
Kumamoto Secondary Intervention (2000)9 132 139 72 75 5.3 5.3 1.3 1.3
UKPDS 1, nonoverweight and sulfonylurea based; UKPDS 2, overweight and sulfonylurea based; UKPDS 3, overweight and metformin based. HDL, High-density lipoprotein; LDL,
low-density lipoprotein; BMI, body mass index; Int, intensified treatment group; Conv, conventional treatment group; na, not applicable.
Table IV. Number of events and corresponding person - years
Study
Person-years Any macrovascular event
Intensified Conventional Intensified Conventional
Type 1 DM
Holman et al (1983)11 72 76 0 1
Verrillo et al (1988)10 110 110 4 3
Lauritzen (1991)7 144 128 1 0
Feldt-Rasmussen et al (1992)7 90 85 0 4
DCCT Primary Prevention (1993)13 2262 2457 12 38
DCCT Secondary Intervention (1993)13 2360 2288 15 46
SDIS (1993)8 360 405 3 6
MCSG (1995)12 178 168 0 1
Total 5576 5717 35 99
Type 2 DM
Veterans Affairs (1997)22 169 176 35 24
UKPDS 1 (1998)6 14760 6067 509 276
UKPDS 2 (1998)6 12571 3126 423 116
UKPDS 3 (1998)23 3659 2199 105 88
Kumamoto Primary Prevention (2000)9 224 216 0 4
Kumamoto Secondary Intervention (2000)9 216 224 4 3
Total 31599 12008 1076 511
UKPDS 1 and 2, in calculations, the number of events and the person-years in the placebo group were halved to prevent double counting. UKPDS 2 and 3, there was overlap in
groups receiving conventional treatment and this was taken into account in the meta-analysis by reducing the weight of the respective groups to prevent double counting. UKPDS 1,
nonoverweight and sulfonylurea based; UKPDS 2, overweight and sulfonylurea based; UKPDS 3, overweight and metformin based.
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32 Stettler et alfound to be reduced significantly. Of note, the number of
patients that need to be treated to prevent one macro-
vascular event (NNT) was lower for type 2 DM compared
with type 1 DM. This reflects a higher incidence ofmacrovascular events in patients with type 2 DM and
thereby a higher a priori risk. Interestingly, improved
glycemic control was particularly beneficial in younger
patients with shorter diabetes duration.
LDL cholesterol
(mmol/L)
Triglycerides
(mmol/L) BMI (kg/m2)
Percentage of
smokers (%)
Int Conv Int Conv Int Conv Int Conv
2.7 2.9 1.6 1.8 24.9 24.8 na na
na na na na na na na na
na na na na na na na na
na na na na na na na na
2.8 3.1 1.1 1.2 26.2 25.1 28 23
2.9 3.0 1.1 1.1 27.2 25.3 27 21
na na na na 23.9 23.3 na na
na na na na na na na na
3.4 3.3 2.0 2.0 31.9 32.7 21 8
3.2 3.2 1.6 1.5 26.0 25.4 29 36
3.4 3.4 2.0 2.0 33.0 32.4 30 25
3.4 3.4 2.2 2.0 31.7 32.2 27 27
na na 1.1 1.2 21.5 21.3 na na
na na 1.1 1.2 21.5 21.3 na na
Cardiac events Peripheral vascular events Cerebrovascular events
Intensified Conventional Intensified Conventional Intensified Conventional
0 1 0 0 0 0
2 0 1 2 1 1
1 0 0 0 0 0
0 0 0 0 0 4
1 11 11 27 0 0
3 12 12 34 0 0
3 5 0 0 0 0
0 1 0 0 0 0
10 30 24 64 1 5
26 18 4 4 5 2
401 184 17 12 91 80
327 87.5 20 10 76 18.5
84 64.5 8 9 13 14.5
0 1 0 1 0 2
3 1 1 1 0 1
841 356 50 37 185 118
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This is the first systematic review and meta-analysis
including all randomized controlled trials done in
patients with type 1 and type 2 DM. The effects ofimproved glycemic control could thus be compared
between the 2 types of DM within the same review
framework, using identical definitions and methodology.
Previous reviews were restricted to one type of DM and
Figure 2
Effect of intensified glycemic control on the risk for any type of macrovascular event in patients with type 1 and type 2 DM. Meta-analysis of
randomized controlled trials.
American Heart Journal
July 2006
34 Stettler et alnot directly comparable.25,26 Our study was based on a
comprehensive literature search. Original investigators
checked the extracted data and contributed additional
information. We acknowledge that the inclusion of large
studies as DCCT in type 1 DM and UKPDS in type 2 DM
could potentially have led to distortion of the results. As
a consequence, whenever a study included severalrandomized comparisons, we included them separately
to minimize individual weight and to maximize the
power to identify factors that may modify the effect of
improved glycemic control. For example, the separate
inclusion of the primary and secondary prevention
cohorts from the DCCT5 and Kumamoto9 studies meant
that the power to detect a possible interaction between
Table V. Incidence rate ratios (95% CI) for any macrovascular event and cardiac, peripheral vascular, and cerebrovascular events
Study Any macrovascular Cardiac Peripheral vascular Cerebrovascular
Type 1 DM
Holman et al (1983)11 0.35 (0.014-8.64) 0.35 (0.014-8.64) 0 events 0 events
Verrillo et al (1988)10 1.33 (0.30-5.96) 5.00 (0.24-104.15) 0.50 (0.05-5.51) 1.00 (0.06-15.99)
Lauritzen (1991)7 2.67 (0.11-65.46) 2.67 (0.11-65.64) 0 events 0 events
Feldt-Rasmussen et al (1992)7 0.10 (0.006-1.95) 0 events 0 events 0.10 (0.006-1.95)
DCCT Primary Prevention (1993)13 0.34 (0.18-0.66) 0.10 (0.013-0.76) 0.44 (0.22-0.89) 0 events
DCCT Secondary Intervention (1993)13 0.32 (0.18-0.57) 0.24 (0.07-0.86) 0.34 (0.18-0.66) 0 events
SDIS (1993)8 0.56 (0.14-2.25) 0.68 (0.16-2.82) 0.38 (0.02-9.21) 0 events
MCSG (1995)12 0.31 (0.013-7.72) 0.31 (0.013-7.72) 0 events 0 events
Combined IRR (fixed effect) 0.38 (0.26-0.56) 0.41 (0.19-0.87) 0.39 (0.25-0.62) 0.34 (0.05-2.57)
Heterogeneity (I2, test of heterogeneity) 0.0%, P = .579 13.6%, P = .326 0.0%, P = .957 16.9%, P = .273
Type 2 DM
Veterans Affairs (1997)22 1.52 (0.90-2.55) 1.50 (0.82-2.74) 1.04 (0.26-4.16) 2.60 (0.50-13.40)
UKPDS 1 (1998)6 0.76 (0.66-0.88) 0.90 (0.75-1.07) 0.58 (0.28-1.22) 0.47 (0.35-0.63)
UKPDS 2 (1998)6 0.91 (0.74-1.11) 0.93 (0.73-1.18) 0.50 (0.23-1.06) 1.02 (0.61-1.70)
UKPDS 3 (1998)23 0.72 (0.54-0.95) 0.78 (0.57-1.08) 0.60 (0.21-1.38) 0.54 (0.25-1.14)
Kumamoto Primary Prevention (2000)9 0.11 (0.006-1.99) 0.32 (0.013-7.89) 0.32 (0.013-7.89) 0.19 (0.009-4.02)
Kumamoto Secondary Intervention (2000)9 1.38 (0.31-6.18) 3.11 (0.32-29.91) 1.04 (0.06-16.58) 0.35 (0.014-8.49)
Combined IRR (fixed effect) 0.81 (0.73-0.91) 0.91 (0.80-1.03) 0.58 (0.38-0.89) 0.58 (0.46-0.74)
Heterogeneity (I2, test of heterogeneity) 52.8%, P = .060 2.0%, P = .404 0.0%, P = .948 52.8%, P = .060
UKPDS 1, nonoverweight and sulfonylurea based; UKPDS 2, overweight and (SU) based; UKPDS 3, overweight and metformin based.
Figure 3
Effect of intensified glycemic control on the risk for any type of macrovascular event and of cardiac, peripheral vascular, and cerebrovascular
events in patients with type 1 and type 2 DM. Combined estimates from meta-analyses of randomized controlled trials.
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control was enhanced. Random-effects model, attribut-
ing increased weight to smaller comparisons, revealed
very comparable IRRs.
Although our study represents the largest body of
evidence from randomized trials ever assembled toaddress this issue, the patients included in these trials
may not be representative of patients with DM at large.
Trials in type 1 DM enrolled young patients, most of
them in their twenties and thirties, who were at low risk
for macrovascular events. Trial participants with type 2
DM were also quite young, typically in their fifties.
American Heart Journal
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36 Stettler et alWomen were enrolled in all but one trial, but they
generally were in the minority. The exclusion of women
and older persons from trials has been documented
previously, for example, in trials of statins.27 It is difficult
to judge whether the risk reductions observed in this
meta-analysis are applicable to older patients and
patients with longer duration of DM. We found that
reductions in macrovascular risk tended to decrease
with increasing age and duration of DM, particularly in
type 2 DM, but in absolute terms, benefits may be as
great or greater because of the increased macrovascular
risk in the elderly. Finally, the duration of follow-up was
generally b10 years, which may be insufficient if
several years of treatment are required for effects to
materialize fully.
Relation to other studies
Epidemiological studies have shown that the degree of
blood glucose control achieved in patients with DM is
associated with cardiac risk. Indeed, a recent meta-
analysis of observational studies showed an increase in
cardiac risk with increasing levels of HbA1c both in
patients with type 1 and type 2 DM.28 Epidemiological
analyses of the UKPDS showed a close relationship
between HbA1c and macrovascular risk.
29 In type 1 DM,
the present analysis confirms an association of HbA1c
with macrovascular complications. Compared with a
previous meta-analysis in patients with type 1 DM,26 the
present analysis included a larger number of studies and
macrovascular events. In contrast to the aforementioned
reports, metaregression analysis did not reveal a signif-
icant dependency of macrovascular risk on HbA1c in
type 2 DM. On one hand, this discrepancy could be due
to statistical reasons in the present analysis and to the
limitations of metaregression technique (analysis in type
2 DM only based on 6 comparisons, differences of HbA1c
lying in a close range). On the other hand, average
changes in HbA1c on study level might not entirely
reflect efforts to improve glycemic control. The
corresponding treatment strategies could nevertheless
have beneficial effects on vascular end points not
detected solely by measurement of HbA1c (eg, reduction
of postprandial hyperglycemia as a significant vascular
risk factor as discussed hereinafter). In contrast to a
broad analysis of interventions to prevent cardiac events
in patients with type 2 DM,25 we excluded the DIGAMI
trial,30 which showed that insulin-glucose infusion
followed by a multidose insulin regimen improved
prognosis in diabetic patients with acute myocardial
infarction. The second DIGAMI trial31 did not confirm a
positive effect of intensified glycemic control in the
setting of acute myocardial infarction. Recently, a
U-shaped relationship of glycemic control with out-
comes in acute coronary syndrome and myocardial
infarction has been shown.32 In contrast to these studies
focusing on glycemic control in the setting of acutemyocardial infarction, the present meta-analysis investi-
gated the effect of improved long-term glycemic control
in a general diabetic population.
Possible mechanisms
What factors could explain the finding that, in type 2
DM, improved glycemic control leads to a more modest
reduction of macrovascular events and does not appear
to have a significant impact on cardiac events? First, the
metabolic abnormalities typical for type 2 DM not only
lead to insulin resistance and hyperglycemia but also to
dyslipidemia, arterial hypertension, endothelial dysfunc-
tion, and increased platelet activity and coagulability.33
Improving blood glucose control without also address-
ing the other abnormalities, most importantly hyper-
tension, dyslipidemia, and platelet hyperactivity, may
therefore produce only limited benefit. Indeed, recent
randomized trials of multifactorial interventions, includ-
ing the tight blood pressure control arm of the UKPDS,
showed substantial reductions in cardiac events.29,34 Of
note, in our analysis, the distribution of cardiac risk
factors was similar both after randomization and at the
conclusion of studies. One exception was the Veterans
Affairs study22 where smoking was more prevalent in
the intensive treatment group. This imbalance, com-
bined with the long duration of diabetes in this study
population, may explain the anomalous results of this
trial. Interventions that reduce insulin resistance have
been shown to have antiatherogenic effects,35-38 and this
may have produced the somewhat larger benefits seen
in overweight UKPDS patients randomized to metfor-
min. In patients with type 1 DM, particularly younger
patients, other macrovascular risk factors are less
common and the nonenzymatic glycation of proteins
and lipids, and the resulting formation of advanced
glycation end products may thus be the predominant
mechanism in the development of macrovascular and
microvascular disease.39,40
Second, in trials in type 1 DM, the intensified regimen
generally included basal and prandial insulin (multiple
insulin injections or continuous subcutaneous insulin
injection), which will have reduced postprandial as well
as basal hyperglycemia. Postchallenge hyperglycemia is
strongly associated with macrovascular complications.
For example, in the DECODE study,41 it was the
postload blood glucose concentration that was inde-
pendently associated with mortality. Furthermore, a post
hoc analysis of the STOP-NIDDM trial42 showed that
decreasing postprandial hyperglycemia with the
a-glucosidase inhibitor acarbose reduced cardiac risk in
patients with impaired glucose tolerance. Intensified
treatment regimens in type 2 DM focused mainly on
normalizing basal blood glucose. The better control of
postprandial hyperglycemia in type 1 DM may thus have
contributed to the differences observed between the
2 types of DM.
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Our results suggest that, in type 1 DM, glycemic
control is the essential treatment strategy leading not
only to the well-documented reduction of microvascular
complications but also to a substantial reduction of
macrovascular disease. In patients with type 2 DM,
improved glycemic control is associated with a more
modest reduction in macrovascular complications. In
these patients, the prevention of cardiac events must be
effected by means of a broader treatment strategy,
including antihypertensive, lipid-lowering, and platelet-
inhibiting measures. The improvement of glycemic
control itself appears to be particularly effective in
younger patients with shorter duration of the disease.
Ongoing studies will help to better define the benefits
and risks of improved blood glucose control in type 2
DM, including the large ACCORD trial.43
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Introduction
Cardiovascular disease is the leading cause of morbidity 
and mortality in patients with type 2 diabetes mellitus1. 
The characteristic dyslipidaemia of insulin resistance, 
i.e. increased concentrations of triglycerides, decreased 
high density lipoprotein (HDL) cholesterol levels 
and increased ‘small dense’ low density lipoproteins 
(LDLs) contribute to the increased cardiovascular risk2. 
Fibrates are well established agonists of the peroxisome 
proliferator-activated receptors alpha (PPARα), which 
are mainly expressed in liver, heart and skeletal muscle3. 
They have been shown to stimulate the expression of 
genes involved in fatty acid and lipoprotein metabolism, 
resulting in a shift from hepatic fat synthesis to fat 
oxidation4,5. This leads to a substantial reduction in 
serum triglycerides and an increase in HDL cholesterol 
concentrations6–8.
Despite well documented lipid lowering effects, 
there is still uncertainty about the role of fibrates in the 
prevention of cardiovascular disease. A recent meta-
analysis of trials comparing fibrates with placebo showed 
little evidence for a reduced cardiac mortality with 
fibrate treatment, but the analysis did not distinguish 
between patients with and without type 2 diabetes 
mellitus9. In patients with type 2 diabetes, several 
randomised controlled trials failed to demonstrate a 
significant reduction of coronary heart disease (CHD) 
with fibrates6,7,11. In contrast, a subgroup analysis of the 
Veterans Affairs High-density lipoprotein Intervention 
Trial (VA-HIT) suggested a beneficial effect of fibrate 
therapy on CHD in patients with type 2 diabetes8. The 
recent Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) trial, which included 9795 patients 
with diabetes, showed a 11% reduction of CHD, which 
failed to reach statistical significance ( p = 0.16)12. 
We performed a systematic review and meta-analysis 
of randomised controlled trials in order to assess the 
effectiveness of fibrates in the prevention of CHD in 
this patient group.
Materials and methods
literature search and eligibility criteria
We aimed to identify all randomised controlled trials of 
lipid lowering treatment by fibrates that prospectively 
assessed cardiovascular outcomes in patients with type 2 
diabetes mellitus. Using Cochrane methodology13 we 
searched MEDLINE (from inception to November 
2005) and the Cochrane Controlled Trials Register 
(issue 3, 2005) for relevant studies in any language. 
Electronic searches were supplemented by manual 
searching of reference lists, reviews, conference 
abstracts and specialist journals. We evaluated each 
study for inclusion in the meta-analysis on the basis of 
five criteria: (1) study design (randomised controlled 
trial); (2) comparison of lipid lowering therapy with a 
fibrate to placebo; (3) inclusion of patients with type 2 
diabetes mellitus; (4) follow-up of at least 2 years; and 
(5) prospective recording of cardiovascular events.
Data extraction and outcome measures
Two reviewers independently assessed publications 
for eligibility and extracted data, with discrepancies 
being resolved in consultation with a third reviewer. 
All relevant publications from a trial were considered, 
including, for example, early publications describing 
the study design. The primary endpoint was the 
incidence of CHD events (defined as a combination of 
non fatal myocardial infarction or death due to CHD). 
Secondary endpoints were: (1) death due to CHD (e.g. 
fatal myocardial infarction, death due to congestive 
heart failure, sudden death); (2) fatal and non fatal 
myocardial infarction; and (3) fatal and non fatal stroke. 
If data on the predefined outcomes were not reported 
for patients with type 2 diabetes separately, original 
investigators were asked for additional information.
Assessment of methodological quality
Two investigators independently assessed the adequacy 
of the concealment of allocation of patients to treatment 
groups and blinding of care providers and research staff 
ascertaining cardiovascular outcomes. Disagreements 
were resolved in discussion with a third reviewer.
Statistical analysis
Incidence rate ratios (IRRs) were combined in a fixed-
effects meta-analysis. We calculated the I-squared 
statistic, which describes the percentage of total 
variation across studies that is due to heterogeneity 
rather than chance, and applied standard tests of 
heterogeneity. In sensitivity analyses, we repeated 
analyses using random effects models and did tests of 
funnel plot asymmetry14.
Separate analyses were performed for trials assessing 
the effect of fibrates in patients without pre-existing 
CHD (primary prevention) and in patients with known 
CHD (secondary prevention). The extent to which 
the effect of treatment with fibrates was modified 
by study-level variables was explored in univariable 
meta-regression models15. The following variables were 
considered: mean age at baseline, duration of diabetes, 
body mass index, proportion of smokers, proportion 
of women, mean total cholesterol at baseline and at 
study follow up, mean LDL cholesterol at baseline 
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and at study follow up, mean HDL cholesterol at 
baseline and at study follow up, mean triglyceride level 
at baseline and at study follow up and parameters of 
methodological quality. The number of patients that 
need to be treated (NNT) in order to prevent one CHD 
event, or one death due to CHD, was calculated by 
applying the combined IRRs to incidence rates typical 
for placebo groups. Finally, analyses were repeated 
after the exclusion of trials that allowed additional lipid 
modifying treatment in the fibrate and control groups. 
All analyses were performed using Stata version 8.2 
(Stata Corporation, College Station, TX, USA).
Results
We screened 226 potentially eligible reports and 
identified 11 trials fulfilling the inclusion criteria (Figure 
1). Five trials were performed in patients with type 2 
diabetes6,7,11,12,16 and six trials included patients with 
and without diabetes10,17–21. For three of these trials 
separate data for diabetic patients were unavailable and 
these trials were therefore excluded18,19,21. Eight trials 
were included in the analysis6–8,10–12,16,22. Trials were of 
high methodological quality; appropriate methods of 
concealment of allocation of patients to treatment group 
were described in all trials, and all but one trial11 reported 
analyses according to the intention-to-treat principle. 
For one trial the degree of blinding of outcome assessors 
remained unclear11. The characteristics of trials and 
patients are shown in Table 1.
Coronary heart disease
All trials contributed to the analysis of the primary 
endpoint. During a follow up of 60 395 person-years 
(30 106 and 30 289 in the treatment and placebo group, 
226 potentially eligible 
reports identified and 
screened for retrieval
197 reports excluded
– Reviews / articles / letters / meta-
analyses (116 reports )
– Studies with other intervention or 
not placebo-controlled (78 reports)
– Case reports (3 reports)
17 studies (29 reports) 
retrieved for more detailed 
evaluation
6 studies (6 reports) excluded
– no patients with type 2 
diabetes mellitus included 
11 studies (23 reports) 
fulfilling inclusion criteria 
3 studies (5 reports) excluded
– data on patients with type 2
diabetes mellitus could not 
be obtained
8 studies (18 reports) 
included in meta-analysis
Figure 1.  Identification of randomised controlled trials 
comparing fibrates with placebo for the prevention of coronary 
heart disease in patients with type 2 diabetes mellitus
Trial 
(year of first publication) 
Treat-
ment 
group, n 
Control 
group, 
n 
Females, 
% 
Mean 
age, 
years 
Current 
smokers, 
% 
Mean dia-
betes duration, 
years 
Mean 
follow 
up, years 
Drug Interven-
tion 
Cullen et al. (1974)11 20 20 60 51 NR 10.6 2.0 Clofibrate PP 
Helsinki (1987)20,22 59 76 NR 49 27 NR 5.0 Gemfibrozil PP 
DIS (1991)6 379 382 44 46 34 0.0 5.0 Clofibric acid PP 
SENDCAP (1998)16 81 83 29 51 18 5.1 3.0 Bezafibrate PP 
VA-HIT (1999)8,17 309 318 0 65 15 NR 5.1* Gemfibrozil SP 
BIP (2000)10 155 154 13 61 NR NR 6.2 Bezafibrate SP 
DAIS (2001)7 207 211 27 57 15 8.6 3.0 Fenofibrate SP 
FIELD (2005)12 4895 4900 37 62 9 5.0* 5.0* Fenofibrate Mixed: 
78% PP
22% SP
*Median 
NR = not reported; PP = primary prevention; SP = secondary prevention; Helsinki = Helsinki Heart Study; DIS = Diabetes Intervention Study; 
SENDCAP = St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study; VA-HIT = Veterans Affairs High-Density 
Lipoprotein Intervention Trial; BIP = Bezafibrate Infarction Prevention Study; DAIS = Diabetes Atherosclerosis Intervention Study; 
FIELD = Fenofibrate Intervention and Event Lowering in Diabetes Trial 
Table 1.  Baseline characteristics of patients with type 2 diabetes mellitus enrolled in eight randomised controlled trials 
comparing fibrates with placebo for the prevention of cardiovascular disease in patients with type 2 diabetes mellitus
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respectively) a total of 924 CHD events (418 and 506 
in the treatment and placebo group, respectively) were 
recorded. The IRR was 0.84 (95% confidence interval 
[CI] 0.74–0.96), indicating a 16% risk reduction of 
CHD events with therapy by fibrates compared to 
placebo ( p = 0.008) (Table 2, Figure 2).
Death due to coronary heart disease
The analysis for this endpoint was based on seven 
trials6,7,8,10,11,12,16 and 327 deaths due to CHD (159 and 
168 in the treatment and placebo group, respectively) 
during a follow up of 59 720 person-years (29 811 
and 29 909 in the treatment and placebo group, 
respectively). The IRR was 0.96 (95% CI 0.77–1.20), 
indicating a risk reduction of 4% for death due to CHD 
after treatment with fibrates ( p = 0.73) (Table 2).
Myocardial infarction and stroke
Five trials were included in each of the analyses of 
myocardial infarction6,7,8,10,16 and stroke7,8,10,12,16. A total of 
268 fatal and nonfatal myocardial infarctions (124 and 
144 in the treatment and placebo group, respectively), 
during a follow up of 10 665 person-years (5296 and 
5369 in the treatment and placebo group, respectively), 
and 461 fatal and nonfatal strokes (214 and 247 in the 
treatment and the placebo group, respectively), during 
Incidence rate ratio (95% confidence interval) Trial (year of first publication) 
CHD events Death due to CHD Myocardial infarction Stroke 
Cullen et al. (1974)11 0.33 (0.014–8.18) 0.33 (0.014–8.18) NR NR 
Helsinki (1987)20,22 0.32 (0.07–1.52) NR NR NR 
DIS (1991)6 1.07 (0.55–2.07) 1.01 (0.06–16.11) 1.07 (0.55–2.07) NR 
SENDCAP (1998)16 0.26 (0.03–2.29) 0.34 (0.014–8.38) 0.34 (0.04–3.28) 0 events 
VA-HIT (1999)8,17 0.70 (0.54–0.91) 0.60 (0.40–0.92) 0.79 (0.58–1.08) 0.66 (0.42–1.04) 
BIP (2000)10 1.06 (0.65–1.73) 1.09 (0.46–2.57) 1.22 (0.69–2.14) 0.99 (0.53–1.88) 
DAIS (2001)7 0.75 (0.34–1.63) 0.76 (0.17–3.42) 0.74 (0.30–1.84) 1.19 (0.40–3.54) 
FIELD (2005)12 0.89 (0.75–1.05) 1.18 (0.90–1.56) NR 0.90 (0.73–1.12) 
Combined incidence rate ratio  
(fixed effect) 
 
0.84 (0.74–0.96) 
 
0.96 (0.77–1.20) 
 
0.88 (0.69–1.12) 
 
0.87 (0.73–1.05) 
Combined incidence rate ratio 
(random effect) 
 
0.84 (0.74–0.96) 
 
0.89 (0.64–1.25) 
 
0.88 (0.69–1.12) 
 
0.87 (0.73–1.05) 
Heterogeneity ( I-squared, p from test 
of heterogeneity) 
 
0%, p = 0.47 
 
23.5%, p = 0.25 
 
0%, p = 0.58 
 
0%, p = 0.56 
CHD = coronary heart disease; NR = not reported; Helsinki = Helsinki Heart Study; DIS = Diabetes Intervention Study; SENDCAP = St. Mary’s, 
Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study; VA-HIT = Veterans Affairs High-Density Lipoprotein Intervention 
Trial; BIP = Bezafibrate Infarction Prevention Study; DAIS = Diabetes Atherosclerosis Intervention Study; FIELD = Fenofibrate Intervention and 
Event Lowering in Diabetes Trial 
Incidence rate ratio
(95% CI)
Cullen et al. (1974) 0.33 (0.01–8.18)
Helsinki (1987) 0.32 (0.07–1.52)
DIS (1991) 1.07 (0.55–2.07)
SENDCAP (1998) 0.26 (0.03–2.29)
VA-HIT (1999) 0.70 (0.54–0.91)
BIP (2000) 1.06 (0.65–1.73)
DAIS (2001) 0.75 (0.34–1.63)
FIELD (2005) 0.89 (0.75–1.05)
Overall 0.84 (0.74–0.96)
0.05 0.1 0.5 1 2 10 20
Favours therapy with fibrates Favours therapy with placebo
Trial
(year of publication)
Incidence rate ratio
Table 2.  Meta-analysis of results from eight randomised controlled trials comparing fibrates with placebo for the prevention 
of cardiovascular disease and stroke in patients with type 2 diabetes mellitus
Figure 2. Meta-analysis of randomised controlled trials comparing fibrates with placebo for the prevention of coronary heart 
disease in patients with type 2 diabetes mellitus. The size of the squares is proportional to the trial’s weight in the fixed-effects 
meta-analysis; horizontal lines indicate 95% confidence intervals
© 2006 libRAPhARM ltD – Curr Med Res Opin 2006; 22() Efficacy of fibrates in type 2 diabetes Allemann et al. 621
a follow up of 55 343 person-years (27 633 and 27 710 
in the treatment and placebo group, respectively), were 
recorded. The corresponding IRRs were 0.88 (95% CI 
0.69–1.12, p = 0.30) and 0.87 (95% CI 0.73–1.05, 
p = 0.14), respectively (Table 2).
Sensitivity analyses
The combined IRRs from random effects models were 
identical or similar to those from the fixed effects 
models (Table 2). There was little evidence of funnel 
plot asymmetry ( p > 0.3 for all endpoints). In meta-
regression analysis, there was a positive association 
between the lowering of triglyceride levels and the 
reduction in CHD events ( p = 0.036). This was not 
the case for total cholesterol, LDL cholesterol and 
HDL cholesterol. Moreover, there was little evidence 
for an association with mean age, body mass index, the 
proportion of women, smoking prevalence or diabetes 
duration. The IRRs did not materially change when 
the study with unclear blinding of endpoint assessors 
was excluded from the analysis11. Two trials were 
confounded by unequal provision of additional lipid 
modifying therapy and re-analysis of the data, excluding 
the Bezafibrate Infarction Prevention (BIP)10 and 
FIELD12 trials, gave an IRR of 0.72 (95% CI 0.57–0.90, 
p = 0.004) for CHD events and 0.61 (95% CI 0.41–
0.91, p = 0.014) for death due to CHD. Analyses of 
trials assessing the effect of fibrates in patients without 
pre-existing CHD (primary prevention)6,11,16,22 and in 
patients with known CHD (secondary prevention)7,8,10 
gave similar results, with non-significant tests of 
interaction; IRRs for CHD events were 0.79 and 0.77 
( p = 0.93 by test of interaction), IRRs for death due 
to CHD were 0.52 and 0.68, ( p = 0.77). The IRR 
from the overall analysis was therefore used in the 
calculation of NNTs.
number needed to treat in primary and 
secondary prevention settings
Based on the mean of the incidences observed in the 
placebo groups, we assumed a typical incidence of 
1.67 CHD events per 100 person-years for patients 
without pre-existing CHD (primary prevention) and 
4.79 CHD events per 100 person-years for patients 
with pre-existing CHD (secondary prevention). When 
the corresponding IRRs were applied to these rates, we 
found that in the primary prevention setting 26 patients 
needed to be treated over 10 years to prevent one 
CHD event. The NNT for patients with pre-existing 
CHD was lower (nine over 10 years), due to the higher 
baseline risk. Similarly, the NNTs to prevent one death 
due to CHD were 32 and 18 over 10 years for primary 
and secondary prevention, respectively.
Discussion
We found that in patients with type 2 diabetes mellitus, 
lipid-lowering therapy with fibrates reduced the rate of 
CHD. The numbers needed to treat over 10 years to 
prevent one CHD event were 9 and 26 for patients with 
and without pre-existing CHD, respectively. There was 
a tendency towards reduction of myocardial infarction 
and stroke, but this did not reach conventional levels 
of statistical significance. More pronounced effects, 
including a reduction of CHD mortality, were found 
when restricting the analysis to trials that were not 
confounded by unequal provision of additional lipid-
lowering therapy.
Relation to other studies and possible 
mechanisms
PPARα agonists may be of particular benefit in 
patients with type 2 diabetes. This may be due to the 
fact that the increased risk for cardiovascular disease 
in patients with type 2 diabetes is related to their 
characteristic dyslipidaemia, consisting of low HDL 
cholesterol, high triglyceride and ‘small dense’ LDL 
concentrations23. Fibrates specifically lower triglyceride 
and increase HDL-cholesterol concentrations, thereby 
improving the atherogenic lipid profile in these 
patients6–8,24. In addition to dyslipidaemia, type 2 
diabetes has been related to a pro-inflammatory and 
pro-atherogenic state, with endothelial dysfunction, 
increased platelet activity and coagulability, further 
promoting atherosclerosis25. Fibrates are known to have 
an anti-inflammatory, antioxidant and antithrombotic 
effect5,24,26. Furthermore, in patients with type 2 
diabetes it has been shown that endothelial function 
improves in the fasting and postprandial state following 
fibrate therapy, which may contribute to explaining 
our findings27. Our meta-analysis of eight trials, which 
included the recently published, large Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) 
trial12, showed a more pronounced beneficial effect of 
fibrates on the risk of CHD than the FIELD trial alone. 
Of note, a considerable proportion of patients in the 
FIELD trial, particularly in the placebo group, received 
additional, non-study lipid-lowering therapy (17% in 
the placebo group and 8% in the fenofibrate group). In 
almost all cases the additional drug was a 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor (statin)12. Statins have been consistently 
shown to reduce cardiac mortality in patients with and 
without type 2 diabetes28. As discussed by the FIELD 
investigators, this unequal provision of statin treatment 
will have introduced confounding, and reduced the 
difference in CHD events between the two study arms12. 
This is in-line with the comparably low incidence of 
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CHD events in the placebo group of FIELD (1.17 
per 100 person-years) compared to the primary and 
secondary intervention trials included in this meta-
analysis (1.67 and 4.79 per 100 person-years, respect-
ively). Additional, open-label lipid-lowering therapy 
was allowed in a further trial, and uptake was again 
higher in the placebo group10. When excluding these 
two trials, the reduction in CHD events and deaths 
associated with fibrates became more pronounced.
Meta-regression analysis revealed a significant 
association between the reduction in triglyceride levels 
and the reduction of CHD events, which is consistent 
with the pharmacological profile of fibrates6–8,24. 
Unfortunately, the present meta-analysis was not 
based on individual patient data and we were therefore 
unable to further characterise the patients most likely 
to benefit from treatment with fibrates. The results 
from a recent individual patient data meta-analysis 
of the effect of statins in type 2 diabetes suggested a 
22% risk reduction of major CHD events per mmol/L 
decrease of LDL cholesterol28. Based on these findings 
the median reduction of LDL cholesterol in the 
present analysis (0.24 mmol/L) would correspond to 
a risk reduction of about 5% for CHD events, leaving 
another 11% reduction in risk, which may be explained 
by favourable changes in levels of HDL cholesterol and 
triglycerides. Important data on the effect of adding 
fibrates to statins will be provided by the ongoing 
Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial29.
Strengths and limitations
This is the first systematic review and meta-analysis 
investigating the effect of fibrates in patients with type 2 
diabetes mellitus. Our study was based on a compre-
hensive literature search and original investigators 
checked the extracted data and provided additional 
information. We acknowledge that our analysis was to 
some extent dominated by the FIELD and Veterans 
Affairs High-Density Lipoprotein Intervention 
(VA-HIT) trials. However, the inclusion of a further 
six trials increased the precision of effect estimates and 
allowed subgroup analyses by trial and average patient 
characteristics. Most of these analyses were planned 
a priori, with the exception of the analysis excluding 
the two trials that allowed additional lipid-lowering 
therapy. Unfortunately, separate data for patients with 
type 2 diabetes were not available for three trials18,19,21, 
despite repeated attempts to contact the study authors, 
and these studies had to be excluded from our analysis. 
However, funnel plot analysis suggests that the included 
studies are a representative sample, indicating that the 
exclusion of these studies did not introduce substantial 
bias. We could not examine the influence of glycaemic 
control on the rate of CHD events; although a protective 
effect of optimised glycaemic control in patients with 
diabetes has been shown30, detailed information on 
glycated haemoglobin A1c (HbA
1c
) was available only 
for a small number of trials12,16,31. Different fibrates were 
used in the trials under investigation. Fibrates reduce 
triglycerides and increase HDL cholesterol levels but 
they may differ in their effects on other cardiovascular 
risk factors, for example fibrinogen32. Furthermore, it 
is clear that trials included in the present analysis are 
heterogeneous in terms of patient characteristics33. 
However, in the present analysis risk ratios did not 
differ significantly in primary prevention and secondary 
prevention trials, respectively. Accordingly, there was 
a small degree of heterogeneity between trials in this 
meta-analysis, indicating that the effects of fibrates on 
cardiovascular disease might be due to a class effect of 
PPARα-agonists.
Conclusions
In conclusion, this systematic review and meta-analysis 
shows that, in patients with type 2 diabetes mellitus, 
fibrates reduce CHD events. Larger benefits were 
found when restricting the analysis to trials that were 
not confounded by unequal provision of additional 
lipid-lowering therapy. More data are needed to better 
define the role of fibrate therapy in type 2 diabetes. An 
individual patient data meta-analysis of existing trials 
might be useful in this context.
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Objective: To examine whether polymer based coronary stents eluting sirolimus or paclitaxel are equally
effective in patients with and without diabetes.
Methods: Systematic review and meta-analysis by indirect comparison of randomised controlled trials
comparing stents eluting sirolimus or paclitaxel with conventional bare metal stents. The overall study
population and patients with and without diabetes were analysed separately by using the ratio of
incidence rate ratios (RIRR).
Results: The analysis was based on 10 trials (six with sirolimus, four with paclitaxel), 4513 patients (1146
patients with diabetes), 5755 years of follow up, and 2464 events. In patients without diabetes sirolimus
eluting stents were superior to paclitaxel eluting stents with respect to in-stent (RIRR 0.21, 95% confidence
interval (CI) 0.10 to 0.48, p , 0.001) and in-segment restenosis (RIRR 0.47, 95% CI 0.24 to 0.92,
p = 0.027), target lesion revascularisation (RIRR 0.54, 95% CI 0.30 to 0.99, p = 0.045), and major
adverse cardiac events (RIRR 0.46, 95% CI 0.26 to 0.83, p = 0.010). In patients with diabetes the two
drug eluting stents did not differ significantly in any of these end points. Meta-regression analysis showed
a significant difference between patients with and without diabetes (tests for interaction for in-stent and in-
segment restenosis, p = 0.036 and p = 0.016).
Conclusion: Indirect evidence indicates that sirolimus eluting stents are superior to paclitaxel eluting stents
in patients without diabetes but not in patients with diabetes.
T
wo drug eluting stents are approved by the US Food and
Drug Administration (FDA), a sirolimus and a paclitaxel
eluting stent. Both drug eluting stents share a similar
stent platform consisting of a stainless steel stent and a non-
biodegradable polymer for controlled drug release. Several
randomised controlled trials and meta-analyses have shown
that both drug eluting stents reduce restenosis and the need
for repeated revascularisation procedures compared with bare
metal stents.1–11
More recently, two large randomised head to head
comparisons and a meta-analysis have shown that sirolimus
is superior to paclitaxel in the prevention of restenosis.12–14
Open questions remain, however. In particular, it is unclear
whether the clinical benefits of these two drug eluting stents
are similar across patient groups who differ in terms of
underlying cardiovascular risk. Diabetes mellitus is a com-
mon and a major risk factor for cardiovascular disease.15 16
Patients with diabetes tend to present with more advanced
coronary artery disease, and outcomes after percutaneous
coronary intervention (PCI) tend to be poorer than for
patients without diabetes.17–19 The beneficial effect of drug
eluting stents appears attenuated in patients with diabetes
compared with patients without diabetes, most probably due
to more severe neointimal hyperplasia.20 21 The objective of
the present study was to indirectly compare the effects of
polymer based sirolimus versus paclitaxel eluting stents and
to evaluate whether they are equally effective in the
prevention of restenosis in patients with and without
diabetes.
METHODS
Literature search and eligibility criteria
We identified all randomised clinical trials that compared the
two commercially available, polymer based drug eluting stent
systems (the Cypher stent, Cordis, Miami Lakes, Florida,
USA, which elutes sirolimus; and the Taxus stent, Boston
Scientific, Natick, Massachusetts, USA, which elutes pacli-
taxel) with bare metal stents. By using Cochrane methods we
searched Medline, Embase, and the Cochrane controlled
trials register (from inception to April 2004) for relevant
studies in any language. Electronic searches were supple-
mented by manual searching of reference lists, reviews,
relevant book chapters, conference abstracts, and specialist
journals. We also scrutinised the proceedings of the relevant
FDA advisory panels.
We evaluated each trial for inclusion in the meta-analysis
on the basis of five criteria: (1) study design (randomised
controlled trial); (2) study population (patients with stable or
unstable angina as defined elsewhere22 23 and signs of
myocardial ischaemia—patients had to have a new target
lesion in a native coronary artery); (3) intervention group
(sirolimus or paclitaxel polymer based stent systems); (4)
control group (bare metal stent); and (5) length of follow up
(at least four months). Two reviewers (CS, SA) indepen-
dently assessed publications for eligibility, with discrepancies
being resolved in consultation with a third reviewer (PD,
BM).
Data extraction and outcome measures
Two investigators (CS and SA) independently extracted data,
with disagreements resolved by a third reviewer (PD or BM).
All relevant publications from a trial were considered,
including, for example, early publications describing the
Abbreviations: BENESTENT II, Belgian Netherlands stent II; CI,
confidence interval; FDA, Food and Drug Administration; IRR, incidence
rate ratio; MACE, major adverse cardiac events; PCI, percutaneous
coronary intervention; RIRR, ratio of incidence rate ratios
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study design. Authors from all studies were contacted and
asked to check the information extracted from published
articles and, where necessary, to provide additional data.
Study end points were defined as follows: (1) in-stent
restenosis (stenosis of 50% or greater of the target lesion,
confirmed by coronary angiography or intravascular ultra-
sound); (2) in-segment restenosis (stenosis of 50% or greater
of the target segment, confirmed by coronary angiography or
intravascular ultrasound); (3) target lesion revascularisation
(coronary artery bypass grafting or repeat PCI procedure at
the original lesion site, including the area inside the stent and
the 5 mm vessel segments adjacent to it); (4) major adverse
cardiac events (MACE) (Q wave and non-Q wave myocardial
infarction, surgical revascularisation (coronary artery bypass
graft), percutaneous revascularisation (PCI), or death).
Assessment of methodological quality
Two of us (CS and SA) independently assessed the adequacy
of the concealment of allocation of patients to treatment
groups and blinding of care providers and research staff
ascertaining cardiovascular outcomes. Disagreements were
resolved in discussion with a third reviewer (ME).
Statistical analysis
We calculated the incidence rate by dividing the number of
events by the number of person years of follow up and
separately analysed all patients, patients with diabetes, and
patients without diabetes. For each comparison and end
point the incidence rate ratio (IRR) was obtained by dividing
the incidence in the drug eluting stent group by the incidence
in the bare metal stent group. Studies with no outcome
events in either group were excluded from the respective
analysis. Comparisons with events in only one group were
analysed by adding one half to all cells. We combined IRRs
in fixed effects meta-analysis by using inverse variance
weighting and calculated the I2 statistic, which describes the
percentage of total variation across studies that is due to
heterogeneity rather than chance. We also did standard tests
of heterogeneity.24 The numbers of patients needed to be
treated with drug eluting rather than bare metal stents to
prevent one adverse event was calculated by applying the
combined IRRs to the median incidence rate in the bare
metal stent group of patients with or without diabetes. In
sensitivity analyses we repeated calculations by using
random effects models and did tests of funnel plot
asymmetry.25 For comparisons between the two drug eluting
stent systems we calculated the ratio of IRRs (RIRR) by using
a random effects meta-regression model.26
Crude and adjusted indirect comparisons were performed
by fitting random effects meta-regression models.26 Variables
entered in the model were the drug (sirolimus versus
paclitaxel), stent strut thickness, study characteristics
(dimensions of trial quality and length of angiographic and
clinical of follow up), angiographic parameters (length of
target lesion, reference vessel diameter, proportion of patients
with angiographic follow up, mean duration of use of
clopidogrel or ticlopidine, proportion of patients receiving
glycoprotein IIb/IIIa antagonists, target artery, American
College of Cardiology/American Heart Association lesion
classification, proportion of patients with multivessel disease,
proportion of patients with stable and unstable angina, and
use of direct stenting), and the characteristics of study
populations at baseline (mean age, proportion of women,
proportion of patients with hypertension or dyslipidaemia,
and proportion of smokers). A recent analysis of data from
the BENESTENT II (Belgian Netherlands stent) study
showed that the inclusion of angiographic follow up
increased the number of repeat revascularisations by a factor
of 1.6.27 28 In a sensitivity analysis we reanalysed the data
with this factor to correct for angiography driven revascular-
isations. Results are presented as IRRs with 95% confidence
intervals (CIs) and numbers needed to treat and 95% CIs. All
analyses were performed with Stata version 8.2 (Stata
Corporation, College Station, Texas, USA).
RESULTS
Identification of eligible studies
We screened the titles and abstracts of 233 potentially eligible
reports, examined the full text of 57 articles reporting on 29
different studies, and identified 10 studies that met our
inclusion criteria (fig 1). Additional, unpublished data were
obtained for seven trials.1–3 5 6 29 30
Characteristics of trials and patients
Six trials1–4 8 30 examined the sirolimus and four5–7 31 the
paclitaxel eluting stent. Trials were of high methodological
quality: appropriate methods of allocation concealment were
described for all trials and most trials reported analyses
according to the intention to treat principle. For one trial the
degree of blinding of outcome assessors was unclear.3 In all
trials patients with recent acute myocardial infarction or a
stenosis of 50% or greater in the left main coronary artery and
patients with heart failure were excluded. In all studies
except one patients with diabetes constituted a subgroup of
the study population.30 Stratified randomisation of patients
with and without diabetes was reported in two trials.4 7 Five
trials were performed in Europe1 5 8 30 31 and three in North
America,3 4 7 and two were multicentre trials performed in
Europe and North, Central, and South America.2 6
The 10 trials included a total of 4513 patients, 1146 (25%)
patients with and 3367 (75%) patients without diabetes.
Table 1 shows the characteristics of the study participants.
Patient characteristics were generally comparable across
trials.1–8 29–33 The mean age of patients at baseline ranged
233 potentially eligible
reports identified and
screened for retrieval
176 reports excluded:
– other subject (92)
– review (71)
– observational study (2)
– case report (4)
– other design (7)
57 reports (29 studies)
retrieved for more detailed
evaluation
38 reports (10 studies)
included in meta-analysis
19 reports (19 studies) excluded:
– single arm study (1)
– use of different DES (12)
– study still ongoing (6)
Figure 1 Identification of eligible randomised controlled trials. DES,
drug eluting stents.
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from 60–67 years. The proportions of women, smokers, and
patients with hypertension or dyslipidaemia varied some-
what. Indications for PCI were similar across trials (table 2).
There was a tendency towards a smaller mean reference
vessel diameter in trials with sirolimus. Mean angiographic
follow up and clinical follow up ranged from six to nine
months and eight to 24 months, respectively.
Outcomes
Table 3 shows IRRs from individual trials for the four
outcomes analysed and combined rate ratios from meta-
analyses. Table 4 and table 5 show the same data for patients
with and without diabetes. Figure 2 presents combined
results from meta-analyses for all patients, and fig 3 shows
these results separately for patients with and without
diabetes. For some trials and outcomes separate data on
patients with and without diabetes were not available, which
meant that the number of trials that contributed to a given
analysis varied. Crude and adjusted RIRR comparing siroli-
mus versus paclitaxel eluting stents were closely similar, and
crude results are therefore presented throughout.
Restenosis
Overall, analyses were based on 604 episodes of in-stent
restenosis and 657 episodes of in-segment restenosis.
Compared with bare metal stents, drug eluting stents were
associated with substantial reductions in the risk of rest-
enosis in all trials reporting this outcome, but reductions
were more pronounced with sirolimus than with paclitaxel
eluting stents. The combined IRRs for in-stent and in-
segment restenosis were 0.10 (95% CI 0.07 to 0.14) and 0.20
(95% CI 0.15 to 0.26), respectively, with sirolimus eluting
stents, and 0.27 (95% CI 0.20 to 0.37) and 0.29 (95% CI 0.22
to 0.39) with paclitaxel eluting stents. Of note, heterogeneity
between study results in these two meta-analyses was
entirely attributable to random variation (I2 = 0%). These
results translated into an RIRR of 0.35 (95% CI 0.21 to 0.57)
for in-stent restenosis indicating that, compared with
paclitaxel, sirolimus eluting stents led to a reduction in
incidence by 65%. The corresponding RIRR for in-segment
restenosis was 0.68 (95% CI 0.45 to 1.01). These differences in
the efficacy of preventing restenosis between the two stent
systems were attributable to lower rates of restenosis with
sirolimus compared with paclitaxel eluting stents in patients
without diabetes, whereas results were comparable in
patients with diabetes (tables 4 and 5, fig 3). Meta-regression
analysis showed a significant difference between patients
with and without diabetes (tests for interaction for in-stent
and in-segment restenosis, p = 0.036 and p = 0.016).
Revascularisation
Overall, analyses were based on 522 target lesion revascular-
isations. Compared with bare metal stents, drug eluting
stents were associated with a substantial reduction in the risk
of revascularisation, but reductions were more pronounced
with sirolimus than with paclitaxel eluting stents (RIRR 0.71,
95% CI 0.46 to 1.09). This difference was also more
pronounced in patients without diabetes (RIRR 0.54, 95%
CI 0.30 to 0.99) than in patients with diabetes (RIRR 0.86,
95% CI 0.40 to 1.86), although the formal test for interaction
did not reach conventional levels of significance (p = 0.36).
Results were closely similar when correcting for angiography
driven revascularisations.
Major adverse cardiac events
Analyses were based on 681 MACE, including 148 myocardial
infarctions, and 41 deaths. The TAXUS trialists included stent
thrombosis in their definition of MACE (17 events).
Reductions were also more pronounced with sirolimus
eluting stents than with paclitaxel stents (RIRR 0.54, 95%
CI 0.39 to 0.76), and the difference between the two types of
drug eluting stents was more pronounced in patients without
diabetes (RIRR 0.46, 95% CI 0.26 to 0.83) than in patients
with diabetes (RIRR 0.60, 95% CI 0.21 to 1.71, test for
interaction p = 0.68).
Numbers needed to treat to prevent one event
Table 6 shows the estimated numbers of patients needed to
treat with drug eluting rather than bare metal stents to
prevent one outcome event. Numbers needed to treat were
lowest for sirolimus eluting stents in patients with diabetes,
followed by paclitaxel eluting stents in patients with
diabetes, sirolimus eluting stents in patients without dia-
betes, and paclitaxel eluting stents in patients without
diabetes. For one end point (MACE) the CI for the IRR of
paclitaxel eluting stents was compatible with benefit and
harm. We accounted for this by calculating numbers needed
to benefit (corresponding to the lower limit of the CI) and
numbers needed to harm (corresponding to the upper limit of
the CI).34
DISCUSSION
The indirect comparisons presented here indicate that
sirolimus eluting stents are superior to paclitaxel eluting
Table 1 Characteristics of randomised trials comparing drug eluting stents with bare metal stents
Study
Diabetes
mellitus Mean age at
baseline
(years)
Women
(%)
Hypertension
(%)
Dyslipidaemia
(%)
Smoking
(%)
Mean follow up (months)
Yes No Angiographic Clinical
Sirolimus eluting stents
SIRIUS (2003)4 279 778 62.3 29.0 68.0 74.0 20.0 8 9
E-SIRIUS (2003)1 81 271 62.3 29.3 64.0 74.0 33.0 8 9
C-SIRIUS (2004)3 24 76 60.5 31.0 52.0 85.0 37.0 8 9
DIABETES (2005)30 160 66.6 37.5 66.3 61.3 47.5 9 9
RAVEL (2002)2 44 194 60.7 24.0 61.0 40.0 30.0 6 12
SES-SMART (2004)8 64 193 63.6 28.4 64.7 63.0 16.3 8 8
Paclitaxel eluting stents
TAXUS I (2003)5 11 49 64.9 11.4 63.9 80.3 50.8 6 12
TAXUS II (2003)6, 32, 33 76 453 60.1 24.4 61.5 76.6 24.8 6 24
TAXUS IV (2004)7, 29 318 996 62.5 27.9 69.8 65.3 21.8 9 24
TAXUS VI (2005)31 89 357 62.6 23.7 57.8 71.9 NA 9 12
C-SIRIUS, Canadian sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; DIABETES, diabetes and sirolimus
eluting stent trial; E-SIRIUS, European sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; NA, not
available; RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent; SES-SMART, randomised comparison of a sirolimus eluting stent
and a standard stent in the prevention of restenosis in small coronary arteries; SIRIUS, sirolimus coated balloon expandable stent in the treatment of patients with
de novo coronary artery lesions.
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stents, and that the difference in the effectiveness between
the two drug eluting stent systems is clearly evident in
patients without diabetes but less certain in patients with
diabetes. Calculations of numbers needed to treat show that,
compared with sirolimus eluting stents, about 10 additional
patients without diabetes have to be treated with paclitaxel
eluting stents to prevent one MACE.
Strengths and limitations
Our review was based on a comprehensive literature search
and included assessments of trial quality and a substantial
amount of additional information supplied by the original
investigators. Although most trials included in this analysis
were not designed to examine the effectiveness of drug
eluting stents in patients with and without diabetes,
randomisation was stratified according to the presence or
absence of diabetes in some studies,4 31 and all studies
prospectively recorded outcomes according to standardised
definitions. Indirect comparisons between sirolimus and
paclitaxel eluting stents were appropriate because trials were
of high methodological quality and had enrolled similar
patient populations. Indeed, results were robust when
adjusted for study characteristics and patient characteristics
at baseline. We acknowledge that such comparisons are
observational in nature and therefore have to be interpreted
with caution. Only 10 trials were identified and average
follow up was relatively short, which means that there was
limited power to detect or exclude differences in effectiveness
for rarer but clinically relevant end points, including
myocardial infarction, stent thrombosis, and death.
The effect of drug eluting stents on MACE was mainly due
to a reduction of revascularisation procedures. As Babapulle
et al9 pointed out, the clinical significance of these additional
revascularisation procedures is unclear because angiography
was done routinely in these trials, at least in a proportion of
the study population. Angiographic follow up may influence
the rate of revascularisation, especially in patients with
diabetes and autonomic neuropathy.35 The impact of angio-
graphy on revascularisation rates has recently been quanti-
fied.28 When we used these estimates to correct incidences for
angiography driven revascularisation, results were not
materially altered. We could not examine the influence of
glycaemic control on the rate of restenosis and revascularisa-
tion; although a protective effect of optimised glycaemic
control in patients with diabetes has been shown, no detailed
information on glycaemic control was available for the trials
we analysed.36
Results in context with other studies
Two meta-analyses have shown that the presence of diabetes
is a risk factor for restenosis, both with drug eluting and bare
metal stents.21 37 Our findings confirm these results: diabetes
clearly remains a risk factor for restenosis in the drug eluting
stent era. Methodological research has shown that indirect
comparisons adjusted at the aggregate level usually agree
with the results of head to head randomised trials.38 In this
study overall results were indeed closely similar to those
reported in a recent meta-analysis of six head to head trials.14
Data from head to head comparisons in patients with
diabetes are, however, more limited, and results are more
heterogeneous. The large REALITY trial showed no overall
difference in restenosis rates between the two stent systems,
although sirolimus eluting stents appeared to be superior in
patients without diabetes.39 The SIRTAX trial, in contrast,
found the sirolimus eluting stent to be superior overall, with
a more pronounced reduction of the rate of restenosis and
revascularisation in patients with diabetes than in patients
without diabetes.12 In both trials the number of patients with
diabetes was relatively small, and formal tests of interaction
Ta
b
le
2
A
ng
io
gr
ap
hi
c
pa
ra
m
et
er
s
fo
r
st
ud
ie
s
w
ith
si
ro
lim
us
el
ut
in
g
st
en
ts
St
ud
y
In
d
ic
a
tio
ns
fo
r
PC
I
M
ea
n
R
V
D
(m
m
)
M
ea
n
le
si
on
le
ng
th
(m
m
)
Ta
rg
et
a
rt
er
y
(%
)
A
C
C
/A
H
A
cl
a
ss
(%
)
M
ul
tiv
es
se
l
d
is
ea
se
(%
)
Pr
ev
io
us
M
I
(%
)
A
P
(%
)
LA
D
R
C
A
LC
X
A
B1
B2
C
St
a
b
le
U
ns
ta
b
le
Si
ro
lim
us
tr
ia
ls
SI
RI
U
S
(2
0
0
3
)4
St
ab
le
or
un
st
ab
le
A
P,
si
gn
s
of
m
yo
ca
rd
ia
l
is
ch
ae
m
ia
2
.8
0
1
4
.4
0
4
4
3
1
2
5
8
3
6
3
3
2
3
4
2
3
1
5
8
5
3
E-
SI
RI
U
S
(2
0
0
3
)1
St
ab
le
or
un
st
ab
le
A
P,
si
le
nt
is
ch
ae
m
ia
2
.5
5
1
5
.0
0
5
6
2
1
2
3
N
A
N
A
N
A
N
A
3
6
4
2
N
A
3
3
C
-S
IR
IU
S
(2
0
0
4
)3
St
ab
le
or
un
st
ab
le
A
P,
si
le
nt
is
ch
ae
m
ia
2
.6
3
1
3
.6
0
3
6
4
1
2
3
N
A
N
A
5
9
4
0
4
2
1
2
5
1
D
IA
BE
TE
S
(2
0
0
5
)3
0
Sy
m
pt
om
s
or
ob
je
ct
iv
e
ev
id
en
ce
of
is
ch
ae
m
ia
2
.3
4
1
5
.0
0
4
1
3
7
2
2
N
A
N
A
8
0
6
5
3
7
N
A
N
A
RA
V
EL
(2
0
0
2
)2
St
ab
le
or
un
st
ab
le
A
P,
si
le
nt
is
ch
ae
m
ia
2
.6
2
9
.5
8
5
0
2
7
2
3
6
3
7
5
7
0
N
A
3
6
3
9
5
0
SE
S-
SM
A
RT
(2
0
0
4
)8
A
C
S,
st
ab
le
A
P,
si
le
nt
m
yo
ca
rd
ia
li
sc
ha
em
ia
as
sh
ow
n
by
ex
er
ci
se
st
re
ss
te
st
2
.2
0
1
1
.8
4
2
8
1
6
3
0
2
5
4
7
2
4
4
6
5
N
A
N
A
N
A
Pa
cl
ita
xe
l
tr
ia
ls
TA
X
U
S
I
(2
0
0
3
)5
St
ab
le
or
un
st
ab
le
A
P
or
si
le
nt
is
ch
ae
m
ia
2
.9
7
1
1
.3
0
4
0
3
0
3
0
2
3
4
1
3
6
0
N
A
2
8
N
A
N
A
TA
X
U
S
II
(2
0
0
3
)6
,
3
2
,
3
3
St
ab
le
or
un
st
ab
le
A
P
or
si
le
nt
is
ch
ae
m
ia
2
.7
5
1
0
.4
8
4
5
3
6
1
9
N
A
N
A
N
A
N
A
N
A
4
0
6
0
3
4
TA
X
U
S
IV
(2
0
0
4
)7
,
2
9
St
ab
le
or
un
st
ab
le
an
gi
na
or
pr
ov
ok
ab
le
is
ch
ae
m
ia
2
.7
5
1
3
.4
0
4
1
3
1
2
8
N
A
N
A
N
A
N
A
N
A
3
0
N
A
3
4
TA
X
U
S
V
I
(2
0
0
5
)3
1
St
ab
le
or
un
st
ab
le
A
P
or
si
le
nt
is
ch
ae
m
ia
2
.7
8
2
0
.6
2
N
A
N
A
2
8
5
6
N
A
N
A
N
A
N
A
A
C
C
,
A
m
er
ic
an
C
ol
le
ge
of
C
ar
di
ol
og
y;
A
C
S,
ac
ut
e
co
ro
na
ry
sy
nd
ro
m
e;
A
H
A
,
A
m
er
ic
an
H
ea
rt
A
ss
oc
ia
tio
n;
A
P,
an
gi
na
pe
ct
or
is
;
LA
D
,
le
ft
an
te
ri
or
de
sc
en
di
ng
co
ro
na
ry
ar
te
ry
;
LC
X
,
le
ft
ci
rc
um
fle
x
co
ro
na
ry
ar
te
ry
;
M
I,
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
PC
I,
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
RC
A
,
ri
gh
t
co
ro
na
ry
ar
te
ry
;
RV
D
,
re
fe
re
nc
e
ve
ss
el
di
am
et
er
.
Drug eluting stents in patients with and without diabetes 653
were non-significant. Lastly, the ISAR-DIABETES trial in 250
patients with diabetes showed larger reductions in angio-
graphic restenosis (p = 0.03) and target lesion revascular-
isation (p = 0.13) with sirolimus than with paclitaxel.13
Possible mechanisms
In-stent restenosis results from neointimal hyperplasia, and
the pharmacological inhibition of vascular smooth muscle
proliferation by local drug delivery has proved effective in
reducing restenosis and thus repeat revascularisation proce-
dures.40 41 The biological mechanisms of action differ between
paclitaxel and sirolimus: paclitaxel treated cells form
abnormally stable and non-functional microtubules, which
inhibit cellular replication and proliferation.42 In contrast,
sirolimus is a macrocyclic lactone that inhibits cytokine
mediated and growth factor induced proliferation of smooth
muscle cells and has immunoregulatory and anti-inflamma-
tory properties.43–45 One would expect these properties to be
particularly beneficial in diabetic atherosclerosis, which is
characterised by increased inflammatory markers.46 On the
other hand, treatment of human platelets with sirolimus has
been shown to result in enhanced agonist induced platelet
aggregation and secretion.47 The more complex and advanced
nature of lesions in patients with diabetes may interact with
the biological mechanisms of action of both drugs but
hamper effects of sirolimus more than effects of paclitaxel.
Differences in local drug concentrations may also have a role:
both drugs are highly lipophilic but different protein binding
characteristics mean that sirolimus is distributed evenly
through the vessel wall, whereas paclitaxel remains primarily
subintimal.48 These distribution patterns and tissue residence
time may be modified in atherosclerotic lesions of patients
with diabetes. It is also possible that differences in the doses
of the two drugs or differences in concomitant medications
have a role.
Stents with thinner struts elicit less angiographic and
clinical restenosis than stents with thicker struts.49 50
Differences in strut thickness can therefore have affected
indirect comparisons. This is, however, unlikely because
differences were small (140 and 130 mm for the sirolimus and
the paclitaxel eluting stent, respectively). Event rates tended
to be somewhat higher in the bare metal stent groups of the
Table 3 Incidence rate ratios (IRRs) from trials of sirolimus and paclitaxel eluting stents and ratio of incidence rate ratios (RIRR)
comparing sirolimus with paclitaxel in all patients
Study
IRR (95% confidence interval)
In-stent restenosis In-segment restenosis TLR MACE
Sirolimus trials
SIRIUS (2003)4 0.09 (0.05 to 0.16) 0.24 (0.16 to 0.36) 0.24 (0.15 to 0.39) 0.38 (0.26 to 0.55)
E-SIRIUS (2003)1 0.09 (0.04 to 0.22) 0.14 (0.07 to 0.28) 0.19 (0.09 to 0.43) 0.35 (0.19 to 0.65)
C-SIRIUS (2004)3 0.02 (0.001 to 0.40) 0.04 (0.01 to 0.32) 0.22 (0.05 to 1.03) 0.22 (0.05 to 1.03)
DIABETES (2005)30 0.15 (0.06 to 0.39) 0.22 (0.10 to 0.47) 0.24 (0.10 to 0.59) 0.31 (0.15 to 0.66)
RAVEL (2002)2 0.02 (0.001 to 0.26) 0.02 (0.001 to 0.26) 0.02 (0.001 to 0.29) 0.20 (0.09 to 0.44)
SES-SMART (2004)8 0.10 (0.04 to 0.23) 0.18 (0.10 to 0.34) 0.33 (0.16 to 0.70) 0.30 (0.16 to 0.57)
Combined IRR 0.10 (0.07 to 0.14) 0.20 (0.15 to 0.26) 0.24 (0.17 to 0.33) 0.33 (0.25 to 0.42)
Heterogeneity* 0.0%, p = 0.63 33.6%, p = 0.18 0.0%, p = 0.51 0.0%, p = 0.78
Paclitaxel trials
TAXUS I (2003)5 0.14 (0.01 to 2.67) NA 0.14 (0.01 to 2.77) 0.25 (0.03 to 2.24)
TAXUS II (2003)6, 32, 33 0.33 (0.19 to 0.55) 0.18 (0.09 to 0.36) 0.27 (0.13 to 0.53) 0.58 (0.38 to 0.86)
TAXUS IV (2004)7, 29 0.23 (0.13 to 0.39) 0.30 (0.19 to 0.47) 0.32 (0.22 to 0.46) 0.56 (0.41 to 0.78)
TAXUS VI (2005)31 0.28 (0.17 to 0.46) 0.35 (0.22 to 0.54) 0.42 (0.25 to 0.72) 0.73 (0.48 to 1.12)
Combined IRR 0.27 (0.20 to 0.37) 0.29 (0.22 to 0.39) 0.33 (0.25 to 0.44) 0.60 (0.48 to 0.75)
Heterogeneity* 0.0%, p = 0.77 16.3%, p = 0.30 0.0%, p = 0.67 0.0%, p = 0.65
RIRR (sirolimus v paclitaxel) 0.35 (0.21 to 0.57)
p,0.001
0.68 (0.45 to 1.01)
p = 0.057
0.71 (0.46 to 1.09)
p = 0.120
0.54 (0.39 to 0.76)
p,0.001
*I2, test of heterogeneity.
MACE, major adverse cardiac events; TLR, target lesion revascularisation.
Table 4 IRRs from trials of sirolimus and paclitaxel eluting stents and RIRR comparing sirolimus with paclitaxel in patients
without diabetes
Study
IRR (95% confidence interval)
In-stent restenosis In-segment restenosis TLR MACE
Sirolimus trials
SIRIUS (2003)4 0.05 (0.02 to 0.14) 0.20 (0.11 to 0.34) 0.21 (0.11 to 0.40) 0.39 (0.25 to 0.62)
E-SIRIUS (2003)1 0.09 (0.03 to 0.24) 0.13 (0.05 to 0.30) 0.20 (0.08 to 0.52) 0.42 (0.20 to 0.85)
C-SIRIUS (2004)3 0.04 (0.002 to 0.68) 0.03 (0.002 to 0.54) 0.13 (0.02 to 1.00) 0.13 (0.02 to 1.00)
RAVEL (2004)2 0.02 (0.001 to 0.37) 0.02 (0.001 to 0.37) 0.02 (0.001 to 0.41) 0.20 (0.08 to 0.53)
SES-SMART (2002)8 NA 0.11 (0.04 to 0.28) NA NA
Combined IRR 0.06 (0.03 to 0.12) 0.15 (0.10 to 0.22) 0.19 (0.11 to 0.31) 0.35 (0.25 to 0.50)
Heterogeneity* 0.0%, p = 0.77 8.8%, p = 0.36 0.0%, p = 0.52 0.0%, p = 0.44
Paclitaxel trials
TAXUS I (2003)5 NA NA 0.16 (0.01 to 3.13) 0.28 (0.03 to 2.53)
TAXUS II (2003)6, 32, 33 NA 0.08 (0.02 to 0.24) 0.29 (0.14 to 0.61) NA
TAXUS IV (2004)7, 29 0.25 (0.13 to 0.47) 0.35 (0.20 to 0.59) 0.30 (0.19 to 0.48) NA
TAXUS VI (2004)31 0.30 (0.17 to 0.53) 0.39 (0.24 to 0.64) 0.49 (0.27 to 0.88) 0.80 (0.49 to 1.29)
Combined IRR 0.28 (0.18 to 0.42) 0.32 (0.23 to 0.45) 0.35 (0.25 to 0.48) 0.76 (0.48 to 1.22)
Heterogeneity* 0.0%, p = 0.67 69.2%, p = 0.04 0.0%, p = 0.53 0.0%, p = 0.37
RIRR (sirolimus v paclitaxel) 0.21 (0.10 to 0.48)
p,0.001
0.47 (0.24 to 0.92)
p = 0.027
0.54 (0.30 to 0.99)
p = 0.045
0.46 (0.26 to 0.83)
p = 0.010
*I2, test of heterogeneity.
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sirolimus trials than in the corresponding groups of the
paclitaxel trials. If the relative reduction in restenosis risk
strongly depended on the control group risk, this can partly
explain the superior efficacy observed for sirolimus eluting
stents. This is unlikely for several reasons. Recent head to
head trials in patient populations that differed in terms of
underlying risk consistently showed that sirolimus is superior
to paclitaxel.14 Moreover, methodological research has shown
that the relative reductions in risk associated with medical
interventions tend be constant across patient populations
with different underlying risks.51
Conclusions
This systematic review and meta-analysis shows substantial
reductions in restenosis and revascularisation rates with the
two widely used polymer based drug eluting stents, in both
patients with and patients without diabetes. Sirolimus
eluting stents appear more effective than paclitaxel eluting
stents in patients without diabetes, whereas efficacy appears
to be comparable in patients with diabetes. We submit that a
collaborative meta-analysis based on individual patient data
Table 5 IRRs from trials of sirolimus and paclitaxel eluting stents and RIRR comparing sirolimus with paclitaxel in patients with
diabetes
Study
IRR (95% confidence interval)
In-stent restenosis In-segment restenosis TLR MACE
Sirolimus trials
SIRIUS (2003)4 0.17 (0.08 to 0.37) 0.35 (0.20 to 0.62) 0.31 (0.15 to 0.64) 0.37 (0.19 to 0.70)
E-SIRIUS (2003)1 0.13 (0.03 to 0.57) 0.19 (0.06 to 0.64) 0.21 (0.05 to 0.91) 0.27 (0.08 to 0.94)
C-SIRIUS (2004)3 0.06 (0.003 to 1.02) 0.13 (0.02 to 1.00) 1.00 (0.06 to 15.99) 1.00 (0.06 to 15.99)
DIABETES (2005)30 0.15 (0.06 to 0.39) 0.22 (0.10 to 0.47) 0.24 (0.10 to 0.59) 0.31 (0.15 to 0.66)
RAVEL (2002)2 0.06 (0.003 to 0.97) 0.06 (0.003 to 0.97) 0.07 (0.004 to 1.19) 0.22 (0.05 to 0.98)
SES-SMART (2004)8 NA 0.39 (0.17 to 0.91) NA NA
Combined IRR 0.15 (0.09 to 0.25) 0.28 (0.20 to 0.41) 0.27 (0.16 to 0.45) 0.33 (0.21 to 0.51)
Heterogeneity* (0.0%, p = 0.92) (0.0%, p = 0.59) (0.0%, p = 0.73) (0.0%, p = 0.89)
Paclitaxel trials
TAXUS I (2003)5 NA NA 0 events 0 events
TAXUS II (2003)6, 32, 33 NA 0.07 (0.004 to 1.17) 0.16 (0.02 to 1.25) NA
TAXUS IV (2004)7, 29 0.16 (0.05 to 0.48) 0.18 (0.07 to 0.49) 0.36 (0.19 to 0.70) NA
TAXUS VI (2005)31 0.20 (0.05 to 0.68) 0.23 (0.08 to 0.66) 0.20 (0.04 to 0.90) 0.55 (0.21 to 1.43)
Combined IRR 0.18 (0.08 to 0.40) 0.19 (0.09 to 0.38) 0.31 (0.18 to 0.56) 0.55 (0.21 to 1.43)
Heterogeneity* 0.0%, p = 0.80 0.0%, p = 0.73 0.0%, p = 0.62 NA
RIRR (sirolimus v paclitaxel) 0.82 (0.31 to 2.18)
p = 0.694
1.51 (0.68 to 3.33)
p = 0.312
0.86 (0.40 to 1.86)
p = 0.703
0.60 (0.21 to 1.71)
p = 0.336
*I2, test of heterogeneity.
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Figure 2 Effect of DES with sirolimus and paclitaxel compared with
bare metal stents on the risks of restenosis, revascularisation, or adverse
events. Combined estimates from meta-analyses of randomised
controlled trials.
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Figure 3 Effect of DES with sirolimus and paclitaxel in patients with and
without diabetes.
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should be performed, which addresses the question whether
the effectiveness of the two stents differs across patient
groups with and without diabetes and, more in general,
between patients at higher or lower risk of complications.
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Abstract
Aims/hypothesis We evaluated the association of QT
interval corrected for heart rate (QTc) and resting heart rate
(rHR) with mortality (all-causes, cardiovascular, cardiac,
and ischaemic heart disease) in subjects with type 1 and
type 2 diabetes.
Methods We followed 523 diabetic patients (221 with type
1 diabetes, 302 with type 2 diabetes) who were recruited
between 1974 and 1977 in Switzerland for the WHO
Multinational Study of Vascular Disease in Diabetes.
Duration of follow-up was 22.6±0.6 years. Causes of death
were obtained from death certificates, hospital records,
post-mortem reports, and additional information given by
treating physicians.
Results In subjects with type 1 diabetes QTc, but not rHR,
was associated with an increased risk of: (1) all-cause
mortality (hazard ratio [HR] 1.10 per 10 ms increase in
QTc, 95% CI 1.02–1.20, p=0.011); (2) mortality due to
cardiovascular (HR 1.15, 1.02–1.31, p=0.024); and (3)
mortality due to cardiac disease (HR 1.19, 1.03–1.36,
p=0.016). Findings for subjects with type 2 diabetes were
different: rHR, but not QTc was associated with mortality
due to: (1) all causes (HR 1.31 per 10 beats per min, 95%
CI 1.15–1.50, p<0.001); (2) cardiovascular disease (HR
1.43, 1.18–1.73, p<0.001); (3) cardiac disease (HR 1.45,
1.19–1.76, p<0.001); and (4) ischaemic heart disease (HR
1.52, 1.21–1.90, p<0.001). Effect modification of QTc by
type 1 and rHR by type 2 diabetes was statistically
significant (p<0.05 for all terms of interaction).
Conclusions/interpretation QTc is associated with long-
term mortality in subjects with type 1 diabetes, whereas
rHR is related to increased mortality risk in subjects with
type 2 diabetes.
Keywords Cardiovascular disease . Diabetes mellitus .
Heart rate .Mortality . QT interval . Risk factors
Abbreviations
bpm beats per min
HR hazard ratio
QTc QT interval corrected for heart rate
rHR resting heart rate
V ventral
Introduction
Compared with the non-diabetic population, subjects with
type 1 and type 2 diabetes mellitus are reported to have an
increase in all-cause mortality [1]. Cardiovascular disease
has been found to be the main reason for this excess
mortality [1–4]. In an effort to identify easily available and
reliable predictors for cardiovascular risk and mortality in
diabetes mellitus, the evaluation of parameters reflecting
myocardial ventricular repolarisation has been of particular
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interest. In subjects with type 1 diabetes, prolongation of
the QT interval corrected for heart rate (QTc) and heart rate
variability have both been shown to be associated with
increased risk of arrhythmia and death, whereas QT
dispersion has been suggested to be less reliable [5].
However, the association between QTc and cardiovascular
mortality in type 2 diabetes is controversial. Some reports
suggest that QTc correlates with an increase in cardiovas-
cular mortality [6–9]. Others have indicated that QT
dispersion might more accurately predict cardiovascular
mortality in this patient group [10–12].
Increased resting heart rate (rHR), which is easily
measurable in clinical practice, has been shown to be an
independent risk factor for cardiovascular death in a non-
diabetic population [13–16]. Recently, rHR has also been
shown to be valuable in estimating the risk of cardiovas-
cular death in patients with type 2 diabetes [8, 10].
However, data directly comparing the role of QTc and
rHR in subjects with type 1 and type 2 diabetes are lacking.
Based on a 23-year follow-up of the Swiss cohort of the
WHO Multinational Study of Vascular Disease in Diabetes
[17], the present study aimed to evaluate the long-term
association of QTc and rHR with mortality in patients with
type 1 and type 2 diabetes within the same study
framework.
Subjects and methods
Study population The WHO Multinational Study of Vascu-
lar Disease in Diabetes is a multicentre international study
with a central protocol applied by 14 centres in 13 countries
[18]. For the original study, each centre recruited stratified
samples of 250 men and 250 women with a clinical
diagnosis of diabetes, aged between 35 and 54 years at
time of recruitment. The present analysis was based on the
Swiss cohort of this study [17], which included 533
subjects randomly selected according to the central protocol
by 231 local practitioners [17, 18]. The sample was
representative of a large area including almost the entire
country. The diagnosis of diabetes mellitus was made on a
clinical basis. Subjects were eligible if diabetes had been
diagnosed at least 1 year prior to study entry and anti-
diabetic treatment (diet, oral glucose-lowering drugs,
insulin) had been initiated by their physicians. If insulin
was needed for treatment within 1 year of diagnosis,
subjects were considered to have type 1 diabetes [18], the
remaining subjects were classified as having type 2
diabetes. These comparably simple clinical definitions with
acknowledged inadequacies were used because of the
constraints on information available and the need for
consistency with earlier reports [19–21]. At baseline, a
standardised clinical examination was performed, including
a detailed questionnaire with information on diabetes
diagnosis, the duration and treatment, as well as on
symptoms of vascular and cardiac disease. Previous
medical history also included the use of other medication
(including diuretics, lipid-lowering drugs and blood pres-
sure-lowering drugs). Central randomisation to the cohort
was stratified according to sex, age (35–41 years, 42–
48 years, 49–54 years) and duration of diabetes (1–6 years,
7–13 years, 14 years and more). In addition, height and
weight were recorded, and blood pressure was measured
after 30 min of rest; hypertension being defined as a
systolic blood pressure of Q160 mmHg, and/or a diastolic
blood pressure Q95 mmHg, and/or the use of antihyperten-
sive medication including diuretics. Urine was tested
semiquantitatively for proteinuria using the salicylsulfonic
acid method, blood samples were drawn to measure fasting
plasma glucose, cholesterol, triacylglycerol and creatinine,
and a 12-lead ECG was recorded. These baseline inves-
tigations were carried out between February 1974 and May
1977. All subjects gave informed consent. Analyses were
carried out in accordance with the Declaration of Helsinki
and the Swiss laws regarding data security. Data used were
made fully anonymous before the analyses.
ECG recordings Standard 12-lead resting ECGs were
recorded with the patient supine and resting for at least
30 min. Analyses were performed according to the
Minnesota code [22]. All tracings were evaluated by the
same two experienced readers. The following items were
derived from the ECG code results: ‘ECG coronary
probable’ consisting of code 1.1, 1.2 and 7.1; ‘ECG
coronary possible’ consisting of codes 1.3, 4.1, 4.2, 4.3,
5.1, 5.2 and 5.3; all other recordings were rated as ‘ECG
coronary unlikely’ [22]. QT and RR intervals were
measured by an experienced cardiologist, blinded to the
diagnosis and outcome of the individual patients. QT
interval length was usually measured in the ventral (V)2
and V3 leads using a digitiser (CalComp, Newbury, Berks,
UK). Measurements in V2 and V3 were chosen, since they
provide a close approximation of maximal QT [23]. QT
interval length was measured from the onset of the QRS to
the end of the T wave. In the presence of U waves, the end
of the QT interval was set at the nadir of the curve between
T and U wave. Maximal QT interval was corrected for the
respective heart rate using the Bazett formula [24]
QTcBazett ¼ QT

RR1=2
 
. In addition, the formulas sug-
gested by Fridericia QTcFridericia¼QT

RR1=3
 
[25] and the
Framingham formula derived by linear regression
QTc Sagie¼ QTþ 0:154 1 RRð Þ
 
were used [26].
Follow-up and outcome definition The status (alive/dead)
and date of death of each subject were ascertained as per 1
January 1998 on the basis of data obtained from population
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registries. In deceased patients, the underlying cause of
each death was determined from a copy of the death
certificate, hospital records, post-mortem reports (where
available), and additional information given by the treating
physicians. Causes of death were coded according to the
International Classification of Disease (ICD-9). Cardiovas-
cular mortality included codes 390 to 459 and 798.1,
cardiac mortality codes 390 to 429 and 798.1, and mortality
due to ischaemic heart disease codes 410 to 414.
Statistical analysis Statistical assessment of potential dif-
ferences in baseline characteristics between patients with
type 1 and type 2 diabetes mellitus was carried out using
the two-tailed unpaired Student’s t test for continuous
variables and the Pearson’s chi-squared test for proportions.
The impact of QTc interval and rHR on mortality rates was
assessed by time-to-event analysis using Cox proportional
hazards models. Date of last clinical contact or documented
date of leaving Switzerland was used for censored subjects,
and exact date of death for subjects who had died. Analyses
were conducted separately for subjects with type 1 and type
2 diabetes respectively, regarding all-cause, cardiovascular
and cardiac mortality, and death due to ischaemic heart
disease. Univariable analyses were performed before
adjusting the regression model for age and sex. Then a
‘full model’ was fitted including the following explanatory
variables: age, sex, BMI, duration of diabetes, total
cholesterol, triacylglycerol, fasting plasma glucose, pres-
ence of hypertension/antihypertensive medication, history
of coronary heart disease, history of microvascular disease,
smoking, alcohol consumption, treatment with insulin
(subjects with type 2 diabetes) and treatment with diuretics.
QTc was included in the analysis of rHR and vice versa.
The model’s assumptions (proportionality) were regularly
checked. Analyses were then repeated using cut-off values
corresponding to the lower limits of the upper quartiles
(QTc interval ≥450 ms or <450 ms in type 1, rHR ≥90 beats
per min [bpm] or <90 bpm in type 2 diabetes). Comparable
cut-off values have been suggested in earlier reports [13,
27, 28]. Based on these cut-off values, Kaplan–Meier
survival analyses were performed for the main endpoint
(overall mortality) and differences were statistically
assessed using log-rank test. To formally assess effect
modification of QTc and rHR by diabetes type a confirma-
tory analysis was performed including terms of interaction
in an analysis by Cox regression. Finally, regression models
using the Bazett formula for QTc were compared with
models using the formula suggested by Fridericia [25] and
by Sagie [26]. All analyses were performed using Stata
version 8.2 (Stata Corporation, College Station, TX, USA).
Results are given as mean±SD and as hazard ratio (HR)
with 95% CI. p values <0.05 were considered statistically
significant.
Results
Study characteristics The entire cohort comprised 533
patients and baseline ECGs were available in 523 patients
(221 type 1 diabetes, 302 type 2 diabetes). During follow-
up 18 patients left the country and were censored
accordingly. This translated into a drop-out rate of 3.4%.
Baseline ECG was normal in more than three-quarters of all
patients (85% and 77% for types 1 and 2 diabetes,
respectively). The mean difference of repeated determina-
tions of QTc was 2.8%. Mean follow-up was 22.6±0.6 years
corresponding to a total of 11,815 person-years. Baseline
characteristics are shown in Table 1. The proportion of
women in the type 1 diabetes group was 54%, that for type
2 diabetes was lower (44%). Overall there were slightly
more men than women (278, 255). Subjects with type 1
diabetes were generally younger, but had a longer duration
of diabetes and a higher prevalence of retinopathy as well
as higher mean values for fasting glucose at baseline. In
contrast, subjects with type 2 diabetes showed higher
values for BMI, blood pressure, and lipids, with coronary
heart disease reported more frequently. Only a minority of
subjects with type 2 diabetes were being treated with diet
alone; two-thirds were using oral glucose-lowering drugs
(e.g. sulfonylureas and/or biguanides), and less than one-
third were being treated with insulin. In contrast, all
patients with type 1 diabetes used insulin, with a minority
also receiving oral glucose-lowering drugs (e.g. bigua-
nides). While the proportion of subjects treated with
antihypertensive drugs other than diuretics as well as with
lipid-lowering drugs was comparable for the two types of
diabetes, the use of diuretics was more frequent in subjects
with type 2 diabetes. At baseline rHR tended to be higher
and QTc interval was significantly longer in patients with
type 1 diabetes than in those with type 2 diabetes.
All-cause mortality During the study period 107 subjects
with type 1 diabetes and 158 subjects with type 2 diabetes
died. In subjects with type 1 diabetes, QTc was positively
associated with overall mortality. The unadjusted HR
was 1.07 per 10 ms increase of QTc (95% CI 1.01–1.15,
p=0.033). This was not substantially altered when the
model was adjusted for age and sex (HR 1.10, 95% 1.02–
1.18, p=0.009). The association persisted after additional
inclusion of further explanatory variables as stated in
Subjects and methods (‘full model’, HR 1.10, 1.02–1.20,
p=0.011). In contrast, no association of rHR with this
endpoint was detected in type 1 diabetes (p=0.924) (Fig. 1,
Tables 2 and 3). Subjects with type 2 diabetes revealed a
strong positive association between rHR and mortality due
to all causes. The unadjusted HR was 1.27 per 10 bpm
(95% CI 1.14–1.41, p<0.001). Again, adjustment for age
and sex revealed a similar HR (1.28, 1.16–1.42, p<0.001),
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which was not substantially altered in the fully adjusted
model (HR 1.31, 1.15–1.50, p<0.001). A comparable effect
was not detected for QTc in these patients (p=0.380). The
analysis of an effect modification of QTc and rHR by
diabetes type revealed a statistically significant association
between QTc and type 1 diabetes and between rHR and
type 2 diabetes (p=0.026 and p=0.014 for terms of
interaction; Fig. 1), thereby underscoring the differences
between the two types of diabetes. Subjects with type 1
diabetes and a QTc ≥450 ms had a twofold increased
mortality risk compared with those with a QTc <450 ms
(HR 2.04, 95% CI 1.27–3.25, p=0.003). In type 2 diabetes,
a comparable increase in risk was observed when subjects
with a rHR ≥90 bpm were compared with those with rHR
<90 bpm (HR 2.23, 95% CI 1.43–3.46, p<0.001). Results
of Kaplan–Meier survival analysis are shown in Fig. 2
(p values for log-rank test 0.019 and 0.001 for type 1 and
type 2 diabetes, respectively).
Cardiovascular mortality In 50 subjects with type 1 and in
76 subjects with type 2 diabetes, death was classified as due
to cardiovascular disease. As for all-cause mortality, QTc
but not rHR was positively associated with cardiovascular
mortality in type 1 diabetes (Fig. 1, Table 2). HRs for QTc
tended to be lower in the unadjusted model and after
inclusion of age and sex when compared with the fully
adjusted model, although conventional levels of signifi-
cance were reached only in the latter (Table 3). Inverse
findings were observed in subjects with type 2 diabetes,
where rHR but not QTc was related to this endpoint (Fig. 1,
Table 2). Again, the HR in the unadjusted model was
similar to those after adjustment for age and sex and to the
‘full model’ (Table 3). Confirmatory analysis using inter-
action terms revealed that the differences between the
two types of diabetes were unlikely to be a chance finding
(p=0.008 and p=0.008 for interaction, respectively; Fig. 1).
In type 1 diabetes, mortality risk for a QTc ≥450 ms was
again increased twofold compared with a QTc <450 ms (HR
2.34, 95% CI 1.16–4.71, p=0.018). In type 2 diabetes a
rHR ≥90 bpm was even associated with a threefold
increased risk (HR 3.27, 95% CI 1.76–6.09, p<0.001).
Cardiac mortality Cardiac mortality was confirmed in 43
type 1 and 71 type 2 diabetic patients. In the former, QTc
Table 1 Study characteristics
Data are mean values±SD
QTc QT interval corrected for
heart rate according to the
formula suggested by Bazett
*Diuretics excluded
a p<0.05 for difference between
type 1 and type 2 diabetes
b p<0.001 for difference be-
tween type 1 and type 2
Type 1 diabetes Type 2 diabetes
Demographic
Total number of patients (n) 225 308
Age (years) 43±6 46±6b
Female patients (n) 121 (54%) 134 (44%)a
Clinical
BMI (kg/m2) 24±4 28±5b
Duration of diabetes (years) 15±10 9±6b
Systolic blood pressure (mmHg) 136±20 141±21a
Diastolic blood pressure (mmHg) 86±11 89±11b
Nicotine consumption (no. cigarettes per day) 4±8 4±8
Alcohol consumption (g/day) 8±17 12±28
ECG performed 221 (98%) 302 (98%)
ECG normal 187 (85%) 234 (77%)
Resting heart rate (bpm) 79±13 77±14
QTc (ms) 433±30 426±32a
Biochemical
Total cholesterol (mmol/l) 6.1±1.4 6.5±1.4a
Triacylglycerol (mmol/l) 1.4±1.2 2.4±2.7b
Fasting glucose (mmol/l) 11.7±6.5 10±4.1b
Serum creatinine (μmol/l) 91.9±43.3 86.6±27.4
Micro- and macrovascular disease
Presence of retinopathy 117 (52%) 68 (22%)b
Presence of proteinuria 51 (23%) 75 (24%)
Presence of coronary heart disease 45 (20%) 96 (31%)a
Medication
Diet alone as glucose-lowering treatment 0 (0%) 27 (9%)b
Use of oral glucose-lowering drugs 27 (12%) 188 (62%)b
Use of insulin 225 (100%) 90 (29%)b
Use of any antihypertensive drug* 33 (15%) 68 (22%)
Use of lipid-lowering drugs 4 (2%) 15 (5%)
Use of diuretics 22 (10%) 60 (20%)a
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but not rHR was significantly associated with cardiac
mortality (Fig. 1, Table 2). HRs tended to be slightly
higher in the fully adjusted model compared with the
unadjusted analysis (Table 3). In type 2 diabetes, rHR was
found to predict cardiac mortality, whereas QTc was not
(Fig. 1, Table 2). Adjustment for age and sex and inclusion
of further explanatory variables did not affect HRs (Table 3).
Again, effect modification showed that QTc was related to
type 1 and rHR to type 2 diabetes (p=0.006 and p=0.009
for interaction, respectively; Fig. 1). HR for subjects with
type 1 diabetes and QTc ≥450 ms was 2.90 (95% CI 1.36–
6.16, p=0.006). In subjects with type 2 diabetes, risk of
cardiac mortality was comparably increased for those with a
rHR ≥90 bpm (HR 3.51, 95% CI 1.86–6.64, p<0.001).
Death due to ischaemic heart disease There were 25 and
52 deaths due to ischaemic heart disease in subjects with
type 1 and type 2 diabetes, respectively. In the former, no
statistically significant association was found for either QTc
nor rHR (Fig. 1, Tables 2 and 3). In subjects with type 2
diabetes, a strong positive association persisted for rHR but
not for QTc (p=0.010 for interaction; Fig. 1, Tables 2 and 3).
Type 2 diabetic subjects with a rHR of ≥90 bpm had a more
than threefold increased risk of dying from ischaemic heart
disease (HR 3.33, 95% CI 1.63–6.77, p=0.001).
Different formulas for correcting QT interval for heart
rate Similar results were obtained using the formulas
proposed by Fridericia [25] or Sagie [26] when compared
with Bazett’s formula [24]. For example, in subjects with
type 1 diabetes, HR for all-cause mortality was 1.10 using
Bazett’s model. Applying Fridericia’s or Sagie’s approach
the corresponding values were 1.12 and 1.13, respectively
(Table 2). The same additional explanatory variables were
used for all three analyses. The current literature is mainly
based on Bazett’s formula. In order to compare the present
findings with previous reports, the formula suggested by
Bazett was included in the final model.
Discussion
The main finding of this 23-year follow-up was a difference
in the prognostic value of rHR and QTc between the two
types of diabetes. In subjects with type 1 diabetes QTc, but
not rHR was associated with an increased risk of all-cause
mortality and mortality due to cardiovascular and cardiac
disease. In contrast, in type 2 diabetes rHR, but not QTc
was consistently related to mortality due to all causes,
cardiovascular, cardiac, and ischaemic heart disease. Inter-
estingly, in type 1 diabetes a QTc interval ≥450 ms
translated into a twofold increase in all-cause mortality
and a threefold increase in cardiac mortality. In subjects
with type 2 diabetes a comparable increase in mortality risk
was found for a rHR of ≥90 bpm compared with a rHR
<90 bpm.
To our knowledge, this is the first study to prospectively
assess the role of QTc and rHR in both types of diabetes
within the same study framework. Its findings confirm the
prognostic value of QTc as an independent risk factor for
all-cause mortality in type 1 diabetes [5, 28–30]. In
addition to the results of Rossing et al. [5], the present
QTc interval Resting heart rate
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Fig. 1 Hazard ratios for
mortality due to all causes,
cardiovascular disease, cardiac
disease, and ischaemic heart
disease per incremental 10 ms
prolongation of QTc interval and
per 10 bpm increase in resting
heart rate, respectively. p values
are for effect modification
by type of diabetes (closed
circles, type 1 diabetes; open
circles, type 2 diabetes)
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analysis found QTc to be associated not only with overall
mortality but also with cardiovascular and cardiac mortality.
Moreover, it also reproduced the findings of Sawicki and
colleagues, which were made in subjects with nephropathy
[28] in a more general sample of subjects with type 1
diabetes. The HR for overall mortality found in the present
analysis was comparable to that in Rossing’s report [5], but
tended to be lower than the risk ratio found in subjects with
overt nephropathy [28] (1.10 and 1.47 per 10 ms, respec-
tively). Earlier reports have suggested that the association
between QTc and cardiovascular disease was stronger in
male than in female subjects with type 1 diabetes [30]. The
present study had slightly more female subjects in the
group with type 1 diabetes, thereby potentially under-
estimating the prognostic value of QTc for this patient
group.
An increased rHR has been found to be related to all-
cause mortality and cardiovascular death in several trials of
non-diabetic subjects [13, 31–34], and in subjects with type
2 diabetes [8, 10]. Our analysis confirmed the role of rHR
as an easily measurable factor for risk assessment of all-
cause and cardiovascular mortality in subjects with type 2
diabetes, and had comparable HRs. In addition to findings
of previous reports, we also observed a relation between
elevated rHR and both cardiac mortality and mortality due
to ischaemic heart disease. On the other hand, the present
analysis did not confirm an association between QTc and
any of the endpoints in type 2 diabetes as has been reported
previously [6, 7, 9, 10, 35]. Given previous hypotheses that
prolongation of QTc as a marker of cardiac autonomic
neuropathy could be of greater importance in type 1 than in
type 2 diabetes [5], our findings on this count are
intriguing, and it can only be speculated on the underlying
mechanisms.
In subjects with type 1 diabetes an increased prevalence
of prolonged QTc has been reported before [30, 36], in
particular in subjects with autonomic neuropathy [36–38].
This may indicate that increased QTc relates to diabetic
autonomic neuropathy [39]. QTc prolongation has been
suggested to result from a reduction in vagal activity and an
Table 2 Hazard ratios (95% CI) for mortality due to all causes, cardiovascular, cardiac, and ischaemic heart disease
Type 1 diabetes Type 2 diabetes
All-cause mortality
QTc Bazett (model with rHR) 1.10 (1.02–1.20) p=0.011 0.97 (0.91–1.03) p=0.380
rHR (model with QTc Bazett) 0.98 (0.83–1.18) p=0.924 1.31 (1.15–1.50) p<0.001
QTc Fridericia (model with rHR) 1.12 (1.03–1.21) p=0.011 0.97 (0.91–1.03) p=0.343
rHR (model with QTc Fridericia) 1.09 (0.93–1.28) p=0.307 1.28 (1.13–1.46) p<0.001
QTc Sagie (model with rHR) 1.13 (1.03–1.23) p=0.012 0.97 (0.90–1.04) p=0.366
rHR (model with QTc Sagie) 1.10 (0.94–1.30) p=0.241 1.28 (1.13–1.46) p<0.001
Cardiovascular mortality
QTc Bazett (model with rHR) 1.15 (1.02–1.31) p=0.024 0.94 (0.85–1.03) p=0.160
rHR (model with QTc Bazett) 0.99 (0.77–1.27) p=0.917 1.43 (1.18–1.73) p<0.001
QTc Fridericia (model with rHR) 1.16 (1.02–1.32) p=0.026 0.93 (0.84–1.02) p=0.140
rHR (model with QTc Fridericia) 1.12 (0.88–1.42) p=0.346 1.35 (1.12–1.63) p=0.002
QTc Sagie (model with rHR) 1.18 (1.02–1.36) p=0.023 0.91 (0.82–1.02) p=0.100
rHR (model with QTc Sagie) 1.14 (0.90–1.46) p=0.272 1.34 (1.11–1.61) p=0.002
Cardiac mortality
QTc Bazett (model with rHR) 1.19 (1.03–1.36) p=0.016 0.94 (0.85–1.03) p=0.182
rHR (model with QTc Bazett) 0.98 (0.74–1.28) p=0.865 1.45 (1.19–1.76) p<0.001
QTc Fridericia (model with rHR) 1.19 (1.03–1.38) p=0.018 0.93 (0.84–1.03) p=0.163
rHR (model with QTc Fridericia) 1.13 (0.88–1.46) p=0.336 1.37 (1.13–1.66) p=0.001
QTc Sagie (model with rHR) 1.21 (1.03–1.42) p=0.017 0.92 (0.82–1.02) p=0.115
rHR (model with QTc Sagie) 1.16 (0.90–1.51) p=0.256 1.36 (1.12–1.66) p=0.002
Death due to ischaemic heart disease
QTc Bazett (model with rHR) 1.08 (0.90–1.30) p=0.397 0.97 (0.87–1.09) p=0.617
rHR (model with QTc Bazett) 0.91 (0.58–1.42) p=0.678 1.52 (1.21–1.90) p<0.001
QTc Fridericia (model with rHR) 1.09 (0.90–1.32) p=0.399 0.97 (0.86–1.09) p=0.581
rHR (model with QTc Fridericia) 0.98 (0.64–1.49) p=0.914 1.48 (1.18–1.85) p=0.001
QTc Sagie (model with rHR) 1.09 (0.89–1.34) p=0.401 0.96 (0.84–1.09) p=0.531
rHR (model with QTc Sagie) 0.99 (0.64–1.51) p=0.946 1.47 (1.18–1.84) p=0.001
Data are given per incremental 10 ms prolongation of QTc interval and 10 bpm increase in rHR, respectively Formulas for calculation of QTc:
Bazett [24], Fridericia [25], Sagie [26], as indicated by subscript All models adjusted for age, sex, BMI, duration of diabetes, total
cholesterol, triacylglycerol, fasting plasma glucose, presence of hypertension, history of coronary heart disease, history of microvascular
disease, smoking, alcohol consumption, treatment with insulin (subjects with type 2 diabetes) and treatment with diuretics.
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increased sympathetic tonus, thereby reflecting myocardial
autonomic instability and an increased risk of arrhythmia
and cardiac death [9, 28, 36, 40]. Compared with previous
publications reporting an association of QTc with mortality
in type 2 diabetes [9, 10, 35], subjects with type 2 diabetes
were substantially younger in the present study. It should
also be noted that some earlier reports revealing an
association between QTc and mortality were cross-sectional
[35] or based on a case–control design [9] and in the case of
prospective trials [6, 7, 10] had a considerably shorter
follow-up.
In type 2 diabetes hyperglycaemia is often associated
with a pro-inflammatory state including obesity, dyslipi-
daemia and hypertension, thereby promoting the develop-
ment of atherosclerosis [41]. Interestingly, impaired
myocardial oxygen supply has also been shown to
influence QT interval [28, 30]. As has been pointed out
before [6, 10], QTc is possibly a composite marker,
reflecting abnormal ventricular repolarisation due to ischae-
mia, fibrosis, left ventricular hypertrophy and dilatation,
autonomic neuropathy, and vascular damage, conditions
frequently present in diabetic myocardium. Although the
models used in this analysis were adjusted for the pre-
existence of coronary heart disease, we could not fully rule
out a potential interference due to silent heart disease in
subjects with diabetes, since invasive cardiac procedures
were not performed.
The strength of the present study lies in the long follow-
up period, the well-defined cohort of diabetic subjects
(Swiss cohort [17] of the WHO Multinational Study of
Vascular Disease in Diabetes [18, 22]), the evaluation of
pre-specified endpoints, and the small drop-out rate.
Considerable efforts were undertaken to adjust for relevant
factors known to affect cardiovascular risk and/or myocar-
Table 3 Hazard ratios (95% CI) for mortality due to all causes, and to cardiovascular, cardiac and ischaemic heart disease
All-cause
mortality
Cardiovascular
mortality
Cardiac
mortality
Death due to ischaemic
heart disease
Type 1 diabetes
QTc Crude/unadjusted 1.07
(1.01–1.15)
p=0.033 1.08
(0.99–1.19)
p=0.098 1.10
(0.99–1.22)
p=0.084 1.04
(0.91–1.19)
p=0.610
Adjusted for age
and sex
1.10
(1.02–1.18)
p=0.009 1.10
(1.00–1.22)
p=0.057 1.12
(1.00–1.25)
p=0.055 1.06
(0.92–1.23)
p=0.410
Full model* 1.10
(1.02–1.20)
p=0.011 1.15
(1.02–1.31)
p=0.024 1.19
(1.03–1.36)
p=0.016 1.08
(0.90–1.30)
p=0.397
Type 2 diabetes
rHR Crude/unadjusted 1.27
(1.14–1.41)
p<0.001 1.35
(1.15–1.57)
p<0.001 1.36
(1.16–1.60)
p<0.001 1.42
(1.18–1.70)
p<0.001
Adjusted for age
and sex
1.28
(1.16–1.42)
p<0.001 1.36
(1.18–1.57)
p<0.001 1.37
(1.18–1.59)
p<0.001 1.41
(1.19–1.68)
p<0.001
Full model* 1.31
(1.15–1.50)
p<0.001 1.43
(1.18–1.73)
p<0.001 1.45
(1.19–1.76)
p<0.001 1.52
(1.21–1.90)
p<0.001
Results are shown from a three-step approach in regression modelling (unadjusted, adjusted for age and sex, and ‘full model’). Data are given per
incremental 10 ms prolongation of QTc interval for type 1 and 10 bpm increase in rHR for type 2 diabetes, respectively.
*Full model adjusted for: age, sex, BMI, diabetes duration; levels of fasting glucose, triacylglycerol and cholesterol; presence or absence of
microvascular disease, hypertension, coronary heart disease; treatment with diuretics, insulin (for type 2 diabetes); alcohol consumption,
smoking. QTc was included in the analysis of rHR and vice versa.
Fig. 2 Kaplan–Meier estimation
of survival probabilities for over-
all mortality. a The survival
probabilities for type 1 diabetes,
comparing patients with a QTc
interval ≥450 ms (solid line) with
those with a QTc interval
<450 ms (dotted line). p=0.019
for difference by log-rank test.
b Survival probabilities for type 2
diabetes comparing patients with
a resting heart rate ≥90 bpm
(solid line) with those with rHR
<90 bpm (dotted line). p=0.001
for difference by log-rank test
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dial ventricular repolarisation This allowed inclusion of
parameters that earlier reports had not been adjusted for,
despite their known influence on mortality (e.g. alcohol
consumption) [42]. Moreover, as the use of Bazett’s
formula [24] to calculate QTc has been questioned before
[8, 26, 43], possible differences in effect were taken into
account by performing sensitivity analyses using the
formulas suggested by Fridericia [25] and by Sagie [26].
In contrast to earlier reports [8], inclusion of different
calculations of QTc did not substantially alter our results
(Table 2). As a consequence, Bazett’s formula was included
in the final model to allow for comparisons with other
reports.
Nevertheless, we must acknowledge some limitations to
our findings. Thus rHR was determined from ECG record-
ings, whereas in clinical practice it is usually measured by
pulse palpation, rendering it subject to variation due to
circumstantial factors (medical setting, circadian rhythm,
body position etc.). In addition, QTc and rHR can
potentially be influenced by specific medication. Although
the use of antihypertensive medication and diuretics was
recorded in the present trial, data did not allow to
specifically adjust for the use of beta blockers. Since it is
known that treatment with these agents can influence both
QTc [44], and rHR, a potential interfering effect on the
present findings cannot be fully excluded. It should,
however, be noted that at the time of study entry only a
limited number of beta blockers was available in Switzer-
land. Moreover, in another study [9] adjustment for use of
beta blockers only modestly attenuated the association
between QTc and the risk of primary cardiac arrest. Another
known factor to influence rHR is physical training [45].
Tachycardia may be a marker of decreased physical fitness,
which in turn may be associated with an increased risk of
mortality [46]. Interestingly, increased rHR was found to be
an independent prognostic factor of cardiovascular mortal-
ity in studies controlling for energy expenditure as an
indicator of physical fitness [31].
In deceased patients, the underlying cause of death was
determined from a copy of the death certificate, hospital
records, post-mortem reports, and additional information
given by the treating physicians. Despite intensive efforts to
collect comprehensive data, the cause of death may, in
some cases, have been misclassified, especially if based
only on death certificates, which are a comparatively
unreliable source of information. Thus, our findings
regarding all-cause mortality are clearly more robust than
those for cause-specific mortality.
Glycaemic control has been shown to be related to
macrovascular complications [47, 48], and was, therefore,
included in the present analysis. Importantly, information
on glycaemic control had to be based on fasting glucose,
since HbA1c was not available at the time of study entry,
thereby potentially limiting the accuracy of adjustment.
With regard to this, however, Veglio et al. did not report a
significant influence of HbA1c levels on QTc [35].
In summary, this study, performed in a large, diabetic
cohort followed over 23 years, confirms that in subjects
with type 1 diabetes prolonged QTc is associated with an
increased mortality risk due to all causes, and to cardio-
vascular and cardiac disease, whereas no association was
found for rHR. In contrast, in subjects with type 2 diabetes,
elevated rHR, but not QTc, is associated with an increased
risk of all-cause mortality as well as risk of death due to
cardiovascular, cardiac and ischaemic heart disease. The
underlying pathophysiological mechanisms are probably
complex and remain to be fully elucidated.
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Objectives. To evaluate the association of
apolipoprotein B (apo B) with mortality due to all
causes, to cardiac disease and to ischaemic heart
disease (IHD) in subjects with type 1 diabetesmellitus.
Subjects. 165 subjects with type 1 diabetes included
in the Swiss Cohort of the WHO Multinational Study
of Vascular Disease in Diabetes were followed for
14.7 ± 0.45 years.
Methods. Causes of death were obtained from death
certificates, hospital records and postmortem
reports. Using a parametric proportional hazards
model the association of apo B with mortality rates
was assessed by time-to-event analysis, including
the absolute cumulative mortality risk over time for
various apo B levels at baseline.
Results. Apo B was positively associated with all-
cause mortality [hazard ratio (HR) 2.65 per g L)1
increase of apo B, 95% CI: 1.11–6.36, P ¼ 0.029],
cardiac mortality (HR 11.64, 1.03–131.11, P ¼
0.047) and IHD mortality (HR 9.36, 1.26–69.66,
P ¼ 0.029). An apo B ‡0.96 g L)1 translated into a
duplication of overall mortality hazard (HR 1.93,
1.00–3.72, P ¼ 0.050), and a sevenfold increase of
mortality because of cardiac disease or IHD (HR
7.44, 1.44–38.42, P ¼ 0.017 and HR 7.38, 0.78–
69.82, P ¼ 0.081). A baseline apo B of 1.5 g L)1
predicted an absolute cumulative risk to die over the
next 10 years of 12.1% (5.2–31.7) for male and of
10.4% (4.7–26.1) for female subjects whereas risks
were 6.3% (1.8–21.4) and 5.4% (0.8–15.8) for an
apo B of 0.8 g L)1.
Conclusion. Apo B is consistently associated with
an increased mortality in type 1 diabetes.
Keywords: apolipoproteins, cardiovascular risk
factors, mortality, type 1 diabetes mellitus.
Introduction
Apolipoprotein B (apo B) has recently been sugges-
ted an easily measurable and valuable estimate of
cardiovascular risk [1–4]. In contrast, current
guidelines in the United States [5, 6] as well as in
Europe [7, 8] recommend the use of low-density
lipoprotein (LDL) cholesterol as the primary target
risk factor. The main advantage of apo B has been
related to the fact that its levels correspond to the
number of atherogenic particles thereby improving
the estimate of total atherogenic burden [1, 4].
Several prospective clinical trials [9–13] and a
recent meta-analysis [14] have underscored the
value of apo B in the assessment of cardiovascular
risk in the general population. Similar results have
been found in multiple cross-sectional [15–19] and
prospective [20–23] trials in subjects with type 2
diabetes mellitus or the metabolic syndrome.
In contrast to the evidence of the value of apo B in
nondiabetic subjects or in subjects with type 2
diabetes, comparably little is known about its role in
type 1 diabetes. Although accounting for only 5–
10% of all diabetic subjects type 1 diabetes remains a
serious chronic disorder with important short-term
and long-term complications [24]. Despite all efforts
to improve treatment strategies recent reports
showed that cardiovascular mortality in type 1
Journal of Internal Medicine 2006 doi:10.1111/j.1365-2796.2006.01690.x
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diabetes is still increased when compared with
healthy subjects [25]. The precise underlying path-
ophysiological abnormalities are currently ill defined
[25]. Dyslipidaemia is a well-established cardiovas-
cular risk factor in the general population and in
subjects with type 2 diabetes. It has been suggested
to contribute to the increased risk in subjects with
type 1 diabetes as well [26, 27]. However, epidemi-
ological data have indicated a stronger association
of apo B with microvascular complications than
with cardiovascular disease in type 1 diabetes [28–
30]. Only one prospectively conducted trial in
subjects with type 1 diabetes has reported an
association of apo B with cardiovascular disease
but not with mortality [31]. Taken together, in type
1 diabetes there is uncertainty about the association
of apo B with cardiovascular disease. In particular,
little is known on the prognostic value of apo B on
mortality in these subjects. Based on a 15-year
follow up of the Swiss Cohort of the WHO Multina-
tional Study of Vascular Disease in Diabetes [32] we,
therefore, assessed the long-term association of apo
B with mortality because of different causes.
Subjects and methods
Study population
In 1972, the ‘WHO multinational study of vascular
disease in diabetes’ was planned to assess the
frequency of microvascular and macrovascular mor-
bidity in subjects with diabetes mellitus in different
countries and to examine the relationship with
potential influencing factors, as for example, race,
diet or therapy. Overall, 6695 subjects with diabetes
mellitus with an age between 35 and 54 years were
recruited in 14 countries [33]. In Switzerland, 225
subjects with type 1 diabetes mellitus were examined
by local practitioners between February 1974 and
May 1977, according to a standardized protocol [32,
33]. For the purpose of this study type 1 diabetes was
diagnosed if insulin was needed for treatment within
1 year of diagnosis [33]. Randomization to the
cohort was stratified according to gender, age and
duration of diabetes. The sample was representative
of a large area including almost the entire country.
Between March 1982 and February 1985 a second
clinical visit was performed in a subset of the entire
cohort. At this time-point a second blood sample was
drawn in 165 subjects with type 1 diabetes.
Data recording and blood sampling
At baseline and at the second visit, a standardized
clinical examination was performed, including a
detailed questionnaire with information on the
diagnosis of diabetes, the duration and treatment
as well as on symptoms of vascular and cardiac
disease. In addition, height, weight and blood
pressure were recorded; proteinuria was measured
semiquantitatively using the salicylsulphonic acid
method. Blood samples were drawn to measure
fasting plasma glucose, cholesterol, triglycerides and
creatinine concentrations, and a 12-lead electrocar-
diogram was recorded. The concentration of apo B
was measured by radioimmunoassay (Behring,
Germany). Analyses were carried out in accordance
with the Declaration of Helsinki and the Swiss laws
regarding data safety. The data were rendered
anonymous before the analyses.
Follow up and outcome definition
The primary outcome was overall mortality, secon-
dary outcomes included death due to cardiac disease
and ischaemic heart disease (IHD). The status (alive/
dead) and date of death of each subject was
ascertained as per 1 January 1998 based on data
obtained from population registries. In deceased
patients, the underlying cause of each death was
determined from a copy of the death certificate,
hospital records, postmortem reports (where avail-
able) and additional information given by the
treating doctors. Causes of death were coded accord-
ing to the International Classification of Disease
(ICD-9). Cardiac mortality included codes 390–429
and 798.1 and mortality due to ischaemic heart
disease (IHD) codes 410–414.
Statistical analysis
The impact of apo B on mortality was assessed by
time-to-event analysis. Date of last clinical contact
or documented date of leaving Switzerland was used
for censored subjects, whereas exact date of death
was included for deceased subjects. Analyses were
conducted separately for all end-points. Using a cut-
off value based on the upper limit of the lowest
quartile (0.96 g L)1), subjects with an apo B level
<0.96 g L)1 were compared to those with an apo B
level ‡0.96 g L)1 in a Kaplan–Meier survival
 2006 Blackwell Publishing Ltd Journal of Internal Medicine
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analysis, and differences were statistically assessed
using log-rank test. To assess prognostic variables,
multivariable parametric proportional hazards mod-
els of the Weibull family were fitted [34]. Univariable
analyses were performed before adjusting the regres-
sion model for age and gender. Then a ‘full model’
was fitted including the following explanatory var-
iables: age, gender, body mass index (BMI), duration
of diabetes, cholesterol, triglycerides, fasting plasma
glucose, presence of hypertension (defined as systolic
blood pressure >140 mmHg and/or diastolic blood
pressure >90 mmHg or treatment with antihyper-
tensive drugs), history of microvascular disease,
treatment with diuretics, treatment with antihyper-
tensive drugs and alcohol consumption.
Finally, to illustrate the prognostic value of apo B,
the cumulative absolute mortality risk over time was
computed for various values of baseline concentra-
tion of apo B. For this analysis all explanatory
variables as specified above were taken into account
and the covariate pattern for continuous variables
was set to the average covariate of the study
population. A separate analysis was performed for
male and female subjects to assess potential gender
differences. Confidence intervals (CI) were obtained
using bootstrapping (300 replications). All analyses
were performed using stata version 8.2 (Stata
Corporation, College Station, TX, USA). Results are
given as mean ± SD and as hazard ratio (HR) with
95% CI. P-values of <0.05 were considered statis-
tically significant.
Results
Study characteristics
Measurement of apo B was performed in 165
subjects with type 1 diabetes between March 1982
and February 1985. Mean follow up was
14.7 ± 0.45 years corresponding to a total of
2424 person-years. No subject was lost to follow
up. Baseline characteristics are shown in Table 1.
The study population consisted of slightly more
females than males. Subjects had a mean age of
about 50 years, weight was generally normal but
blood pressure tended to be elevated although only
about a quarter of the subjects used antihyperten-
sive drugs. Total cholesterol levels were comparably
high whereas triglycerides were in the normal
range. Less than 4% of subjects were under lipid-
lowering therapy. In two-thirds of the study popu-
lation evidence of diabetic retinopathy was found
whereas nephropathy was less frequently documen-
ted. Apo B levels ranged from 0.6 to 2.9 g L)1 with
a mean of 1.2 g L)1.
All-cause mortality
During the study period 72 subjects died. Apo B
levels were positively associated with an increased
mortality risk. The unadjusted HR was 2.78
per g L)1 increase of apo B (95% CI: 1.35–5.75,
P ¼ 0.006). This was not substantially altered when
the model was adjusted for age and gender (HR 2.62
per g L)1, 95% CI: 1.17–5.83, P ¼ 0.019; Table 2).
The association persisted after additional inclusion
of further explanatory variables as stated in the
Subjects and Methods section (‘full model’; HR 2.65
per g L)1, 95% CI: 1.11–6.36, P ¼ 0.029; Table 2).
Of note, the fully adjusted model revealed no
association of total cholesterol levels with all-cause
mortality (HR 0.96 per g L)1, 95% CI 0.81–1.13,
P ¼ 0.598). The levels of triglycerides were posi-
tively associated with overall mortality, although
Table 1 Study characteristics
All subjects
(n ¼ 165)
Demographic
Age (years) 51.0 ± 6.3
Males/females 72/93
Clinical
Body mass index (kg m)2) 24.3 ± 3.9
Duration of diabetes (years) 23.5 ± 9.2
Systolic blood pressure (mmHg) 143.5 ± 22.4
Diastolic blood pressure (mmHg) 86.7 ± 11.6
Alcohol consumption (dL day)1)a 1.3 ± 2.3
Biochemical
Fasting glucose (mmol L)1) 10.2 ± 5.3
Serum creatinine (mmol L)1) 103.6 ± 70.9
Total cholesterol (mmol L)1) 7.5 ± 6.2
Triglycerides (mmol L)1) 1.6 ± 0.8
Apo B (g L)1) 1.2 ± 0.3
Medications [n (%)]
Diuretics 43 (26)
Antihypertensive drugs 39 (24)
Lipid-lowering drugs 6 (4)
Microvascular disease [n (%)]
Retinopathy 108 (66)
Proteinuria 49 (30)
Data are given as mean ± SD or as numbers (percentage) of
subjects.
aIncludes consumption of wine, beer and all types of liquors.
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the HR per g L)1 increase was lower than for apo B
and association did not reach conventional levels of
statistical significance (HR 1.35 per g L)1, 95% CI:
0.99–1.84, P ¼ 0.054). Subjects in the lowest
quartile for apo B (<0.96 g L)1) had a significantly
lower risk of mortality when compared with the
remainders of this cohort. Unadjusted Kaplan–Meier
survival analysis for this cut-off value is illustrated in
Fig. 1 (P ¼ 0.020 by log-rank test). The increased
mortality of subjects with an apo B ‡0.96 g L)1
persisted after adjusting for all explanatory variables
(HR 1.93, 95% CI: 1.00–3.72, P ¼ 0.050).
Cardiac mortality
A death due to cardiac disease was confirmed in 28
subjects. Again, apo B was significantly associated
with this outcome for all models that were tested
(Table 2). However, whilst the univariate model
revealed a HR that was very similar to the model
adjusted for age and gender (HR 3.07 and 3.17,
respectively) the fully adjusted model resulted in a
considerably higher HR of 11.64 (95% CI: 1.03–
131.11). In contrast, no association was found for
total cholesterol and cardiacmortality (HR0.55, 95%
CI: 0.18–1.71, P ¼ 0.300) whereas the HR for
triglycerides was again lower than for apo B (HR
1.89, 95% CI: 1.14–3.14, P ¼ 0.014). In Kaplan–
Meier survival analysis subjects in the lowest quartile
(apo B <0.96 g L)1) differed significantly from those
with an apo B level >0.96 g L)1 (P ¼ 0.011, Fig. 1).
The HR after adjustment for all explanatory variables
was seven times lower for subjects in the lowest
quartile compared to subjects with apo B ‡0.96 g L)1
(HR 7.44, 95% CI: 1.44–38.42, P ¼ 0.017).
Death due to ischaemic heart diseases
Fifteen deaths were related to IHD. As for overall
mortality and mortality due to cardiac disease apo B
was consistently associated with this outcome, too
(Table 2). Hazard ratios were again very similar for
the crude model and after adjustment for age and
gender (HR 5.76 and 6.85, respectively). Fully
adjusting for explanatory variables resulted into a
higher HR of 9.36 (95% CI: 1.26–69.66) that was
still statistically significant (P ¼ 0.029). In contrast,
neither total cholesterol nor triglycerides were found
to be related to death due to IHD (HR for total
cholesterol 0.99, 0.63–1.56, P ¼ 0.960; HR for
triglycerides 1.66, 0.87–3.15, P ¼ 0.123). Compar-
able with the analysis of cardiac mortality an apo B
level >0.96 g L)1 was associated with a sevenfold
increase in mortality (HR 7.38, 95% CI 0.78–69.82)
although this did not reach conventional levels of
statistical significance (P ¼ 0.081).
Prediction of cumulative absolute mortality risk over
time for different apo B levels
Figure 2 shows the predicted cumulative absolute
mortality risk over time for two specific baseline
levels of apo B (0.8 and 1.5 g L)1, representing
typical values of the lowest and the highest quar-
tiles, respectively). Results are separated according
to gender status. For example, the overall cumula-
tive risk to die in the next 10 years was found to be
12.1% (95% CI: 5.2–31.7) for a male subject with
type 1 diabetes and an apo B level of 1.5 g L)1 at
baseline. In contrast, the cumulative mortality risk
over the same time period was about halved (6.3%,
1.8–21.4) when considering a male subject having
an apo B level of 0.8 g L)1. This indicated an excess
mortality of about six of 100 male subjects with type
1 diabetes over 10 years for the high when com-
pared with the low apo B level. Female subjects
revealed a lower absolute cumulative mortality risk
over time than males. However, after 10 years the
absolute predicted mortality in a female subject with
an apo B level of 1.5 g L)1 was again about doubled
Table 2 Hazard ratios per g L)1 increase in apo B
All-cause mortality;
P-value
Cardiac mortality;
P-value
Death due to ischaemic
heart disease; P-value
Crude/univariate 2.78 (1.35–5.75); 0.006 3.07 (0.99–9.49); 0.051 5.76 (1.37–24.31); 0.017
Adjusted for age
and gender
2.62 (1.17–5.83); 0.019 3.17 (0.85–11.92); 0.087 6.85 (1.26–37.38); 0.026
Full Modela 2.65 (1.11–6.36); 0.029 11.64 (1.03–131.11); 0.047 9.36 (1.26–69.66); 0.029
aFull Model: adjusted for age, gender, body mass index, diabetes duration; levels of fasting glucose, triglycerides, and cholesterol; presence or
absence of microvascular disease, hypertension; antihypertensive treatment, treatment with diuretics; alcohol consumption.
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when compared with the same subject having an
apo B of 0.8 g L)1 at baseline (10.4%, 95% CI: 4.7–
26.1 and 5.4%, 0.8–15.8).
Discussion
This 15-year follow up showed that in type 1
diabetes apo B is consistently associated with a
significantly increased risk of mortality due to all
causes as well as to cardiac disease and to IHD. An
apo B level ‡0.96 g L)1 translated into a duplication
of overall mortality risk and a sevenfold increase of
mortality due to cardiac disease or IHD. When the
absolute cumulative mortality risk over time was
calculated based on different apo B levels a consid-
erable excess mortality was predicted for higher apo
B values in male and female subjects.
To the best of our knowledge this is the first study
that has prospectively assessed the association of
apo B with overall mortality and mortality due to
cardiac disease and IHD in type 1 diabetes. The
findings of the present analysis are in accordance
with results of recent reports showing an association
of apo B and cardiovascular risk in nondiabetic
subjects [9–14] as well as in subjects with type 2
diabetes [16–22] and in those with the metabolic
syndrome [15, 23]. In type 1 diabetes there is
conflicting evidence of the association of apo B and
cardiovascular disease or mortality. Several cross-
sectional trials showed an association of apo B with
microvascular complications but there is a lack of
consistent evidence with regard to cardiovascular
disease or mortality [28–30]. In contrast, one
prospective trial reported that apo B content of
modified lipoproteins was related to progression of
carotid intima-media thickness [35], a surrogate
marker of atherosclerosis. So far, only one prospect-
ive trial investigated the association of apo B with a
combined end-point of cardiovascular morbidity and
mortality in subjects with type 1 diabetes [31]. The
authors reported a limited prognostic value of apo B
on the development of coronary artery disease
whereas no association was found with overall
mortality. They concluded that the measurement of
apo B was of limited value in subjects with type 1
diabetes [31]. In contrast to these findings, the
present study revealed a consistent and positive
association of apo B levels with overall mortality as
well as with mortality due to IHD and cardiac
disease. These differences may be due to the fact that
the subjects of the current study were generally
older (51 vs. 32 years) and tended to have more
microvascular complications at baseline thereby
implicating an increased a priori cardiovascular risk.
This is underscored by the higher absolute mortality
rate in the present trial (72 of 165 vs. 28 of 147). Of
note, the odds ratio of 65.5 per g L)1 of apo B for
cardiovascular disease found by Weis et al. [31] was
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substantially higher than the HRs for mortality due
to cardiac disease or IHD as well as for overall
mortality in the present analysis. Whilst direct
comparability is limited by differences in outcome
definitions as stated above the present analysis did
also include more explanatory variables. Of interest,
the present study suggests that in subjects with type
1 diabetes apo B is a stronger risk factor for
mortality than total cholesterol or triglycerides. This
is in full accordance with previous studies in the
general population showing that total cholesterol
was predictive for cardiovascular disease in univa-
riate analyses but not when corrected for apo B and
triglycerides [13, 36].
The strength of the present study lies in the well-
defined cohort of diabetic subjects (Swiss cohort [32]
of the ‘WHO Multinational Study of Vascular
Disease in Diabetes’ [33]), the comparably long
follow up with no drop-out cases for this analysis,
and the evaluation of prespecified end-points. Con-
siderable efforts were undertaken to adjust for
relevant factors known to affect cardiovascular risk.
This allowed us to adjust not only for age and
gender as in an earlier report in type 1 diabetes [31],
but also for further parameters with known influ-
ence on mortality (e.g. alcohol consumption) [37].
In addition, a direct comparison of the prognostic
values of apo B, total cholesterol and triglycerides
was enabled. Measurement of apo B was performed
in one central laboratory, thereby limiting potential
variation.
Still, there are some limitations to our findings.
First, although the present study included the
largest number of subjects with type 1 diabetes
for a prospective analysis of apo B and mortality
the absolute number of participants is comparably
small. Secondly, in deceased patients, the underly-
ing cause of each death was determined from a
copy of the death certificate, hospital records,
postmortem reports and additional information
given by the treating doctors. Despite intensive
efforts to collect comprehensive data in some cases,
the cause of death may have been misclassified,
especially if it was only based on death certificates,
which are a comparatively unreliable source of
information. Thus, our findings regarding all-cause
mortality are clearly more robust than cause-
specific mortality. Thirdly, information on glycae-
mic control had to be based on fasting glucose
since HbA1c was not available at the time of study
entry. As glycaemic control has been related to
macrovascular complications [38, 39] this fact
could potentially have limited the accuracy of
adjustment for this parameter. Finally, no state-
ment can be drawn on the prognostic values of
LDL, high-density lipoprotein (HDL) and non-HDL
cholesterol because of the fact that only total
cholesterol and triglycerides were measured when
the study was initiated.
Current guidelines are based on LDL cholesterol
concentration as a principal factor in the assessment
of cardiovascular risk as well as a main target in the
treatment of dyslipidaemia in subjects with and
without diabetes mellitus [5–8]. However, the
measurement of apo B has recently been suggested
to offer a useful alternative [1–4]. As lipid compo-
sition of all atherogenic lipoprotein particles can
considerably vary between subjects, the measure-
ment of LDL cholesterol concentration may not
adequately reflect atherogenic risk. Due to the fact
that each particle of very low-density lipoprotein
(VLDL), IDL, LDL and Lp(a) contains one molecule of
apo B100 and chylomicrones and its remnant form
contain one molecule of apo B48 the sum of total
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apo B was stated to represent a better estimate of
atherogenic risk [1–4].
The present study emphasizes the value of apo B
as a prognostic factor for mortality end-points and
extends its validity to subjects with type 1 diabetes
mellitus. In contrast to the considerable amount of
studies in type 2 diabetes and the metabolic
syndrome comparably little is known on the meta-
bolism of lipoproteins in type 1 diabetes. Lipid
profiles in well-controlled subjects with type 1
diabetes tend to be similar to those seen in nondi-
abetic controls but altered lipoprotein composition
has consistently been demonstrated despite normal
lipoprotein metabolism in these subjects [26, 27].
The finding of an increased secretion of triglyceride-
rich VLDL associated with an increased number of
small-dense LDL particles – a constellation known to
be highly prevalent in premature coronary artery
disease in nondiabetic subjects as well as in type 2
diabetes [4, 40, 41] – was also suggested to be
associated with accelerated atherosclerosis in type 1
diabetes [27]. Of note, it has been shown before that
improved metabolic control positively influenced
lipoprotein composition in type 1 diabetes [42].
However, the role of apo B as a prognostic risk
factor must be separated from its potential role as a
therapeutical target. Lipid-lowering treatment with
statins has been shown to lower apo B in a general
population [43–46] as well as in type 2 diabetes [47]
and subjects with type 1 diabetes are likely to
behave similarly. Whilst apo B still appeared to be a
useful parameter under lipid-lowering therapy, the
value of LDL cholesterol has been questioned under
these conditions [3, 41, 45]. In type 1 diabetes lipid-
lowering therapy is also becoming more frequent in
clinical practice. The importance of apo B as a risk
marker might be even greater under these circum-
stances. Recent guidelines for a general population
recommend a lowering of apo B below 0.9 g L)1, in
high-risk situations even lower [48, 49]. The obser-
vational nature of the present study precludes a solid
statement on therapeutical effects and goals. It may
be of interest, though, that in the present analysis
subjects with apo B levels in the lowest quartile
(<0.96 g L)1) had a significantly lower mortality
risk than the rest of the cohort. Absolute cumulative
mortality risk over 10 years was 50% lower for a
subject with an apo B of 0.8 g L)1 compared with a
level of 1.5 g L)1 thereby implicating that lowering
apo B to comparable levels as suggested above could
be beneficial in type 1 diabetes, too. However, this
has to be confirmed by prospective interventional
trials.
Apo B has been shown to have several advantages
when compared with conventional lipid parameters
[1, 4, 49]. First, it can be measured in a nonfasting
sample. Secondly, methods are standardized and
automated thereby minimizing interferences by
methodological or biological factors. Thirdly, the
measurement of apo B is comparably simple, inex-
pensive and widely available.
Conclusion
In conclusion, this study confirms that in subjects
with type 1 diabetes apo B is consistently associated
with an increased risk of mortality due to all causes
as well as due to cardiac disease and IHD. Due to the
fact that the measurement of apo B is accurate and
easily obtainable in clinical practice its use should be
encouraged in the risk assessment of subjects with
type 1 diabetes.
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General discussion & conclusions 
4. General discussion & conclusions 
The five studies of this thesis focussed on the prevention and therapy of 
macrovascular complications and on the definition of prognostic factors for mortality 
in type 1 and type 2 diabetes mellitus (DM). An approach from two sides was used. 
The first part of the thesis consisted of three studies (Studies A-C) evaluating 
specific treatment strategies in type 1 and type 2 DM. In this context, Study A 
investigated the effect of improved glycaemic control on macrovascular complications 
in type 1 and type 2 DM. Focussing on type 2 DM, Study B examined the role of 
fibrates in the prevention of coronary heart disease in this type of DM. Study C 
aimed at analysing outcomes after coronary stenting using drug-eluting stents in 
patients with and without DM. 
 
The second part of the thesis included two studies (Studies D and E), focussing on 
the definition of novel mortality risk indicators for patients with DM. In Study D the 
prognostic value of two parameters (QT interval and resting heart rate) on mortality 
risk was assessed in type 1 and type 2 DM, respectively. Study E examined the role 
of apolipoprotein B (apo B) in the mortality risk assessment of patients with type 1 
DM. A brief summary of the results is given in Table 6. 
 
Taken together, this thesis demonstrated potential differences in the effectiveness of 
specific treatment forms in patients with compared to patients without DM. In 
addition, the effectiveness of treatment forms may vary between type 1 and type 2 
DM despite hyperglycaemia being a common factor.  
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Table 6. Brief summary of all studies of the thesis 
 Study Aim Main Results 
A To assess the effect of improved glycaemic control on 
cardiac, cerebrovascular and peripheral vascular 
complications in type 1 and type 2 DM 
Any macrovascular event: 
Type 1 DM: 62% reduction in incidence (95% CI 44-74%)  
Type 2 DM: 19% reduction in incidence (95% CI 9-27%)  
- Type 1 DM: effect mainly based on reductions of cardiac and peripheral vascular 
events  
- Type 2 DM: effect based on reductions in stroke and peripheral vascular events  
- Effects particularly important in younger patients with shorter duration of diabetes 
B To examine the effectiveness of fibrates (PPARα-
agonists) in the prevention of coronary heart disease in 
type 2 DM 
Coronary events: 
16% risk reduction (95% CI 4-26%) with fibrate therapy compared to placebo 
- Benefits even larger when analyses restricted to trials not confounded by unequal 
provision of additional lipid-lowering therapy 
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C To indirectly compare the effects of polymer based 
sirolimus versus paclitaxel eluting stents and to examine 
whether they are equally effective in the prevention of 
restenosis in patients with and without DM 
Patients without DM: 
Superiority of sirolimus eluting stents to paclitaxel eluting stents for all end points (in-
stent- and in-segment restenosis, target lesion revascularisation, major adverse 
cardiac events) 
Patients with DM: 
No significant difference of the two drug eluting stents in any of the end points 
D To evaluate the long-term association of QT interval 
corrected for heart rate (QTc) and resting Heart Rate (rHR) 
with mortality in patients with type 1 and type 2 DM 
Type 1 DM: 
QTc associated with long-term mortality, but not rHR 
Type 2 DM: 
rHR related to increased mortality risk, but not QTc 
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E To evaluate the long term association of apo B with 
mortality risk in patients with type 1 
- Apo B positively related to all cause and cardiac mortality, and mortality due to 
ischemic heart disease 
- Apo B >0.96 g L-1 translated into a doubling of overall mortality hazard and a 
sevenfold increase of mortality because of cardiac disease or IHD 
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4.1 Comparison of patients with and without diabetes mellitus 
As patients with DM have a higher cardiovascular risk compared to non diabetic 
patients [81, 114, 115], DM has been considered as an independent risk factor [72, 
73]. In contrast to patients without DM, heart disease in patients with DM appears 
earlier in life, affects women almost as often as men, and is more often fatal [78-80]. 
Patients with DM also tend to present with more advanced coronary artery disease, 
and outcomes after percutaneous interventions consequently tend to be poorer in 
these individuals [116-118]. The fact that the more severe neointimal hyperplasia in 
diabetic patients may lead to a different effectiveness of these interventions in 
patients with compared to patients without DM, was also reflected in the results of 
Study C on coronary stenting. In non-diabetic persons the sirolimus eluting stent was 
superior to the paclitaxel eluting stent in all end points under investigation. In 
contrast, this superiority disappeared in the analyses of patients with DM. In addition 
to the results of Study C, the findings of Study B demonstrated a potential difference 
in the effectiveness of treatments between patients with and without DM: A 
substantial reduction of coronary heart disease was found in this study when patients 
with type 2 DM were treated with fibrates compared to placebo. This was in contrast 
to a recent meta-analysis that showed little evidence for a reduction in cardiac 
mortality with fibrate treatment in a general population not distinguishing between 
patients with and without type 2 DM [119]. 
 
4.2 Within the patients with diabetes mellitus – comparison of type 1 and 
type 2 
Concerning the therapy of macrovascular complications within the group of DM, 
again possible differences in the effectiveness of specific treatment forms have to be 
considered [2]. While hyperglycaemia represents the predominant abnormality in 
patients with type 1 DM, patients with type 2 DM exhibit additional cardiovascular risk 
factors, as hypertension, dyslipidaemia and central obesity. In type 2 DM, 
cardiovascular risk is, therefore, influenced by several risk factors at the same time 
leading to differences in the process of developing late complications when 
compared to type 1 DM [120]. The results of Study A emphasise this difference of 
the underlying diseases in type 1 and type 2 DM by a difference in the efficacy of 
improved glycaemic control. Relative effects appeared to be more modest in type 2 
DM, probably due to the fact that with improving glycaemic control not all risk factors 
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are considered. In this context, is has been suggested that cardiovascular risk in type 
2 DM can be best reduced by a multifactorial therapy [121].  
 
Regarding the evaluation of mortality risk, again a potentially different impact of 
certain risk indicators has to be considered in the two types of DM. While the findings 
of Study D revealed a discrepancy in the prognostic values of parameters reflecting 
myocardial ventricular repolarisation between the two types of DM, the results of 
Study E, performed in type 1 DM, were in accordance with earlier studies performed 
in type 2 and non diabetic individuals. Studies D and E, therefore, underscore the 
need to differentiate between the two types of DM. 
 
4.3 Strengths and limitations of the thesis 
For the first part of the thesis (Studies A-C), work was based on a comprehensive 
literature search and efforts were undertaken to include all relevant trials in the 
respective field. Whenever data was not available from the publication, attempts were 
made to contact the principle investigators to obtain the information. All three studies 
were performed according to the QUOROM guidelines [110], thereby fulfilling widely 
accepted quality criteria for systematic reviews and meta-analyses. All studies were 
planned using a predefined study protocol. The three studies, therefore, provide a 
summary of all the currently available evidence in the respective research field in one 
review framework. Nevertheless, some limitations have to be acknowledged. First, 
despite a good collaboration with many of the principle investigators of the original 
studies, it was not always possible to obtain all the lacking information. Still, funnel 
plot analysis suggested that the available data illustrated a representative sample, 
and that no substantial bias was introduced. Second, due to the fact that these meta-
analyses were not based on individual patient data, no statement could be made on 
sub-categories of patients most likely to benefit. For example, research based on 
individual patient data could examine, whether drug eluting stents are equally 
effective in patients with DM and long coronary lesions compared to those with 
shorter lesions. In Studies D and E the prognostic value of specific risk indicators 
was assessed prospectively allowing inclusion of almost all patients of the cohort. 
Furthermore, the analyses could be adjusted for additional parameters potentially 
influencing the outcome compared to previous studies. Despite attempts to include all 
relevant parameters, not always all the desired information had been collected when 
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the study was initiated. Since the studies were based on data of the Swiss arm of the 
cohort exclusively, no statement can be made on effects in other areas.  
 
4.4 Conclusions 
In conclusion, this thesis showed that: 
 
• Attempts to improve glycaemic control reduce the incidence of macrovascular 
events both in type 1 and type 2 DM. In absolute terms benefits are 
comparable, although effects on specific manifestations of macrovascular 
disease differ between the two types of DM. 
 
• Fibrates are associated with a substantial reduction of CHD events in patients 
with type 2 DM. Their exact role in lipid lowering treatment, however, remains 
to be defined. 
 
• Sirolimus as well as paclitaxel eluting stents reduce the rates of 
revascularisation procedures when compared to bare metal stents. Based on 
indirect evidence, stents eluting sirolimus appear to be superior to paclitaxel 
eluting stents in patients without DM but not in patients with DM. 
 
• Prolonged QTc is associated with long-term mortality in patients with type 1 
DM, whereas elevated rHR is related to increased mortality risk in patients 
with type 2 DM. 
 
• Higher apo B levels are consistently associated with an increased mortality in 
type 1 DM. 
 
In addition to these conclusions, two general statements can be made:  
 
• The effectiveness of therapeutic interventions may be different in patients with 
compared to patients without DM.  
 
• Within the group of patients with DM, the effectiveness of interventions may 
vary between type 1 and type 2 DM. Furthermore, in the evaluation of 
macrovascular risk, specific risk indicators may play a different role in the two 
types of DM.  
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